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 ABSTRACT 
 
Epidemiological and clinical studies have shown that very long chain n-3 
polyunsaturated fatty acids (n-3 PUFA) such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) possess anti-inflammatory properties.  The mechanisms by 
which n-3 PUFA exert their anti-inflammatory effects remain undefined.  Extending 
earlier observations that actin remodeling at the immunological synapse (IS) is 
suppressed in CD4+ T cells supplemented with n-3 PUFA, we hypothesized that the lipid 
mediator phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2], which modulates actin 
remodeling, is perturbed by n-3 PUFA.  Utilizing the transgenic Fat-1 mouse model that 
synthesizes n-3 PUFA de novo and enriches the plasma membrane with n-3 PUFA, and 
wild type (WT) mice fed either a 5% corn oil (CO, control) or a 4% DHA triglyceride-
enriched diet, we found that splenic CD4+ T cells from Fat-1 mice and WT mice fed a 
DHA-enriched diet, when compared to WT and CO-fed CD4+ T cells, exhibited i) 
decreased PI(4,5)P2; ii) unchanged PI(4,5)P2 upon activation; and iii) suppressed actin 
remodeling, as assessed by immunofluorescence, upon activation, which was rescued in 
Fat-1 CD4+ T cells by incubation with exogenous PI(4,5)P2.  Mechanistically, 
recruitment of the Wiskott-Aldrich syndrome protein (WASP), an actin-remodeling 
protein regulated by PI(4,5)P2, to the IS upon anti-CD3/anti-CD28 coated bead 
stimulation was inhibited in Fat-1 CD4+ T cells.   
 Since discrete pools of PI(4,5)P2 may exist in the plasma membrane, we also 
determined whether n-3 PUFA modulate the spatial organization of PI(4,5)P2 relative to 
ii 
 
 raft and non-raft domains by transducing CD4+ T cells from WT and Fat-1 mice with 
fluorescence resonance energy transfer (FRET) lipid raft probes Lck(N10) and 
LAT(ΔCP), and the non-raft probe Src(N15).  Co-clustering of PH(PLC-δ1), a PI(4,5)P2 
probe, and Lck(N10) or LAT(∆CP), was not affected by n-3 PUFA; however, co-
clustering of PH(PLC-δ1) and Src(N15) exhibited a decrease in Fat-1 CD4+ T cells, 
suggesting that n-3 PUFA alter the spatial organization of PI(4,5)P2.  Incubation with 
exogenous PI(4,5)P2 rescued the effects on the non-raft PI(4,5)P2 pool, and reversed the 
corresponding suppression of T cell proliferation in Fat-1 CD4+ T cells.   
Previous research has shown that n-3 PUFA can inhibit Fyn palmitoylation.  
Therefore, we proposed an alternative hypothesis that n-3 PUFA affect the 
palmitoylation, and hence activation, of signaling proteins upon T cells activation.  
Using a newly developed technique in which palmitoylated proteins are coupled to 
biotin via Click chemistry, we demonstrated that n-3 PUFA do not affect the 
palmitoylation of signaling proteins, such as LCK, in Fat-1 CD4+ T cells. 
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 NOMENCLATURE 
 
µm Micrometer 
AA Arachidonic acid 
Ag Antigen 
APC Antigen presenting cell 
AICD Activation-induced cell death 
BAR Bin-amphiphysin-Rvs 
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CCL CC chemokine ligand 
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DPA Docosapentaenoyl acid 
ECFP Enhanced cyan fluorescent protein 
EGFR Epidermal growth factor receptor 
ENTH Epsin N-terminal homology 
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 EPA Eicosapentaenoic acid 
ER Endoplasmic reticulum 
F-actin Filamentous actin 
FERM Four-point one, ezrin, radixin, moesin 
FRAP Fluorescence recovery after photobleaching 
FRET Fluorescence resonance energy transfer 
G-actin Globular actin 
GADS Grb2 (growth-factor-receptor-bound protein 2)-related adaptor 
protein 
GM1 Monosialotetrahexosylganglioside 
GPR G-protein coupled receptor 
IBD Inflammatory bowel disease 
IFN-γ Interferon-gamma 
IL Interleukin 
Inp54p Inositol polyphosphate 5-phosphatase 
IP3 Inositol (1,4,5)-trisphosphate 
IS Immunological synapse 
ITK Interleukin-2 inducible T-cell kinase 
kDa Kilodalton 
LAT Linker of activated T cells 
Lck Lymphocyte-specific protein tyrosine kinase 
LKU Lipid kinase unique 
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 Lo Liquid-ordered 
MARCKS Myristoylated alanine-rich C kinase substrate 
MHCII Major histocompatibility class II 
Na+ Sodium 
NCK Non-catalytic region of tyrosine kinase adaptor protein 
NLRP NOD-like receptor family, pyrin domain containing 
Nm Nanometer 
NMR Nuclear magnetic resonance 
NSAIDs Non-steroidal anti-inflammatory drugs 
OA Oleic acid 
PAK p21-activated kinase 
PALM Photoactivation localization microscopy 
PH Pleckstrin homology domain 
PI Propidium iodide 
PI(4)P Phosphatidylinositol-4-phosphate 
PI(4.5)P2 Phosphatidylinositol-(4,5)-bisphosphate 
PI(5)P Phosphatidylinositol-5-phosphate 
PIP Phosphoatidylinositol phosphate 
PIP4KII Type II phosphatidylinositol-5-phosphate 4-kinases 
PIP5KI Type I phosphatidylinositol-4-phosphate 5-kinases 
PLC Phospholipase C 
PMA Phorbol 12-myristate 13-acetate 
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 PPARγ Peroxisome proliferator-activated receptor-γ 
pSMAC Peripheral supramolecular activation cluster 
PTEN Phosphatase and tensin homolog 
PUFA Polyunsaturated fatty acids 
RNA Ribonucleic acid 
RXRα Retinoid X receptor-α 
SLP76 SH2 (Src homology 2) domain-containing leukocyte protein of 76 
kDa 
Src Sarcoma proto-oncogene tyrosine-protein kinase  
STIM1 Stromal interaction molecule 1 
TC Cytotoxic T lymphocytes 
TCR T cell receptor 
TGFβ Transforming growth factor-beta 
TH Helper T lymphocytes 
TPN Total parenteral nutrition 
VAV1 VAV1 guanine nucleotide exchange factor 
WASP Wiskott-Aldrich syndrome protein 
WT Wild type 
YPet Yellow fluorescent protein for energy transfer 
ZAP70 Zeta (ζ)-chain (TCR)-associated protein kinase of 70 kDa 
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 CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Plasma membrane and the cytoskeleton 
 The cell, a basic unit of life, is composed of macromolecules such as 
carbohydrates, DNA, RNA, protein, and lipids.  These macromolecules sustain life by 
processing complex chemicals in the environment into simple compounds to be used for 
energy metabolism.  As well, the cell replicates by faithfully preserving its genetic 
materials.  The cell membrane, composed mainly of a phospholipid bilayer, constitutes 
the outer boundary of the cell; not only does the cell membrane control molecule 
transport, but also regulates the transmission of signals into and out of the cell.  Thus, it 
represents the first line of defense against external threats, while providing the 
compartment for the cell to perform biochemistry. 
 The first model of the plasma membrane was proposed in 1972 by Singer and 
Nicolson (1).  In this model, coined the fluid mosaic model, the phospholipid bilayer is 
thought of as a fluid, dynamic, passive solvent in which proteins either transverse across 
(i.e. integral proteins), or loosely associate (i.e. peripheral proteins), with the 
phospholipid bilayer.  The heterogeneity of the proteins and phospholipids that comprise 
the plasma membrane allow the cell to perform a diverse spectrum of biochemistry.  
Although the contribution of the protein heterogeneity to the function of a cell can be 
easily understood, the heterogeneity of the lipids in the plasma membrane is less well 
studied, leading to questions about the role these lipids play at the cellular level. 
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  The heterogeneity of proteins results in the classical four levels of protein 
structures (i.e. primary, secondary, tertiary, and quaternary) to describe the three-
dimensional structures of the proteins, and linking them to protein functions.  Lipids, 
however, lack this system of classification to describe how these hydrophobic molecules 
interact with each other to form higher order structures, and ultimately how these lipid 
structures function in the cell.  The plasma membrane is composed of amphiphilic 
phospholipids, which contain both hydrophobic and hydrophilic components, to create 
an energetically favorable bilayer.  Analogous to the primary structure of proteins, where 
twenty amino acids are the building blocks of the polypeptide, phospholipids in the 
plasma membrane are generally characterized by three functional groups attached to a 
glycerol backbone.   
 The plasma membrane contains three classes of amphiphilic lipids: 
phospholipids, glycolipids, and sterols.  These lipids are further subdivided into various 
fatty acids and headgroups at the sn-1, sn-2, and sn-3 positions (2).  For example, a 
major species of phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] is composed of a 
saturated C18:0 fatty acid at the sn-1 position, an unsaturated C20:4∆5,8,11,14 fatty acid at 
the sn-2 position, and myo-inositol 4,5-bisphosphate at the sn-3 position.  With all these 
layers of complexity, could lipids in the plasma membrane form local structures, 
analogous to secondary structures such as alpha-helices and beta-sheets found in 
proteins? 
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Figure 1.1.  Three-tiered organization of the plasma membrane.   A)  Favorable interactions between cholesterol, sphingolipids, and 
saturated fatty acids result in the formation of “lipid rafts” in the plasma membrane.  These domains are heterogeneous in nature, 
dynamic, but are important for localization of signaling proteins.  B)  Lipid-protein interactions between phosphatidylinositol-(4,5)-
bisphosphate and actin-binding proteins can stabilize these mesoscale lipid rafts by the actin cytoskeleton.  C)  Protein-protein 
interactions via the formation of signaling complex can also induce mesoscale lipid raft formation in the plasma membrane. 
 
 
1.1.1 Lipid rafts are mesoscale domains generated by lipid-lipid interactions in  
the plasma membrane 
 In a simple model system where two lipids (one high melting temperature, one 
low melting temperature) and cholesterol are mixed together, micron-scale domains 
phase separate and are easily visualized using conventional fluorescence microscopy (3).  
These micron-sized microdomains, one example of local structures in the plasma 
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 membrane, can be observed in epithelial cells, where the apical plasma membrane is 
enriched in sphingolipids, while the basolateral plasma membrane is enriched in 
phosphatidylcholine (4).  Small invaginations in the plasma membrane, enriched with 
cholesterol, sphingolipids, and the caveolin protein, can also be found in many cells such 
as endothelial cells and adipocytes (5).  Smaller, highly dynamic, nanoscale lipid rafts 
enriched in sphingolipids, cholesterol, and saturated fatty acids, have been proposed to 
play a role in signal transduction (Figure 1.1).  In fact, stable nanodomains can be 
visualized in yeast vacuole membranes upon various stresses such as nutrient deprivation 
and pH change; proteins that sort to these vacuolar membranes also segregate to one of 
two domains, similar to what would be predicted by the simple system composed of two 
lipids and cholesterol (5).  These nanodomains are thought to organize select proteins to 
optimize their signaling capacity upon ligand engagement.  For example, receptors such 
as epidermal growth factor receptor (EGFR) and the Fas receptor localize into lipid rafts 
of the plasma membrane, and their association with lipid rafts is critical for downstream 
signaling transduction upon engagement with their respective ligands (6-9).  In fact, 
computer simulations suggest that in order for lipid rafts to promote protein-protein 
interactions, these mesoscale domains must be small (6 to 14 nm in diameter) to operate 
as protein concentrators in the plasma membrane (3).     
 Due to the diffraction limitation of conventional optical microscopy widely 
employed to study cells such as confocal and epifluorescence microscopy (lateral 
resolution ~ 200 nm), lipid rafts have yet to be visualized in contrast to phase-separated 
vesicles composed of two lipids and cholesterol.  Thus, one criticism of the lipid raft 
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 model is that these mesoscale domains have not been visualized in intact cells.  Further, 
early history of lipid rafts defined these structures as resistant to detergent extraction (so-
called detergent-resistant fraction), and/or under cold temperature, possibly introducing 
artifacts for identifying proteins that localize in lipid rafts; similarly, using cross-linking 
reagents to biochemically prepare detergent extraction can also introduce artificial 
localization into detergent-resistant fractions.  On a cellular level, experiments extracting 
cholesterol, one component of the lipid rafts, from the plasma membrane with methyl-β-
cyclodextrin to disrupt lipid rafts may result in additional artifacts since methyl-β-
cyclodextrin can interact with not only cholesterol, but other phospholipids and 
membrane proteins as well (4).   
Recently, using a technique known as secondary ion mass spectrometry imaging 
(lateral resolution ~50 nm), in which the primary ion is bombarded onto the cell surface, 
and the secondary ions ejected from the plasma membrane are collected and analyzed, 
sphingolipid-enriched domains were detected in primary fibroblasts, supporting the 
existence of lipid rafts; however, these sphingolipid-enriched domains were not enriched 
with cholesterol (10, 11).  In addition, the emergence of super-resolution microscopy, in 
which lateral resolution of ~50 nm can be achieved, has provided further insight into the 
biophysical properties of these lipid rafts.  By using photoactivation localization 
microscopy (PALM), in which only a few fluorescent probes are activated at each pulse 
of activating light to reconstruct the final image, and lipid-binding domains for 
cholesterol and sphingomyelin, it was recently determined that cholesterol-enriched 
microdomains are ~118 nm in diameter, while sphingomyelin-enriched microdomains 
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 are ~124 nm in HeLa cells (12).  Interestingly, the same study demonstrated that both 
microdomains were sensitive to cholesterol depletion, but only sphingomyelin-enriched 
microdomains were affected by sphingomyelin depletion, corroborating the results from 
secondary ion mass spectrometry imaging studies. 
1.1.2 Lipid rafts and actin cytoskeleton are mesoscale domains stabilized by lipid-
protein interactions 
 Although lipid rafts can associate and dissociate as a mechanism to regulate the 
formation of raft phases in the plasma membrane, one way to achieve a stabilized raft 
phase (i.e., stabilize the size and/or lifetime of the raft) is the presence of the actin 
cytoskeleton.  Monomeric actin is a 42 kDa globular protein (G-actin) that is capable of 
polymerization to form long, complex filamentous actin (F-actin) that can provide the 
force required for organelle movement, and the scaffold required for stabilization of 
membrane raft phases.  F-actin is bridged to the plasma membrane by interacting with 
integral and membrane-associated proteins; an example is the various protein-actin 
cytoskeleton interactions in erythrocytes (13).  One current model is that these 
“membrane skeletons” form the “fences” in the plasma membrane, impeding the 
diffusion of membrane proteins and lipids (14). 
 The participation of the actin cytoskeleton in the formation of mesoscale domains 
was first postulated when it was observed that the coefficient of diffusion of 
phospholipid probes were significantly lower in live cells (15, 16), than those estimated 
in artificial membranes (17, 18).  This difference was also observed for transmembrane 
protein markers and glycosylphosphatidylinositol-anchored protein markers (14).  One 
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 suggestion to explain the difference in the diffusion coefficient is the presence of the 
membrane cytoskeleton in live cells compared to artificial membranes.  Indeed, it was 
observed that the lipid probe 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) 
had a macroscopic (i.e. across the whole membrane) diffusion coefficient of 9.4 µm2/s in 
large unilamellar vesicles, but this diffusion coefficient was reduced to 0.99 µm2/s in 
normal rat kidney fibroblasts, suggesting that component(s) of the cell could interact 
with the cellular membrane, and compartmentalize membrane macromolecules such as 
lipids and proteins.  Treatment of live cells with trypsin (removes extracellular matrix), 
methyl-β-cyclodextrin (removes cholesterol), or jasplakinolide (stabilizes the actin 
cytoskeleton) did not affect the size of the compartmentalized DOPE probe.  However, 
the mesoscale domain increased in size by treating the live cells with latrunculin-A 
(sequesters G-actin to suppress actin polymerization), suggesting that actin cytoskeleton 
plays a crucial role in the generation of mesoscale domains in the plasma membrane 
(19).  The requirement for the actin cytoskeleton in maintaining the properties of 
mesoscale domains was also observed using secondary ion mass spectrometry, in which 
treatment of NIH 3T3 mouse fibroblasts with latrunculin A resulted in a random 
distribution of sphingomyelin instead of sphingomyelin-enriched microdomains in 
control fibroblasts (11). 
 The actin cytoskeleton is bridged to membranes through interactions with 
integral proteins, or through proteins recruited to the plasma membrane by specific 
phospholipids.  One such phospholipid is phosphatidylinositol-(4,5)-bisphosphate 
[PI(4,5)P2], which comprises 5% of the total phosphatidylinositol species, and 1% of the 
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 total plasma membrane phospholipid (20).  Classically, PI(4,5)P2 is important in signal 
transduction because the products of hydrolysis by phospholipase C are diacylglycerol 
(DAG), which is important for the recruitment of protein kinase C to the plasma 
membrane, and inositol  (1,4,5)-trisphosphate (IP3), which diffuses into the cytosol in 
order to bind to the endoplasmic reticulum (ER) inositol trisphosphate receptor that 
releases Ca2+ upon activation.  These two classical second messengers amplify signal 
transduction from the plasma membrane.  In addition to the generation of second 
messengers, PI(4,5)P2 can also recruit proteins to specific sites like a second messenger.  
For example, recently, it has been found that PI(4,5)P2 can interact with ion channels at 
the plasma membrane to activate and open these channels (21).   
One of the functions of PI(4,5)P2 is to recruit actin remodeling proteins to 
localized sites at the plasma membrane.  It is typically thought that PI(4,5)P2 activate 
actin-regulatory proteins that induce actin polymerization, while concurrently inhibiting 
those proteins that promote actin disassembly.  Indeed, the increase in local PI(4,5)P2 
results in stress-fiber formation, indicative of increased actin filament formation (20).  
Due to multiple acidic phosphate groups on PI(4,5)P2, basic protein domains are thought 
to play a role in recruiting proteins to the plasma membrane.  For example, the Wiskott-
Aldrich syndrome protein (WASP) is released from its autoinhibitory conformation 
when the basic domain binds to PI(4,5)P2 (22).  Talin utilizes the basic cleft in the 
FERM domain (four-point one, ezrin, radixin, moesin) to interact with PI(4,5)P2 (23).  
Additional motifs such as the pleckstrin-homology (PH) domain are also known to 
interact with PI(4,5)P2 (24, 25).  Similarly, PI(4,5)P2 can recruit and activate Rho family 
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 GTPase through its polybasic region, of which some small GTPases play a role in 
cytoskeletal remodeling (23).  PI(4,5)P2 is not exclusively involved in the recruitment of 
actin remodeling proteins.  It is known that in CD4+ T cells, the ER Ca2+ channel STIM1 
is coupled to its plasma membrane counterpart Orai1 through interaction between the 
polybasic domain of STIM1 and the plasma membrane PI(4,5)P2 (26, 27).  PI(4,5)P2, 
and its role in regulating the actin cytoskeleton is further described in Section 1.2. 
1.1.3 Lipid rafts and higher-ordered protein complexes form mesoscale domains formed 
by protein-protein interactions 
 A third interaction to consider in the formation and organization of optimal 
mesoscale lipid rafts, is the role of higher-ordered protein complexes (i.e., protein-
protein interactions), as proposed by Kai Simons and Akihiro Kusumi (28, 29).  As an 
example, epidermal growth factor receptor (EGFR) undergoes conformational change 
and dimerization upon binding of its ligand, epidermal growth factor, resulting in 
downstream signaling (7, 30).  Optimal EGFR signaling, however, takes place in lipid 
rafts, highlighting the role of protein-protein interactions in driving the formation and 
organization of optimal lipid rafts for cellular signaling.  Another example is the Fas-
mediated cell death receptor.  Similar to EGFR, Fas receptor (FasR) localizes in lipid 
rafts, and upon engagement with its ligand, Fas ligand (FasL), FasR undergoes 
oligomerization to induce favorable interactions between lipid rafts, again highlighting 
how protein-protein interactions can mediate lipid raft formation and organization (8, 9, 
31). 
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 1.2 Phosphatidylinositol-(4,5)-bisphosphate 
 PI(4,5)P2 is generated from the phosphorylation of phosphatidylinositol-4-
phosphate [PI(4)P] by type I phosphatidylinositol-4-phosphate 5-kinases (PIP5KI).  The 
phosphorylation of phosphatidylinositol-5-phosphate PI(5)P by type II 
phosphatidylinositol-5-phosphate 4-kinases (PIP4KII) also contributes to a minor 
portion of PI(4,5)P2.  There are three isoforms of PIP5KI (α, β, γ), with PIP5KIα 
containing three, PIP5KIβ containing two, and PIP5KIγ containing three splicing 
variants.  The most identifiable domain in the PIP5KI family is the catalytic kinase 
domain, but it is known that the PIP5KI family is activated by phosphatidic acid (20, 
32).  The C-terminal seems to play a role in the targeting of the various PIP5KI to 
cellular compartments and for substrate specificity.  Due to the different isoforms and 
the splicing variants, the localization of PIP5KI remains unclear; however, it is believed 
that these kinases are recruited to the plasma membrane from the cytoplasm.  Recent 
studies have demonstrated that PIP5KIα can be found at the nucleus to interact with the 
non-canonical poly(A) polymerase Star-PAP to regulate the expression of mRNAs (33). 
 PI4KII has two isoforms (α and β), which contain the kinase and the lipid kinase 
unique (LKU) domains seen in PI(4,5)P2  3-kinase PI3K.  The α isoform also contains a 
nuclear localization sequence and a PH domain, while the β isoform contains a Rab-
association domain that may be important for its translocation from the Golgi to the 
plasma membrane.  In the rat, PI4KIIα has been found to localize to various membrane 
organelles, including ER, mitochondria, vesicles, and nucleus (34, 35), whereas PI4KIIβ 
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 is localized to the early Golgi compartments in the MDCK cell line and the nucleus in 
NIH 3T3 cells (34, 36, 37). 
PI(4,5)P2 can also be generated from the dephosphorylation of PI(3,4,5)P3 by the 
phosphatase and tensin homolog (PTEN).  PTEN has attracted a lot of attention due to 
its ability to suppress tumor development; conversely, mutations in PTEN have been 
implicated in cancer development (38).  PTEN contains the 3-phosphatase domain 
(CX5R) conserved in other 3-phosphatases, as well as other domains that are known for 
recruitment of PTEN to the plasma membrane (C2 domain), for protein-protein 
interactions (PDZ domain), and for proteolytic control (proline-glutamine-serine-
threonine PEST domain).  PI(4,5)P2 generated by PTEN is mostly considered the by-
product of the regulation of PI(3,4,5)P3 (32). 
PI(4,5)P2 regulates the recruitment and activity of actin-binding proteins that 
contain domains such as PH, ENTH, or BAR domains (23).  Actin-binding proteins 
serve to promote the polymerization of G-actin into F-actin (i.e. Arp2/3 complex), to 
stimulate the severing and depolymerization of F-actin (i.e. ADF/cofilin), or to regulate 
the actin dynamics by interacting with G- or the F-actin (i.e. profiling, actin capping 
proteins).  Additionally, actin-binding proteins are involved in the higher-ordered 
structure of actin filaments by promoting cross-linking and bundling of actin filaments.  
Presently, it is thought that PI(4,5)P2 promotes the polymerization of F-actin since many 
actin-binding proteins that promote polymerization are activated by PI(4,5)P2, whereas 
those that promote depolymerization are inhibited by PI(4,5)P2. 
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 Evidence for a role of PI(4,5)P2 in regulating the spatial organization of 
mesoscale domains comes from studies using membrane-targeted inositol polyphosphate 
5-phosphatase (Inp54p) that dephosphorylates PI(4,5)P2 in either raft or non-raft 
membrane compartments (39).  By targeting Inp54p to the raft to deplete the raft pool of 
PI(4,5)P2, the number of filopodia in Jurkat T cells, cytoplasmic protrusions that contain 
extensive actin cytoskeleton, were decreased.  Conversely, targeting Inp54p to the non-
raft region of the plasma membrane increased the number of filopodia in Jurkat T cells, 
suggesting that i) different pools of PI(4,5)P2 exist at the plasma membrane; and ii) 
different pools of PI(4,5)P2 regulate distinct actin cytoskeleton processes (39).  In fact, 
Inp54p targeted to the raft pool of PI(4,5)P2 suppressed not only the formation of F-actin 
at the immunological synapse, but also increased the number of membrane blebs that is 
indicative of the dissociation of actin cytoskeleton from the plasma membrane, further 
supporting the concept that PI(4,5)P2 regulates actin cytoskeleton processes and the 
organization of mesoscale domains in the plasma membrane (39-41).   
Parallel to using targeted phosphatases to examine the different pools of 
PI(4,5)P2 in regulating actin cytoskeleton, it has been proposed that different type I 
phosphatidylinositol-4-phosphate 5-kinases (PIP5KI) synthesize the different pools of 
PI(4,5)P2.  For example, overexpression of PIP5KIβ increased PI(4,5)P2 in both 
detergent-resistant and detergent-soluble membrane fractions, whereas overexpression of 
PIP5KIγ increased PI(4,5)P2 in only the detergent-soluble membrane fraction in RBL-
2H3 mast cells, suggestive of different pools of PI(4,5)P2 present at the plasma 
membrane (42).  From a functional perspective, increasing both pools of PI(4,5)P2 by 
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 PIP5KIβ increased the association of STIM1 and Orai1 in RBL-2H3 mast cells, while 
increasing the detergent-soluble fraction of PI(4,5)P2 by PIP5KIγ decreased the 
association of STIM1 and Orai1, providing further evidence of the different pools of 
PI(4,5)P2.  The role of various PIP5KI isoforms in regulating actin cytoskeleton is also 
highlighted by the fact that only the loss of PIP5KIγ, and no other forms of PIP5KI, 
alters the association of the actin cytoskeleton and plasma membrane in megakaryocytes 
and platelets, further supporting the role of PI(4,5)P2 in organizing mesoscale domains 
by regulating the membrane actin cytoskeleton (43, 44). 
Controversy exists in regard to the presence of specific pools of PI(4,5)P2 at the 
plasma membrane.  Examination of the diffusion coefficient of PI(4,5)P2 at the inner 
leaflet of plasma membrane showed a two-fold decrease when compared to another 
phospholipid, phosphatidylethanolamine (45), demonstrating a restricted lateral 
diffusion.  Interestingly, the restricted lateral diffusion of PI(4,5)P2 can be abrogated by 
actin depolymerization (46), suggesting that cytoskeleton and/or cytoskeletal proteins 
can play a role in restricting simple diffusion of PI(4,5)P2.  This observation is consistent 
with the hop-fence model proposed by Dr. Akihiro Kusumi where actin-based 
membrane “fences” are anchored at the plasma membrane by transmembrane protein 
pickets to form confinements (28).  Experiments have suggested that PI(4,5)P2 is 
enriched in microdomains of the cells associated with caveolin, and this pool is sensitive 
to agonist stimulation (47).  Further studies have demonstrated the localization of 
PI(4,5)P2 in lipid rafts outside of caveolin (48); however, these early studies used 
detergent extraction to localize PI(4,5)P2, which in itself may generate experimental 
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 artifacts.  Regardless, proteins can sequester PI(4,5)P2 at specific sites.  One of these 
proteins is the myristoylated alanine-rich C kinase substrate (MARCKS).  The polybasic 
region of MARCKS can bind to three PI(4,5)P2 to induce PI(4,5)P2 clustering.  The 
cellular level of MARCKS in the neuronal tissue is similar to that of PI(4,5)P2, 
suggesting that MARCKS can sequester a significant amount of PI(4,5)P2 (49).  These 
findings indicate the likelihood of distinct pools of PI(4,5)P2 that can activate proteins, 
recruit site-specific actin remodeling, and generate second messengers locally. 
 Interestingly, PI(4.5)P2 has been localized to the nucleus, where it may play a 
role in transcriptional regulation (50).  As mentioned earlier, PIP5Kα associates with the 
non-canonical poly(A) polymerase Star-PAP to regulate mRNA expressions (33).  
Specifically, PI(4,5)P2 stimulated the poly(A) polymerase activity of Star-PAP.  
PI(4,5)P2 may also regulate cytoskeletal control of transcription in the nucleus.  For 
example, there are reports of nuclear cytoskeletal proteins that bind to nuclear PI(4,5)P2 
(51).  There are also evidence that PI(4,5)P2 may control chromatin remodeling by 
interacting with various chromatin remodeling complexes, such as BRG1 (52).  The role 
of PI(4,5)P2 in the nucleus is still rather unclear, as there is also evidence of distinct 
pools of PI(4,5)P2 that are not associated with the membrane (53), thus there remain 
many questions about the nuclear pool of PI(4,5)P2, and phosphatidylinositols, in 
general. 
1.3 CD4+ T Cells 
The mammalian immune system is critical in defending the host against foreign 
pathogens. Under normal conditions, T lymphocytes circulate around the body in order 
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 to survey for foreign antigens and target them for destruction.  However, under 
pathophysiological conditions such as autoimmune diseases, the adaptive immune 
system is unable to differentiate between self and foreign antigens, resulting in aberrant 
T lymphocyte activation and response.  This could manifest itself in autoimmune 
diseases such as inflammatory bowel disease (IBD), i.e. Crohn’s disease and ulcerative 
colitis (54), and affect the patient’s quality of life.  Additionally, the adaptive immune 
system may become over-reactive against foreign antigens and unable to resolve 
appropriately, resulting in pathophysiological chronic inflammation such as Rheumatoid 
arthritis.  The mammalian immune system is comprised of the innate and the adaptive 
system; within the adaptive immune system, there are two predominant cell types: i) B 
lymphocytes, responsible for antibody mediated (humoral) immunity; and ii) T 
lymphocytes, responsible for the regulation of humoral and cell mediated immunity.  T 
lymphocytes can be separated into cytotoxic T lymphocytes (CD8+ T lymphocytes, or TC 
lymphocytes), and helper T lymphocytes (CD4+ T lymphocytes, or TH lymphocytes).   
While CD8+ T lymphocytes play an important role in host defense and autoimmune 
disease, CD4+ T lymphocytes due to their ability to further differentiate into other 
effector cell types (TH1, TH2, Treg, TH17), have opposing roles in autoimmune diseases 
such as IBD (54). 
   
15 
 
  
Figure 1.2.  Immunological synapse at the A) cellular; and B) biochemical level.  When CD4+ T cell recognizes cognate antigen 
presented by the antigen presenting cell, an immunological synapse is formed at the cellular level.  At the biochemical level, major 
lipididomic and proteomic rearrangement occurs to propagate T cell activation.  At the lipidomic level, lipids found to be associated 
with lipid rafts are found to coalesce at the immunological synapse (represented in red).  Adhesion molecules, such as LFA-1, are 
important for the stabilization of the immunological synapse, while CD45, which is required to terminate T cell activation, is 
excluded from the immunological synapse.  Additionally, the actin cytoskeleton is important for T cell activation by stabilizing the 
immunological synapse. 
 
 
 
1.3.1 Role of lipid rafts in CD4+ T cell activation 
The engagement of the T cell receptor (TCR) with antigen presented in the major 
histocompatibility complex II (MHCII) molecule results in the formation of the 
immunological synapse (IS, Figure 1.2), where proteins essential for propagating the 
signal are enriched to form the central supramolecular activation cluster (cSMAC), and 
where adhesion molecules necessary to stabilize the IS form the peripheral 
supramolecular activation cluster (pSMAC); this patterning leads to the “bull’s eye” 
description of the IS (55, 56).  Proteins that regulate T cell activation, such as 
phosphatases that can abrogate signaling, are excluded from the cSMAC and pSMAC in 
order for T cell activation to take place.  At the IS, tyrosine kinases Lck and ZAP70 are 
activated and subsequently phosphorylate the adaptor protein linker for activation of T 
cells (LAT), leading to the assembly of the signalsome comprised of many proteins, 
including GADS, SLP76, NCK, ITK, VAV1, PAK, and PLC-γ1 (57).   The proper 
formation of the IS, required for sustained T cell activation, is stabilized by the actin 
cytoskeleton (58-60).    When the adhesion proteins coalesce to form the pSMAC, the 
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 actin cytoskeleton is bridged to the IS by proteins such as talin, vinculin, and WASp.  
The dynamics of the actin cytoskeleton, however, are also important for sustained T cell 
activation.  It is thought that the centripetal flow of F-actin to the initial engagement site 
between TCR and MHCII is important for the strength and duration of T cell activation; 
indeed, disruption of T cell activation can be achieved by inhibiting actin polymerization 
(61-64). 
Lipid rafts in the plasma membrane are thought to be critical in CD4+ T cell 
activation, where the interaction between Ag:MHCII and TCR on the surface of the 
antigen presenting cell (APC) and the T cell, respectively, results in the major 
reorganization of the mesoscale lipid rafts and signaling proteins, forming the 
immunological synapse (IS) (60, 65, 66).  The reconfiguration of lipid rafts to form the 
IS involves changes to lipid-lipid interactions in the membranes; specifically, liquid 
ordered (Lo) lipids such as cholesterol and sphingolipids accumulate at the IS (67-69).  
The involvement of lipid rafts in CD4+ T cell activation is conclusive; disruption of lipid 
rafts with various agents such as methyl-β-cyclodextrin (70), 7-ketocholesterol (71), or 
n-3 PUFA such as EPA (discussed below, 67) resulted in suppressed T cell activation. 
1.3.2 Role of lipid rafts in CD4+ T cell differentiation 
Activated CD4+ T cells differentiate into the pro-inflammatory effector subsets in 
the presence of the cytokines in the microenvironment such as interferon-γ (IFN-γ) and 
interleukin-12 (IL-12) for TH1 CD4+ T cells, and Tumor growth factor-β (TGFβ), 
interleukin-6 (IL-6), and interleukin 21 (IL-21) for TH17 CD4+ T cells (72).  The role of 
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 the plasma membrane, however, in directing the differentiation of CD4+ T cells is 
underappreciated.   
 Early reports suggest that different effector CD4+ T cell populations have distinct 
plasma membrane characteristics, and utilize these distinct membrane properties.  For 
example, treatment of T cells with methyl-β-cyclodextrin as a proxy for lipid raft 
dependence, demonstrated that TH1, but not TH2, CD4+ T cells were more sensitive to 
disturbance in lipid rafts as detected by suppressed Ca2+ influx upon antigen stimulation 
(73).  Indeed, later studies demonstrated that TH1 and TH2 CD4+ T cells have distinct IS.  
The TH1 CD4+ T cell IS is characterized by the bull’s eye IS where the cSMAC, 
comprised of Ag:MHCII/TCR interactions, is surrounded by the pSMAC populated with 
adhesion molecules.  Meanwhile, TH2 CD4+ T cell IS is described as multifocal and 
dependent on the concentration of antigens (74).  Furthermore, individual human CD4+ 
T cell can be categorized into three classes based on the lipid order of its plasma 
membrane (low, intermediate, and high), as determined by the generalized polarization 
of di-4-ANEPPDHQ, a probe that changes fluorescence intensities at 570 nm and 620 
nm based on the lipid order of its surrounding microenvironment upon incorporation into 
the plasma membrane (75).  CD4+ T cells with intermediate membrane order were 
associated with IFN-γ production (i.e. TH1 phenotype), while high membrane order was 
associated with IL-4 production (i.e. TH2 phenotype); low membrane order CD4+ T cells 
were associated with increased apoptosis.  When CD4+ T cells were cultured in either 
TH1 or TH2-polarizing conditions, the membrane order of the CD4+ T cells changed to 
the corresponding T cell subset; intermediate membrane order was observed under TH1 
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 condition, while high membrane order was seen under TH2 condition.  To further link the 
role of membrane order with CD4+ T cell differentiation, the reduction of membrane 
order with 7-ketoxycholesterol resulted in an increase in the number of CD4+ T cell 
producing IFN-γ, indicative of a switch to an intermediate membrane order, associated 
with TH1 phenotype.  Clinically, CD4+ T cells isolated from human patients with 
systemic lupus erythematosus, Sjogrens Syndrome, or rheumatoid arthritis have an 
increased population of intermediate membrane order CD4+ T cells, associated with 
IFN-γ production and pro-inflammatory phenotype (75, 76).  TH17 CD4+ T cells are also 
known to be affected by membrane order.  By lowering glycosphingolipid, a lipid known 
to be associated with lipid rafts, in CD4+ T cells, resulted in decreased TH17 
differentiation (77).  These studies demonstrate the structural importance of membrane 
mesoscale domains in directing CD4+ T cell differentiation. 
1.4 n-3 polyunsaturated fatty acids 
Very long chain n-3 polyunsaturated fatty acids (n-3 PUFA) such as 
eicosapentaenoic acid (EPA, 20:5∆5,8,11,14,17) and docosahexaenoic acid (DHA, 
22:6∆4,7,10,13,16,19) are thought to be the major bioactive components of fish oil, the 
commercial value of which is predicted to reach $1.7 billion dollars globally in 2018 
according to the Transparency Market Research (Albany, N.Y.).  EPA and DHA are 
incorporated into the two major classes of phospholipids in the plasma membrane, 
phosphatidylenthanolamine and phosphatidylcholine at the sn-2 position (68, 78), 
consistent with the observation that saturated fatty acids occupy the sn-1 position of 
phospholipids, while unsaturated fatty acids are inserted at the sn-2 position.  Studies on 
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 DHA, with 22 carbons and 6 double bonds, demonstrate that DHA is highly disordered 
and adopts various conformations on the subnanosecond time scale (79, 80).  By 
eliminating the double bond at the n-3 position to generate docosapentaenoyl acid (DPA, 
22:5∆4,7,10,13,16), chain dynamics of the fatty acid are reduced (79), suggesting that the 
unsaturation at the n-3 position affords unique properties to EPA and DHA in the plasma 
membrane. 
1.4.1 Biophysical properties of n-3 polyunsaturated fatty acids 
Studies on ion channels have demonstrated that n-3 PUFA such as EPA and 
DHA can modulate membrane protein properties.  The incorporation of docosahexaenoic 
acid into the lipid bilayer resulted in a decrease in bilayer stiffness without changing the 
negative curvature of the bilayer (81).  Functionally, DHA increased the appearance and 
lifetime of gramicidin channels, and decreased the free energy for channel formation; the 
fatty acid oleic acid (OA, 18:1∆9) that intercalated into the plasma membrane at a greater 
rate, had no effect on gramicidin channel formation, suggesting that the effect of DHA 
was due to changes in bilayer properties, and not due to specific binding (81, 82).  Other 
channels that are modulated by EPA and DHA include inhibiting cardiac Na+ and L-type 
Ca2+ channels (83, 84), activating TRAAK-1 and TRPV1 channels (85, 86), and 
increasing desensitization of nAChR and GABAa channels (87, 88). 
1.4.2 n-3 polyunsaturated fatty acids alter the biophysical properties of lipid rafts in the 
plasma membrane 
In the context of plasma membrane lipid rafts, DHA is thought to play a major 
role in altering the size and/or stability of these mesoscale lipid rafts.  As a result of the 
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 highly disordered nature of DHA, one proposed mechanism by which DHA modifies the 
lateral organization of the plasma membrane is by forming a distinct non-raft DHA 
domain (89, 90).  This DHA domain is distinct from the sphingolipid and cholesterol 
enriched lipid rafts due to the highly flexible DHA, which is incompatible with the 
rigidity of sphingolipids and cholesterol.  Incorporation of DHA into the plasma 
membrane results in the distinct non-raft DHA domain inserting itself into lipid rafts, 
increasing the size of lipid rafts.  This mechanism would explain findings using nuclear 
magnetic resonance (NMR) indicating that both EPA and DHA are incorporated into raft 
and non-raft domains in a phosphatidylethanolamine/sphingomeylin/cholesterol 
membrane mixture (91).  Similar results have also been observed in vivo by analyzing 
phospholipids of CD4+ T cells after isolating the detergent-resistant and –soluble 
membrane fractions (68, 78). 
An alternative mechanism proposed to explain the effects of n-3 PUFA on lipid 
raft organization comes from the fact that the flexibility of n-3 PUFA is incompatible 
with the rigid cholesterol, paradoxically promoting the aggregation of cholesterol in the 
plasma membrane, resulting in the coalescence of sphingolipid and cholesterol lipid rafts 
from the bulk membrane (92).  Indeed, it has been shown that n-3 PUFA such as EPA 
and DHA can increase the size of lipid rafts in HEK cells, CD4+ T cells, and B cells (93-
95). 
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 1.4.3 Additional biochemical mechanisms by which n-3 polyunsaturated fatty acids 
modulate cell function 
 In addition to the effects of n-3 PUFA on the plasma membrane, n-3 PUFA can 
further exert biological effects by regulating i) eicosanoid metabolism; ii) nuclear 
transcription factor activation; and iii) activation of G-protein coupled receptors.   
Eicosanoids are lipid compounds that act in an autocrine or paracrine fashion that 
can regulate immune response.  Arachidonic acid–derived (AA, 20:4∆5,8,11,14) eicosanoids 
such as prostaglandin E2 are thought to be pro-inflammatory due to their ability to 
promote CD4+ TH1 and TH17 inflammatory subsets (96-99).  Indeed, patients with 
chronic inflammatory diseases such as Crohn’s disease and ulcerative colitis have 
increased levels of AA-derived eicosanoids (100-105).  The presence of EPA and DHA 
in the plasma membrane, however, can impact the levels of AA-derived eicosanoids by 
first depleting the cell of AA (106), and second by competing for the same enzymes to 
synthesize alternative ligands (i.e., prostaglandin E3) that are less potent for signal 
transduction (107, 108).  The recently discovered non-classical eicosanoids such as 
resolvins and protectins derived from EPA and DHA have been shown to exert potent 
anti-inflammatory effects on a physiological level, demonstrating another mechanism by 
which n-3 PUFA can exert anti-inflammatory effects by acting through eicosanoid 
metabolism (109-112). 
The best characterized nuclear receptor that is activated by n-3 PUFA is 
peroxisome proliferator-activated receptor-γ (PPARγ).  CD4+ T cells isolated from 
PPARγ knockout mice exhibited an increase in IFN-γ secretion and lymphoproliferation 
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 upon activation.  In addition, the differentiation of anti-inflammatory Treg cells was also 
suppressed in PPARγ-null CD4+ T cells, demonstrating that activation of PPARγ can 
exert anti-inflammatory effects.  The crystal structure of PPARγ in complex with 4-
oxodocosahexaenoic acid was solved, and shown to be a potent activator of PPARγ 
(113).  The non-oxidized versions of n-3 PUFA themselves have been shown to activate 
PPARγ, but at a micromolar range (114, 115).  In the young adult mouse colonocyte 
model, DHA was shown to modulate the transactivation of retinoid X receptor-α 
(RXRα), highlighting the likelihood that other nuclear receptors are also activated by n-
3 PUFA (116).  
Similar to the mechanism by which n-3 PUFA can act as a ligand itself to 
activate nuclear receptors, only recently has a G-protein coupled receptor been identified 
for DHA, GPR120 (117).  With sub-micromolar potency, DHA can exert anti-
inflammatory effects by activating GPR120 expressed on the surface of macrophages 
and adipoctyes and alter the gene expression profiles favoring a reduction in 
inflammation (118).  Additionally, DHA can activate GPR120 in macrophages to 
attenuate NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome 
activation to prevent metabolic disorder caused by high fat diet (119).  Not all beneficial 
effects of n-3 PUFA are mediated through GPR120, as n-3 PUFA suppressed obesity 
induced-tumor progression in breast cancer model independent of GPR120, highlighting 
the pleotropic properties of n-3 PUFA. 
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 1.5 Effects of n-3 polyunsaturated fatty acids on CD4+ T cells 
 n-3 PUFA have been shown in many clinical studies to attenuate human 
inflammatory responses (120-125).  Although inflammatory responses are orchestrated 
by a wide spectrum of cells, CD4+ T cells play an important role in the etiology of many 
chronic inflammatory diseases, such as inflammatory bowel disease (54, 126-128), and 
obesity (129-131).  In light of recent concerns over the safety profiles of non-steroidal 
anti-inflammatory drugs (NSAIDs), alternatives such as bioactive nutraceuticals are 
becoming more attractive for the use in medical treatments (132). 
In terms of T cell activation, lipid rafts coalesce to form the IS.  Importantly, an 
alteration in the size of rafts can impact IS formation, and thus regulate T cell activation 
(67, 71).  Studies using the immortalized Jurkat T cell line demonstrated that n-3 PUFA 
displaced many of the signaling proteins necessary for T cell activation, including the 
Src family kinases Lck and Fyn from detergent-resistant membrane fractions (133), and 
LAT (134).  Additional studies demonstrated that the recruitment and activation of 
signaling proteins such as PKCθ, LAT, Fas, PLC-γ1, and F-actin were also altered (78, 
94).  n-3 PUFA, however, did not universally inhibit protein localization; Ly et al. 
observed an enhancement of surface CTLA-4 expression, a negative regulator of T cell 
activation, in CD4+ T cells isolated from mice fed an EPA-enriched diet (135).  It is now 
appreciated that n-3 PUFA broadly suppress downstream activation signaling, including 
mitochondrial translocation (136), IL-2 secretion (78, 135, 137-140), and 
lymphoproliferation (94, 138, 141). 
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 Similar to the dual roles in which lipid rafts play in CD4+ T cell activation and 
differentiation, n-3 PUFA not only suppress CD4+ T cell activation, but also specific 
CD4+ T cell differentiation.  Early studies examining activation-induced cell death 
(AICD) demonstrated that only TH1-like CD4+ T cells exhibited enhanced AICD upon 
enrichment with n-3 PUFA (142, 143).  In addition, CD4+ T cells enriched with n-3 
PUFA failed to polarize into TH1 or TH17 cells as efficiently when compared to control 
CD4+ T cells (144-146).  One mechanistic possibility by which n-3 PUFA suppress 
CD4+ T cell polarization into TH17 CD4+ T cells was recently explored.  Allen and 
colleagues demonstrated the presence of a membrane-targeted alteration in the 
IL6/gp130/Stat3 pathway (147), corroborating the membrane-specific effects of n-3 
PUFA on CD4+ T cell activation and differentiation. 
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 CHAPTER II  
n-3 POLYUNSATURATED FATTY ACIDS SUPPRESS 
PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE DEPENDENT ACTIN 
REMODELING DURING CD4+ T CELL ACTIVATION* 
2.1 Introduction 
One role that the actin cytoskeleton plays is in stabilizing the IS for sustained T 
cell activation (58-60).  The role of actin remodeling is also observed in human disease; 
for example, Wiskott-Aldrich syndrome, characterized partly by deficient T cell 
activation (148), is attributed to mutations in the gene encoding the Wiskott-Aldrich 
syndrome protein (WASP), which regulates de novo nucleation of actin filaments (149).  
Additionally, to emphasize the importance of the actin cytoskeleton to T cell activation, 
many actin regulating proteins such as ERM proteins, talin, WAVE, and ADF/cofilin, 
are known to be localized at the IS (59, 150-152).  Thus, one mechanism by which n-3 
PUFA could suppress CD4+ T cell activation is through inhibition of F-actin remodeling.  
Indeed, Kim et al. has previous demonstrated that the number of CD4+ T cells with F-
actin localizing to the IS was decreased when T cells were enriched with n-3 PUFA (94).   
Many of the aforementioned actin remodeling proteins, including WASP, are 
regulated by PI(4,5)P2 (23). Both the magnitude and the kinetics of PI(4,5)P2 metabolism 
*This research was originally published in Biochemical Journal.  Hou TY, Monk JM, Fan YY, Barhoumi R, Chen 
YQ, Rivera GM, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress phosphatidylinositol 4,5-
bisphosphate-dependent actin remodelling during CD4+ T-cell activation. Biochem J. (2012); 443(1): 27-37.  © the 
Biochemical Society.  Reprinted with permission from Biochemical Society. 
*FADS-1 research was originally published in Journal of Lipid Research.  Fan YY, Monk JM, Hou TY, Callway E, 
Vincent L, Weeks B, Yang P, Chapkin RS. Characterization of an arachidonic acid-deficient (Fads1 knockout) mouse 
model. J Lipid Res. (2012); 53(7): 1287-95.  © the American Society for Biochemistry and Molecular Biology.  
Reprinted with permission from American Society for Biochemistry and Molecular Biology. 
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 are important in actin remodeling, as demonstrated during i) macrophage phagocytosis 
(153); ii) release of ERM proteins from the plasma membrane of T cells after chemokine 
stimulation (154); and iii) release and activation of cofilin in carcinoma cells upon EGF 
stimulation (155).  Since PI(4,5)P2 colocalizes in raft domains in T cells (39), and n-3 
PUFA such as DHA can increase the size of lipid rafts (93), we tested the hypothesis that 
PI(4,5)P2 is perturbed by the presence of n-3 PUFA, leading to a suppression of 
downstream actin remodeling. 
2.2 Materials and methods 
2.2.1 Animals and CD4+ T cell isolation 
All animal protocols have been approved by the Institutional Animal Care and 
Use Committee at Texas A&M University and follow guidelines approved by the U.S. 
Public Health Service.  The generation, genotyping, and phenotyping of Fat-1 and 
FADS-1 transgenic mice on a C57BL/6 background have been described previously 
[APPENDIX A; (78, 94, 116, 136)].  Mice were fed a 10% safflower diet enriched in n-
6 PUFA (Research Diets, New Brunswick NJ), provided ad libitum in a 12:12 light:dark 
cycle.   
In the diet experiment, 4 to 6 weeks old C57BL/6 mice were fed either an n-6 
PUFA enriched 5% corn oil diet or a 4% DHA (n-3 PUFA) triglyceride-enriched diet.  
Diets differed only in their oil composition, either (control) 5% corn oil by weight or a 
mixture of 57% pure DHA triglyceride (Martek, Columbia, MD) and corn oil (4:1 w/w).  
Additional diet components, expressed as g/100 g, were 20 casein, 41.9 sucrose, 22 corn 
starch, 6 cellulose, 3.5 AIN-76 mineral mix, 1 AIN-76 vitamin mix, 0.3 DL-methionine, 
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 0.2 choline chloride, and 5 dietary oil (68, 78, 142).  Mice were fed ad libitum for 3 to 4 
weeks in a 12:12 light:dark cycle and diet changed daily to prevent the formation of 
oxidative byproducts.     
Spleens were removed aseptically and CD4+ T cells were isolated by positive 
selection using magnetic CD4 (L3T4) microbeads according to manufacturer’s protocol 
(APPENDIX B; Miltenyi Biotec, Auburn, CA).  CD4+ T cells were resuspended in 
complete RPMI media composed of 93% RPMI (contains 25 mM HEPES, Irvine 
Scientific, Santa Ana, CA), 5% heat-inactivated fetal bovine serum (Irvine Scientific), 
1% glutamax (Gibco, Carlsbad, CA), and 1% penicillin-streptomycin (Gibco), 
henceforth referred to as “complete media”, at assay-specific concentrations (5 x 105 
cells/mL for basal PI(4,5)P2 measurements using a PI(4,5)P2 mass kit from Echelon 
Biosciences (Salt Lake City, UT),  5 x 105 cells/100 μL for T cell activation, 3 x 106 
cells/mL for immunofluorescence, 1.5 x 107 cells/250 μL for immunoisolation). 
2.2.2 CD4+ T cell stimulation time course 
Ninety-six well flat-bottom plates containing plate bound anti-CD3 (0.2 μg/mL, 
eBiosciences, San Diego, CA) and anti-CD28 (1 μg/mL, eBiosciences) were incubated 
overnight at 4 °C.  The wells were washed with PBS and replaced with 200 μL of 
complete RPMI media.  The plates were then placed in 37 °C, 5% CO2 incubator for at 
least one h before seeding CD4+ T cells (156).  For PMA/ionomycin stimulation, 0.5  
μg/mL PMA (Sigma, St Louis, MO) and 500 nM ionomycin (EMD Chemicals, 
Gibbstown, NJ) in complete media were added into each well and incubated at 37 °C, 
5% CO2, for at least one h before seeding T cells (94).  CD4+ T cells were seeded into 
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 each well, stimulated for specified times (0 to 30 min), and then transferred into a low-
retention 1.5 mL microcentrifuge tubes and immediately placed on ice to quench cell 
activation.  CD4+ T cells were centrifuged at 4 °C, 4000g for 5 min, and washed in cold 
PBS before lipid extraction. 
2.2.3 Extraction of PI(4,5)P2 for detection using PI(4,5)P2 mass kit or anti-PI(4,5)P2 
ELISA 
Extraction of PI(4,5)P2 has been previously described, with some modifications 
[APPENDIX C; (157)].  Briefly, after washing with cold PBS, the cells were pelleted at 
4000 g, 5 min at 4 °C (described above), supernatant was removed and the pellet was 
resuspended in 800 μL of 1:1 MeOH:CHCl3.  The mixture was vortexed for 1 min, and 
centrifuged at 7500 g, 5 min at 4 °C.  The supernatant was removed, and the pellet was 
resuspended in 400 μL of 80:40:0.3 MeOH:CHCl3:HCl.  The mixture was vortexed for 5 
min and subsequently centrifuged at 3000 g for 1 min at 4 °C.  An additional 80 μL of 1 
N HCl was added to the extract and vortexed for 15 sec before centrifugation at 18000 g 
for 15 sec at 4 °C.  The organic layer was collected and dried under a stream of N2 gas.  
The lipid film was dissolved in PBS supplemented with 0.0025% of protein stabilizer 
(Echelone Biosciences, Salt Lake City, UT) and used for detection of PI(4,5)P2. 
2.2.4 Detection of PI(4,5)P2 
For basal level PI(4,5)P2 detection, the PI(4,5)P2 mass kit (Echelon Biosciences) 
was used according to the manufacturer’s protocol.  Briefly, the mass kit utilizes a 
PI(4,5)P2 protein detector that is added to a PI(4,5)P2-coated strip for competitive 
binding.  The colorimetric signal is inversely proportional to the amount of PI(4,5)P2.  
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 For determination of the CD4+ T cell stimulation time course, an indirect ELISA 
was developed to detect the level of PI(4,5)P2 (APPENDIX D).  PI(4,5)P2 dissolved in 
PBS supplemented with 0.0025% protein stabilizer was added in duplicate into 96-well 
flat bottom plates and incubated at room temperature for 2 h.  The wells were then 
washed with PBS 3X, and then blocked in 5% BSA in PBS overnight at 4 °C.  The wells 
were again washed with PBS 3X, and incubated with primary mouse anti-PI(4,5)P2 
(Abcam, Cambridge, MA) in blocking solution at a dilution of 1:2500 for 1.5 h at room 
temperature.  The wells were washed with PBS and incubated with secondary goat anti-
mouse IgG labeled with horseradish peroxidase (KPL, Gaithersburg, MD) in blocking 
solution at a dilution of 1:5000 for one h at room temperature, protected from light.  The 
wells were washed with PBS four times, and incubated in TMB high sensitivity substrate 
solution (BioLegend, San Diego, CA) for 5 min at room temperature, protected from 
light.  The reaction was stopped by the addition of 1 N H2SO4, and the absorbance was 
read at 450 nm.  A standard curve was generated with known concentrations of PI(4,5)P2 
(Echelon Biosciences), and was used to quantify the PI(4,5)P2 levels.  To test the cross-
reactivity of the primary antibody, 50 pmol of PI(4)P (Avanti, Alabaster, AL) and 
PI(3,4,5)P3 (Avanti) were dissolved in PBS supplemented with 0.0025% protein 
stabilizer, and  added into separate wells and subjected to the same ELISA protocol as 
described.  No detectable signals were observed. 
2.2.5 Extraction and detection of PI(4,5)P2 using mass spectrometry 
Purified splenic CD4+ T cells were isolated and washed as described above.  For 
mass spectrometry, cells from two animals were pooled to increase detection of 
30 
 
 PI(4,5)P2.  After washing, purified splenic CD4+ T cells were dissolved in a solvent 
composed of CHCl3:MeOH:H2O  (32.6:65.3:2.1 v/v/v) and extracted as described 
previously (158).  Dipalmitoyl phosphatidylinositol-4,5-bisphosphate (200 ng) was 
added into each sample as an internal standard prior to extraction.  Lipid extracts were 
evaporated under argon gas and redissolved in 50 µL of  CHCl3:MeOH:H2O  (5:5:1 
v/v/v) and analyzed by LC-MS/MS.  Mass spectrometry (Thermo TSQ Quantum 
Discovery Max) operated in the negative ion mode was optimized to detect 
phosphoinositides as [M-H]- ions.  Using the peak areas, the mass of individual 
phosphoinositides was estimated and corrected by using the internal standard.  Samples 
were normalized to cell number as determined using a Coulter Counter (Beckman 
Coulter, Brea, CA). 
2.2.6 Immunofluorescence 
Immunofluorescence was conducted as previously described [APPENDIX E; 
(78, 94)].  Briefly, 4.0 cm2 per well chamber cover slides (Nalge, Rochester, NY) were 
pre-coated with 0.01% poly-L-lysine (Sigma) for 30 min.  The solution was removed 
and the slides were allowed to air dry for one h at room temperature.  For T cell 
stimulation, chamber cover slides were additionally coated with anti-CD3 and anti-CD28 
at a concentration of 1 μg/mL and 5 μg/mL, respectively.  The unstimulated (control) 
slides were incubated with PBS overnight.  Following CD4+ T cells isolation, 3 x 106 
cells in complete RPMI media were seeded into chamber slides and incubated for 30 min 
at 37 °C, 5% CO2.  For bead stimulation, 3 x 106 CD4+ T cells were incubated in the 
presence of Dynabeads Mouse T-activator CD3/CD28 (APPENDIX F; Invitrogen, 
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 Carisbad, CA) at a 1:1 ratio for 30 min, at 37 ºC, 5% CO2.  For exogenous PI(4,5)P2 
rescue experiment, 3 x 106 Fat-1 CD4+ T cells were incubated in the presence of  
exogenous PI(4,5)P2 at specific concentrations (Echelon Biosciences) for one h, at 37 
°C, 5% CO2, washed one time with warm PBS before stimulation as described above 
using plated anti-CD3/anti-CD28. 
  Cells were washed with PBS 3X and immediately fixed in 4% paraformaldehyde 
for 20 min at room temperature.  The chamber slides were washed with PBS, and 
incubated in 10 mM glycine for 10 min at room temperature, followed by 
permeabilization using 0.2% Triton X-100 for 5 min at room temperature.  The chamber 
slides were subsequently washed with PBS, followed by overnight incubation at 4 °C in 
a humid chamber with blocking solution (1% IgG-free BSA, 0.1% NaN3, 99% PBS).  
The slides were washed with PBS before the addition of 200 μL of 20 U/mL Alexa 568 
conjugated phalloidin (Invitrogen) and incubated for one h in a humid chamber at room 
temperature, and then washed with PBS 3X, and incubated in 70% ethanol, 95% ethanol, 
100% ethanol, and fresh xylene, for 2 min each.  ProLong antifade medium (Invitrogen) 
was applied to each coverglass, and the slides were allowed to dry in the dark overnight 
at room temperature.  Slides were sealed with fingernail polish before examination under 
microscopy.  
For bead-stimulated samples, slides were fixed, washed, treated, and blocked 
overnight as described above.  Two-hundred µL of 20 U/mL Alexa 568 conjugated 
phalloidin and 4 µg/mL rabbit anti-WASP (Santa Cruz, Santa Cruz, CA) was applied to 
slides for one h in a humid chamber at room temperature before the slides were washed 
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 with PBS twice.  The addition of 6 µg/mL of goat anti-rabbit Alexa 647 (Invitrogen) to 
slides for one h in a humid chamber at room temperature preceded washes and treatment 
as described above. 
2.2.7 Immunoisolation 
Immunoaisolation was conducted as previously described with minor 
modifications [APPENDIX G; (159)].  1.5 x 107 CD4+ T cells were incubated with anti-
CD3/anti-CD28 coated Dynabeads (Invitrogen) at a cell-to-bead ratio of 2:1 on ice for 7 
min before stimulation at 37 °C for 30 min.  Samples were then subjected to nitrogen 
cavitation at 800 psi for 7 min, transferred to 1.5 mL microcentrifuge tubes, and washed 
3X with 1 mL of complete homogenization buffer. Input samples (100 μL) were assayed 
prior to magnetic bead collection to determine the yield of the cavitation using Western 
blotting.  Samples (12 μL) were analyzed using immunoblotting.  
CD4+ T cells were homogenized in ice-cold homogenization buffer composed of 
50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM NaF, 
100 mM NaVO4, 1% Triton X-100, 40 µL/mL protease cocktail, and 10 mM β-
mercaptoethanol, passed through a 27-guage needle twice, incubated on ice for 30 min, 
and centrifuged at 16000 g for 20 min.  The supernatant was collected and protein 
concentration determined by Commassie Plus Protein assay (Pierce, Rockford, IL).  
Twenty-five µg of protein was treated with pyronin sample buffer and loaded on a 4-
20% Tris-glycine polyacrylamide precast gels (Invitrogen) and separated for 1 h at 4 ºC.  
Proteins were then transferred onto a polyvinylidene fluoride membrane at 400 mA for 
90 min.  Membranes were blocked at room temperature for 1 h in 4% nonfat dry milk.  
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 Primary antibodies (Rabbit anti-WASP, Santa Cruz; mouse anti-β-actin, Sigma) were 
incubated overnight at 4 ºC.  Membranes were subsequently washed and incubated with 
secondary horseradish peroxidase conjugated goat anti-rabbit IgG or horseradish 
peroxidase conjugated human anti-mouse IgG (KPL) and developed using Pierce 
SuperSignal West Femto maximum sensitivity substrate.  Membranes were then scanned 
using Fluor-S Max MultiImager system (BioRad, Hercules, CA) and analyzed using 
QuantityOne (BioRad).  Enrichment factor was calculated by dividing the intensity of 
the band in the IS by the intensity of the band in the input for WASP. 
2.2.8 Microscopy and image processing 
Slides were examined using a Zeiss 510 META NLO laser scanning microscope 
equipped with argon laser, LSD software and a 63X objective.  Images were exported 
into TIFF format using AxioVision LE 4.8 and imported into NIS-Elements AR 3.10 
(Nikon, Melville, NY).  To correct for background, a rectangular region of interest (ROI) 
was drawn in an area without any cells.  This area was used to subtract the background 
from the image.  ROIs were then drawn around cells that were not in contact with other 
cells, and the mean intensity was recorded.  This value was then divided by the number 
of cells in the field measured to obtain the average mean intensity per cell. 
For bead-stimulated samples, slides were examined using a Nikon Ti-E inverted 
microscope equipped with X-cite 120 fluorescent microscopy illuminator and 60X 
objective, with 1.5 magnification.  Images were captured using a Photometrics Cool-
SNAP EZ CCD camera and analyzed in NIS-Elements AR.  2D Fast deconvolution was 
applied to all captured images.  An ROI was drawn around the cell excluding the beads, 
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 and the total intensity was recorded.  This value was divided by the area of the cell to 
obtain the average mean intensity per square micron.  For the IS, the ROI was drawn as 
an oval at the T cell proximal to the bead as previously described (94).  The total 
intensity was recorded and divided by the area of the IS.  There were no differences 
between the size of the cell or the IS between genotypes (data not shown); furthermore, 
the area of the IS was approximately 10% ± 5% of the whole cell in both genotypes (data 
not shown). 
2.2.9 Chemotaxis assay 
 After CD4+ T cell isolation, chemotaxis assay was performed as previously 
described (160).  Briefly, cells were resuspended to a final concentration of 1 x 106/100 
μL RPMI media with 0.5% (w/v) fatty acid-free BSA (Roche Diagnostics).  100 μL of 
the cell suspension was seeded into a 3.0 μm pore size, 6.5 mm diameter, transwell 
(Sigma), which was then carefully placed into a 15.6 mm well (24 well plate) containing 
600 μL of RPMI media with 0.5% (w/v) fatty acid-free BSA supplemented with 0.25 
μg/mL of CCL19 (R&D Systems, Minneapolis, MN).  The plate was then incubated for 
4 h, at 37 °C.  Cells from the lower chamber was collected and counted using a Coulter 
counter.  % migration was calculated by dividing the number of cells collected from the 
lower chamber to the total number of cells seeded.  The assay was repeated in triplicates.  
2.2.10 Statistical analysis 
Data were expressed as mean ± SEM unless otherwise noted and analyzed using 
SAS 9.2 for Windows.  The time course was tested by two-way ANOVA (main effects: 
genotype and time).  In cases where the interaction between genotype and time was 
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 insignificant, an LSD post-hoc test was conducted.  In the cases where the interactions 
between genotype x time were significant, a Tukey post-hoc test was conducted.  
Differences between genotypes in single treatment were analyzed by two-tailed 
Student’s t-test.   P < 0.05 was considered to be statistically significant. 
2.3 Results 
2.3.1 Basal PI(4,5)P2 concentration is reduced in Fat-1 CD4+ T cells 
Since PI(4,5)P2 is one of the key mediators of actin remodeling, we determined 
whether the level of PI(4,5)P2 is perturbed in Fat-1 CD4+ T cells.  Total lipid analysis 
revealed enrichment of n-3 PUFA in Fat-1 CD4+ T cells as compared to wild type 
(Figure 2.1).  In addition, we have previously shown that dietary n-3 PUFA were readily 
incorporated into the plasma membrane of splenic CD4+ T cells (68, 78).  We first used 
mass spectrometry to determine both total PI(4,5)P2 mass and the acyl species of 
PI(4,5)P2 present in purified splenic CD4+ T cells isolated from wild type and Fat-1 
mice.  Total PI(4,5)P2 in purified Fat-1 splenic CD4+ T cells was decreased by 50% 
compared to wild type (P = 0.04, Figure 2.2).  In addition, there were significant 
decreases in the 18:0,20:4 species (P = 0.02), and an increase in the 18:1,20:4 species of 
PI(4,5)P2 (P = 0.04) in Fat-1 splenic CD4+ T cells (Figure 2.2).  Using two additional 
methods (PI(4,5)P2 mass kit, and indirect anti-PI(4,5)P2 ELISA), we further validated 
our observations, demonstrating a decrease in the total PI(4,5)P2 content in Fat-1 splenic 
CD4+ T cells (Figure 2.3). 
Examination of PIP molecular species revealed a decrease only in the 16:0,20:4 
species  (P = 0.03, Figure 2.3).  There were no effects on the 18:0,20:4 (P = 0.09) 
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 18:1,20:4 PIP (P = 0.53), or the minor species of PIP (P = 0.32) between wild type and 
Fat-1 CD4+ T cells (Figure 2.3).  Furthermore, the total PIP level was not significantly 
different between genotypes (P = 0.17).  Taken together, these results demonstrate that 
the basal PI(4,5)P2 concentration is decreased in purified splenic CD4+ T cells isolated 
from Fat-1 mice. 
 
 
Figure 2.1.  Splenic CD4+ T cell total lipid fatty acid composition for A) Saturated and monounsaturated fatty acids; B) n-6 PUFA; 
C) n-3 PUFA; and D) n-3 vs n-6 PUFA.  Isolated cells were extracted from wild type (WT) and Fat-1 mice fed a 10% safflower diet, 
or wild type animals fed a 5% corn oil diet (5% CO) or 4% DHA triglyceride-enriched diet plus 1% corn oil diet (4% DHA).  Fatty 
acid composition was analyzed by gas chromatography/mass spectrometry after extraction as previously described (94, 141).  Values 
are expressed as moles of individual fatty acids divided by moles of total fatty acids (mol%), n=3 mice per treatment.  Different 
letters denote a significant difference of P < 0.05. 
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Figure 2.2.  Total PI(4,5)P2 is decreased in Fat-1 CD4+ T cells.  A)  Relative PI(4,5)P2 was decreased by 50% in Fat-1 CD4+ T cells.  
CD4+ T cells were isolated from wild type and Fat-1 spleens (n = 8 for Fat-1; 12 for wild type).  CD4+ T cell populations from two 
spleens were pooled for analysis using mass spectrometry as described in the Methods.  Total PI(4,5)P2 was quantified following 
comparison to an internal standard and normalized relative to total CD4+ T cells counted using a Coulter Counter.  Relative PI(4,5)P2 
levels were compared by normalizing to wild type PI(4,5)P2.  B)  PI(4,5)P2 molecular species were altered in Fat-1 CD4+ T cells.   
 
 
 
2.3.2 Metabolism of PI(4,5)P2 upon T cell activation is altered in Fat-1 CD4+ T cells 
We have previously demonstrated that Fat-1 CD4+ T cells have a suppressed activation 
status, e.g., decreased localization and phosphorylation of PLC-γ1 at the IS (94).  
Therefore, we examined the metabolism of PI(4,5)P2 upon T cell activation by anti-
CD3/anti-CD28 or PMA/ionomycin in purified splenic Fat-1 CD4+ T cells.  In both 
stimulation conditions, Fat-1 CD4+ T cells failed to respond to stimulation (Figure 2.4).  
In contrast, in wild type CD4+ T cells activated with anti-CD3/anti-CD28, the level of 
PI(4,5)P2 decreased by 50% in 5 min (P = 0.05), followed by a recovery phase of ~30 
min.  In addition, Fat-1 CD4+ T cells showed no change upon activation with anti-
CD3/anti-CD28.  Similarly, PI(4,5)P2 levels in wild type CD4+ T cells activated with 
PMA/ionomycin were decreased by 50% within 5 min of stimulation (P = 0.008).  
However, PI(4,5)P2 levels did not recover possibly due to the non-physiological (TCR-
independent) activation of the T cells.  In contrast, Fat-1 CD4+ T cells showed no 
response to PMA/ionomycin. 
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Figure 2.3.  PIP is altered in Fat-1 CD4+ T cells, and confirmation of PI(4,5)P2 in Fat-1 CD4+ T cells.  A)  Relative PIP was 
moderately altered in Fat-1 CD4+ T cells.  CD4+ T cells were isolated from wild type and Fat-1 spleens (n = 8 for Fat-1; 12 for wild 
type).  CD4+ T cell populations from two spleens were pooled for analysis using mass spectrometry as described in the Methods.  
Minor species included 40:6, 40:5, 40:4, and 42:4.  Relative PI(4,5)P2 levels in unstimulated purified splenic CD4+ T cells isolated 
from wild type and Fat-1 mice as determined by B) PI(4,5)P2 mass kit (Echelon Biosciences); and C) indirect anti-PI(4,5)P2 ELISA 
(Abcam). 
 
 
 
 
Figure 2.4 Metabolism of PI(4,5)P2 upon A) anti-CD3/anti-CD28; and B) PMA/ionomycin stimulation, is suppressed in Fat-1 CD4+ 
T cells.  Splenic CD4+ T cells were isolated from wild type and Fat-1 mice (n = 4). CD4+ T cells (5 x 105) were seeded in 96 well 
plates containing plated anti-CD3 and anti-CD28 for the indicated times.  PI(4,5)P2 was subsequently extracted using acidic organic 
solvents, dried down under N2, and dissolved in PBS containing 0.0025% protein stabilizer.  PI(4,5)P2 was detected using indirect 
anti-PI(4,5)P2 ELISA as described in the Methods.  Absolute values were determined using a standard curve, and normalized relative 
to wild type PI(4,5)P2.  A two-tailed t-test was used to compare individual times points between genotypes (* P < 0.05 between 
genotypes at specific time points). 
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 2.3.3 Actin remodeling following anti-CD3/anti-CD28 stimulation is suppressed in Fat-1 
CD4+ T cells 
 
Since we observed both a decrease in the basal concentration of PI(4,5)P2 and a 
suppression in PI(4,5)P2 metabolism, we subsequently determined whether PI(4,5)P2-
mediated actin remodeling was altered in splenic Fat-1 CD4+ T cells.  For this purpose, 
purified splenic CD4+ T cells were isolated from wild type and Fat-1 mice and 
stimulated with anti-CD3/anti-CD28 for 30 min, and actin morphology was examined 
using alexa-568 phalloidin immunofluorescence (Figure 2.5).  When compared to 
unstimulated wild type CD4+ T cells, there was a 2.5-fold increase (P < 0.05) in actin 
fluorescence intensity in anti-CD3/anti-CD28 stimulated wild type CD4+ T cells (Figure 
2.5).  In contrast, there was no difference (P > 0.05) between stimulated and 
unstimulated CD4+ T cells isolated from Fat-1 mice.  These data indicate that actin 
remodeling is defective in activated splenic CD4+ T cells isolated from Fat-1 mice. 
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Figure 2.5.  Actin remodeling upon anti-CD3/anti-CD28 stimulation is suppressed in Fat-1 CD4+ T cells.  A)  Representative alexa-
568 phalloidin immunofluorescence images of wild type and Fat-1 CD4+ T cells seeded on slides containing only poly-L-lysine 
(unstimulated) or on slides containing anti-CD3/anti-CD28 (stimulated) for 30 min.  Images were pseudo-coloured with increasing 
intensity from blue to red.  B) Quantification of actin remodeling as assessed by alexa 568-phalloidin fluorescence.  Purified splenic 
CD4+ T cells (n = 4 per genotype) were seeded, fixed, permeabilized, and labeled as described in the Methods.  Regions of interest 
(ROIs) were drawn around individual cells, and background was subtracted by drawing ROIs not occupied by cells.  Fluorescence 
values were divided by the number of cells present in each field.  Six fields were obtained per group, with each field containing 
between 3 and 7 cells.  Four independent experiments were conducted.  Different letters denote a significant difference of P < 0.05. 
 
 
 
2.3.4 WASP recruitment to the immunological synapse is suppressed in Fat-1 CD4+ T 
cells 
WASP, a well-characterized actin-regulatory protein, is known to be localized at 
the IS upon stimulation (161), and to be regulated at the plasma membrane by PI(4,5)P2 
(162).  Since PI(4,5)P2 metabolism and actin remodeling were both defective in Fat-1 
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 CD4+ T cells, we examined whether WASP recruitment to the IS was also decreased in 
stimulated Fat-1 CD4+ T cells.  Actin recruitment at the IS, as measured by fluorescence 
intensity per µm2, was decreased in Fat-1 CD4+ T cells (Figure 2.6), confirming our 
previous results ((94) and Figure 2.5).  Under unstimulated conditions, WASP levels 
were not different between wild type and Fat-1 CD4+ T cells as assessed by immunoblot 
(Figure 2.7); similarly, whole cell levels of WASP were not different between 
genotypes upon anti-CD3/anti-CD28 coated bead stimulation (Figure 2.7).  However, 
upon measuring the fluorescence intensity at the IS, there was a 2.5 fold decrease in the 
fluorescence intensity per µm2, suggesting that the recruitment of WASP to the IS in 
Fat-1 CD4+ T cells was impaired (Figure 2.6).  Colocalization between Alexa 568 (F-
actin) and Alexa 647 (WASP) at the IS as determined by Pearson’s correlation 
coefficient showed a decrease in Fat-1 CD4+ T cells (wild type = 0.45 ± 0.28 (n = 33), 
Fat-1 = 0.31 ± 0.22 (n = 35), Figure 2.7).  To further corroborate the impairment of 
WASP recruitment to the IS in Fat-1 CD4+ T cells, we isolated IS fractions using 
immunoisolation (159) to biochemically probe the level of WASP at the IS upon anti-
CD3/anti-CD28 stimulation.  Examination of the IS fraction revealed that in wild type 
CD4+ T cells, the enrichment factor between IS versus input was 1.7 ± 0.5 (n = 3) while 
the enrichment factor in Fat-1 CD4+ T cells was 0.4 ± 0.1 (n = 4) (Figure 2.6).  These 
results demonstrate that the suppressed actin remodeling in Fat-1 CD4+ T cells is 
correlated with decreased WASP recruitment to the IS upon T cell activation. 
 
 
42 
 
  
Figure 2.6. WASP localization to the IS and colocalization with actin at the IS are decreased in Fat-1 CD4+ T cells.  A) Actin 
remodeling at the IS was suppressed in Fat-1 CD4+ T cells.  Purified splenic CD4+ T cells (n = 3 per genotype) were seeded, 
stimulated with anti-CD3/anti-CD28 coated beads, fixed, permeabilized, and labeled as described in the Methods.  Regions of interest 
(ROIs) were drawn and fluorescence values divided by the area of the IS.  Ten to 15 cells were analyzed per genotype.  Three 
independent experiments were conducted.  A two-tailed t-test was used to compare between genotypes.  B) WASP recruitment to the 
IS was suppressed in Fat-1 CD4+ T cells.  Refer above for experimental details.  C) Representative immunofluorescence images of 
purified splenic CD4+ T cells isolated from wild type and Fat-1 mice.  Cells were seeded onto poly-L-lysine and stimulated with anti-
CD3/anti-CD28 coated beads.  The ROI was drawn as an oval or polygon (white dashed line) as shown in the wild type panels.  D) 
WASP recruitment to the IS as assessed by immunoisolation.  IS fractions from WT (n = 3) and Fat-1 (n = 4) mice were prepared as 
described in the Methods.  WASP (66 kDa) was probed in both the IS and input fractions.  Enrichment factor was determined by 
calculating the ratio of the band intensities from the IS divided by the input.  A two-tailed t-test was used to compare between 
genotypes.   
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Figure 2.7.  Whole cell A) actin and B) WASP levels are not different between wild type and Fat-1 CD4+ T cells as detected by 
immunofluorescence.  Purified splenic CD4+ T cells (n = 3 per genotype) were seeded, stimulated with anti-CD3/anti-CD28 coated 
beads, fixed, permeabilized, and labeled as described in the Methods.  Regions of interest (ROIs) were drawn around the whole cell, 
excluding the bead, and fluorescence values divided by the area of the ROI.  Ten to 15 cells were obtained per genotype.  Three 
independent experiments were conducted.  A two-tailed t-test was used to compare between genotypes.  C) Whole cell WASP levels 
were not different in wild type and Fat-1 CD4+ T cells as detected by immunoblotting.  Whole cell lysates were prepared and 
detected as described in Supplemental Methods.  Levels of WASP were normalized to β-actin.  A two-tailed t-test was used to 
compare between genotypes.  D) Dot plot of Pearson’s correlation coefficients at the IS between wild type and Fat-1 CD4+ T cells.  
A two-tailed t-test was used to compare between genotypes.   
 
 
 
2.3.5 Defects in actin remodeling following anti-CD3/anti-CD28 stimulation are rescued 
by incubation with exogenous PI(4,5)P2 in Fat-1 CD4+ T cells 
  Since Fat-1 CD4+ T cells exhibited decreased basal PI(4,5)P2 (Figure 2.3), we 
determined whether preincubation of Fat-1 CD4+ T cells with exogenous PI(4,5)P2 
would “rescue” the defects in actin remodeling (Figure 2.5).  Treatment of Fat-1 CD4+ 
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 T cells with exogenous PI(4,5)P2 at increasing concentrations showed a dose-dependent 
rescue of actin remodeling following stimulation with anti-CD3/anti-CD28 (Figure 2.8).  
Significantly, incubation of Fat-1 CD4+ T cells with 1.25 and 2.5 µM of exogenous 
PI(4,5)P2 restored actin remodeling to the level seen in wild type CD4+ T cells (Figure 
2.8).  These results not only demonstrate the direct role of PI(4,5)P2 in regulating actin 
remodeling upon CD4+ T cell activation, but also show that defects in Fat-1 CD4+ T cell 
actin remodeling can be rescued using exogenous PI(4,5)P2. 
 
.  
Figure 2.8.  Incubation of Fat-1 CD4+ T cells with exogenous PI(4,5)P2 can rescue defects in actin remodeling following anti-
CD3/anti-CD28 stimulation.  Fat-1 CD4+ T cells were isolated and incubated with PI(4,5)P2 at various concentrations (0.5, 1.25, 2.5 
μM) or PBS (0 μM) for one h prior to stimulation with plated anti-CD3/anti-CD28 for 30 min.  Cells were analyzed as described in 
Figure 3.  Images were pseudo-coloured with increasing intensity from blue to red.  A two-tailed t-test was used to compare 
stimulation within specific concentrations (* P < 0.05 at specific concentrations of PI(4,5)P2). 
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 2.3.6 CD4+ T cells isolated from mice fed a DHA triglyceride-enriched diet exhibit a 
phenotype similar to Fat-1 CD4+ T cells 
The effect of exogenous (dietary) DHA on PI(4,5)P2-dependent actin remodeling 
was also examined.  For this purpose, mice were fed a 4% DHA triglyceride-enriched 
diet in an attempt to mimic the phenotype observed in Fat-1 CD4+ T cells.  No 
difference was observed between the body weights of animals fed a 5% CO diet (control, 
contains no n-3 PUFA) or the 4% DHA triglyceride-enriched diet (data not shown).  
Total lipid analysis was carried out to verify that DHA was incorporated into CD4+ T 
cells (Figure 2.1).  In unstimulated CD4+ T cells, there was a 25% decrease in the  
amount of PI(4,5)P2 detected in CD4+ T cells isolated from mice fed a 4% DHA-
enriched diet (Figure 2.9A, P = 0.04) compared to control. Furthermore, there was a 
suppression of PI(4,5)P2 metabolism following anti-CD3/anti-CD28 stimulation and 
PMA/ionomycin stimulation in purified splenic CD4+ T cells from mice fed 4% DHA 
(Figure 2.9B & C, P = 0.005 and 0.01, respectively) compared to the control diet, as 
revealed by two-way ANOVA.  Interestingly, actin morphology remained unchanged in 
splenic CD4+ T cells isolated from animals fed a DHA-enriched diet, while splenic CD4+ 
T cells isolated from animals fed the control diet showed a significant increase upon 
anti-CD3/anti-CD28 stimulation (P < 0.05, Figure 2.9).  These results indicate that 
CD4+ T cells isolated from Fat-1 mice or animals fed a 4% DHA triglyceride-enriched 
diet exhibit similar phenotypes with regard to PI(4,5)P2 metabolism and actin 
remodeling. 
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Figure 2.9.  CD4+ T cells isolated from mice fed a 4% DHA triglyceride-enriched diet exhibit altered PI(4,5)P2 metabolism and actin 
remodeling upon anti-CD3/anti-CD28 stimulation.  A) Relative PI(4,5)P2 levels in unstimulated splenic CD4+ T cells isolated from 
mice fed a 5% corn oil diet (control, n = 7) or 4% DHA triglyceride-enriched (n=8) diet were determined by indirect anti-PI(4,5)P2 
ELISA as described in Methods.  Relative PI(4,5)P2 levels were compared by normalizing to wild type PI(4,5)P2.  B)  PI(4,5)P2 levels 
upon anti-CD3/anti-CD28 stimulation in CD4+ T cells isolated from mice fed a 5% CO or 4% DHA triglyceride-enriched diets.  
CD4+ T cells were seeded in 96 well plates with plate bound anti-CD3 and anti-CD28 as described in the Methods.  A two-way 
ANOVA indicated statistical significance between two diet groups (P = 0.005).  C) PI(4,5)P2 levels upon PMA/ionomycin 
stimulation in CD4+ T cells isolated from mice fed a 5% CO or 4% DHA triglyceride-enriched diet.  A two-way ANOVA indicated 
statistical significance between the diet groups (P = 0.01).    A two-tailed t-test was used to compare individual times points between 
treatment groups (* P < 0.05 at specific time points). 
 
 
 
2.3.7 Basal PI(4,5)P2 concentration is reduced in FADS-1 null CD4+ T cells 
Since the acyl backbone is predominantly the stearate (C18:0) at the sn-1, and 
arachidonate (C20:4∆5,8,11,14) at the sn-2 position, we wanted to examine whether the 
depletion of arachidonic acid affects the PI(4,5)P2 concentration in CD4+ T cells.  To 
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 test the hypothesis that depleting arachidonic acid would decrease PI(4,5)P2, we isolated 
CD4+ T cells from FADS-1 null mice, in which the enzyme responsible for desaturating 
the n-6 carbon (delta-5 desaturase) is deleted.  Using an indirect ELISA method, we 
show that the basal level of PI(4,5)P2 is decreased by approximately 24% in the FADS-1 
null CD4+ T cells (Figure 2.10).   
 
 
Figure 2.10.  Level of PI(4,5)P2 in FADS-1 knockout mouse CD4+ T cells is decreased.  Splenic CD4+ T cells were isolated and 
PI(4,5)P2 was quantified using an indirect ELISA method.  Data were normalized to wild type level (n = 4 – 6 per genotype, mean ± 
sem).  Values not sharing the same letter indicate significant differences using one way ANOVA. 
 
 
 
2.3.8 n-3 PUFA do not inhibit chemotactic response to CCL19 in CD4+ T cells 
 We reasoned that since n-3 PUFA perturbed PI(4,5)P2-dependent actin 
remodeling in CD4+ T cells by n-3 PUFA, additional cellular processes that require actin 
remodeling, such as chemotaxis, would also be affected.  To test this hypothesis, we 
determined the chemotactic response of wild type and Fat-1 CD4+ T cells to the 
chemokine CCL19 (Figure 2.11), which is an important chemokine to attract naïve 
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 CD4+ T cells (160).  Based on the results, although n-3 PUFA suppressed PI(4,5)P2-
dependent actin remodeling, n-3 PUFA had no effect on chemokine-induced actin 
remodeling, as assessed by the chemotactic ability of CD4+ T cells to migrate towards 
CCL19. 
 
 
Figure 2.11.  Migration of CD4
+
 T cells in response to CCL19 is not affected by n-3 PUFA.  A)  In vitro chemotaxis assay set-up.  
B)  Splenic CD4+ T cells were isolated from wild type and Fat-1 mice and assayed for their chemotactic response to CCL19 (0.25 
µg/mL, naïve T cells).  % migration was determined by dividing the number of cells collected from the lower chamber to the total 
number of cells seeded.  Experiments were performed in triplicates with n = 5.  Values represent mean ± sem. 
 
 
 
2.4 Discussion 
In the current study, we have shown that n-3 PUFA i.e., DHA, critically regulate 
PI(4,5)P2-dependent actin remodeling in CD4+ T cells.  This novel effect was associated 
with decreased levels of PI(4,5)P2 in unstimulated CD4+ T cells, and suppressed 
metabolism of PI(4,5)P2 upon anti-CD3/anti-CD28 or PMA/ionomycin stimulation.  
PI(4,5)P2 can be synthesized via two pathways: i) the de novo pathway (Kennedy 
pathway); and ii) the remodeling pathway (Lands’ cycle).  Since the incorporation of 
polyunsaturated fatty acids at the sn-2 position of PI(4,5)P2 is predominantly driven by 
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 the Lands’ cycle rather than the Kennedy cycle (163, 164), the phospholipid composition 
of the membrane can potentially influence the acyl composition of phosphoinositides 
(165).  Indeed, it has been shown that platelet 1-acyl-glycero-3-phosphoinositol 
acyltransferase, which catalyzes the condensation between fatty acyl Co-A and 
lysophospholipid,  prefers n-6 PUFA over n-3 PUFA (166).  Our results support this 
model as the presence of n-3 PUFA decreased the 16:0,20:4 and 18:0,20:4 species of 
PI(4,5)P2, while concomitantly increasing the 18:1,20:4 species of PI(4,5)P2 (Figure 
2.2).  To target the sn-2 position of PI(4,5)P2, we also utilized the FADS-1 knockout 
mouse model, in which levels of arachidonic acid were depleted by deleting the delta-5 
desaturase (167).  Similar to the presence of n-3 PUFA acting as a competitive inhibitor 
for the remodeling of PI(4,5)P2, depleting the remodeling enzyme’s preferred substrate 
also led to a decrease in the amount of PI(4,5)P2 in CD4+ T cells (Figure 2.10), 
demonstrating how attacking the sn-2 position of PI(4,5)P2 can decrease its level in 
CD4+ T cells. 
With regard to PI(4,5)P2 metabolic turnover plots (Figure 2.3), wild type data are 
similar to previously published work (47).  Furthermore, PI(4,5)P2 metabolism in Fat-1 
and 4% DHA CD4+ T cells are consistent with published results showing that porcine 
cardiac myocytes incubated with DHA exhibited no change in IP3 generation after 
stimulation by an α1-adrenoreceptor agonist (168).  Similarly, we have previously shown 
that diacylglycerol production in purified murine T lymphocytes isolated from mice fed 
dietary EPA and DHA is suppressed upon stimulation (137).  The PI(4,5)P2 metabolic 
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 profile in Fat-1 CD4+ T cells also corroborates our previous data that PLC-γ1 and 
phosphorylated PLC-γ1 are down-regulated in T cells at the IS (94). 
The magnitude and kinetics of PI(4,5)P2 metabolism are important for actin 
remodeling, as demonstrated in various cell types and physiological processes (153-
155).  For example, the overexpression of PIP5K, which increases the availability of 
PI(4,5)P2, perturbs stress actin fibers and membrane ruffling, indicative of defects in 
actin reorganization (169).  Our data reveal that the distortion of PI(4,5)P2 levels is 
associated with the suppression of actin remodeling in Fat-1 and 4% DHA derived CD4+ 
T cells (Figures 2.4 and 2.9).  We also demonstrate that the defects in actin remodeling 
observed in Fat-1 CD+ T cells can be rescued by the introduction of exogenous PI(4,5)P2 
(Figure 2.8).  It is interesting to note that mitochondrial translocation in CD4+ T cells is 
inhibited by latrunculin, a drug that sequesters actin monomers, preventing actin 
polymerization (170).  We have previously shown that mitochondrial translocation after 
stimulation in Fat-1 CD4+ T cells is suppressed (136), thus our results that actin 
remodeling is suppressed in Fat-1 CD4+ T cells may partially explain the lack of 
mitochondrial translocation upon CD4+ T cell stimulation. 
It is interesting to note that not all actin remodeling processes are perturbed by n-
3 PUFA.  For example, chemotaxis of CD4+ T cells, which utilizes actin cytoskeleton, is 
not affected by n-3 PUFA (Figure 2.11).  This may be due to the fact that chemotaxis 
involves other, compensatory signals that may be able to overcome the inhibition exerted 
by n-3 PUFA (171).  It is interesting to note that chemotaxis of the immortalized young 
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 adult mouse colonoytes treated with EPA or DHA was suppressed, as assessed by the 
wounding assay (172). 
WASP, an actin regulatory protein, is activated by PI(4,5)P2 though interaction 
between the basic domain of WASP and the acidic PI(4,5)P2 to release WASP from its 
autoinhibitory conformation (149, 162).  Interestingly, activation of N-WASP, a member 
of the WASP family, is dependent upon PIP2 density, i.e., increased PIP2 density leads to 
hyperactivation of N-WASP in vitro (22).  Furthermore, depletion of the PIP2 fraction in 
the raft pool resulted in decreased T cell capping upon T cell activation (39).  One can 
speculate, therefore, that PI(4,5)P2 metabolism upon activation of CD4+ T cell leads to a 
local increase in PI(4,5)P2 density, which results in the recruitment and activation of 
WASP at the IS and subsequent actin remodeling.  In the presence of n-3 PUFA, not 
only is basal PI(4,5)P2 decreased, but PI(4,5)P2 fails to metabolize upon activation, 
leading to suppressed WASP recruitment to the IS and actin remodeling (Figure 2.6).  
Further experiments are required to test this hypothesis. 
In the 4% DHA triglyceride-enriched diet, DHA contributed approximately 5% 
toward the total energy (kcals) intake.  In a typical Greenland Inuit diet, n-3 PUFA 
constitutes approximately 2.7 – 6.3% of daily energy (173-175).  Thus, our 4% DHA 
diet is within the physiological range achievable though diet.  In humans, comparable 
intakes could also be achieved through the ingestion of DHA supplements.  At this level, 
we did not observe any adverse effects, as food intake and changes in body weight were 
similar between the dietary groups (data not shown). 
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 In summary, our results demonstrate the novel effects of n-3 PUFA on critical 
mechanisms of early T cell activation (Figure 2.12).  We have previously demonstrated 
that n-3 PUFA can suppress T cell activation, in part, by affecting recruitment and 
activation of signaling proteins such as PLC-γ1, PKCθ, and F-actin, as well as 
mitochondrial translocation necessary to sustain Ca2+ signaling for nuclear NF-κB and 
AP-1 activation and IL-2 secretion (78, 94, 136).  We extend this model by 
demonstrating that n-3 PUFA, such as DHA, can also affect PI(4,5)P2-dependent actin 
remodeling by decreasing steady-state PI(4,5)P2 levels, suppressing PI(4,5)P2 
metabolism upon stimulation, and inhibiting PI(4,5)P2-dependent actin remodeling.  In 
addition, a mechanism by which n-3 PUFA suppress PI(4,5)P2-dependent actin 
remodeling is through decreased WASP recruitment to the IS.  In contrast to commonly 
used pharmacological perturbations, our in vivo genetic and dietary intervention studies 
carry significant biological relevance. Overall, our findings highlight a novel modality 
by which n-3 PUFA influence membrane microorganization, thereby modulating 
biological responses. 
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Figure 2.12.  n-3 PUFA alter early steps of T cell activation.  In wild type CD4+ T cells, upon stimulation with anti-CD3 (and 
costimulatory signal from CD28), the TCR signalsome composed of Lck, ZAP70, LAT, GADS, SLP76, NCK, ITK, VAV1, PAK, 
and PLC-γ1 is formed, recruiting additional proteins such as PLC-γ1.  PLC-γ1 hydrolyzes the lipid mediator PI(4,5)P2 to DAG and 
IP3, leading to induction of Ca2+ signaling and the PKCθ signaling pathway.  The hydrolysis of PI(4,5)P2 is also important for actin 
remodeling by releasing actin regulating proteins localized at the plasma membrane.  Additionally, PI(4,5)P2 is phosphorylated by 
class I PI3K to generate PI(3,4,5)P3 which also triggers actin remodeling.  WASP is recruited to the plasma membrane and activated 
by PI(4,5)P2 to regulate actin remodeling.  These pathways synergistically regulate actin remodeling at the plasma membrane for 
mitochondrial translocation and T cell activation.  We have previously shown that n-3 PUFA suppress total and phosphorylated PLC-
γ1 translocation to the IS (dotted hammerheads signify suppression) (94); and mitochondrial translocation to the IS (136).  We now 
show that n-3 PUFA such as DHA can suppress i) the basal level of PI(4,5)P2 in unstimulated CD4+ T cells; ii) the metabolism of 
PI(4,5)P2 upon anti-CD3/anti-CD28 or PMA/ionomycin stimulation; iii) WASP recruitment to the IS; and iv) actin remodeling upon 
anti-CD3/anti-CD28 stimulation.  The suppression of these early immediate events in T cell activation leads to inhibition of T cell 
function, and thus may suppress inflammatory responses. 
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 CHAPTER III  
n-3 POLYUNSATURATED FATTY ACIDS UNIQUELY ALTER 
PHOSPHOTIDYLINOSITOL-(4,5)-BISPHOSPHATE ORGANIZATION AND 
REGULATE THE CD4+ T CELL PROLIFERATIVE RESPONSE, AS REVEALED 
BY IMAGING PLASMA MEMBRANE LIPID DOMAINS 
3.1 Introduction 
Previous published data and data from the last chapter demonstrated using the 
transgenic Fat-1 mouse model, which generates n-3 PUFA de novo and enriches the 
membrane with n-3 PUFA (176), that early signaling events critical to T cell activation 
are suppressed, including PI(4,5)P2-dependent actin remodeling, signaling protein and 
mitochondrial translocation to the IS, and calcium signaling (78, 94, 136, 177).  
Complementary studies have shown that incorporation of EPA or 7-ketocholesterol into 
the plasma membrane of Jurkat T cells can not only change the biophysical properties of 
the plasma membrane, but also suppress T cell activation (67, 71), demonstrating the 
intricate link between the biophysical properties of the plasma membrane and T cell 
signaling.  
 Since the plasma membrane plays a critical role in T cell signaling, and we have 
previously demonstrated that n-3 PUFA can increase its lipid order (93, 94, 178), we 
hypothesized that n-3 PUFA suppress T cell signaling and function, in part, by 
modifying the membrane topography and spatial organization of PI(4,5)P2 in the plasma 
membrane.  By using a variety of fluorescence resonance energy transfer (FRET) 
probes, we demonstrate, for the first time, that dietary bioactive molecules such as EPA 
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 and DHA can not only modify the biophysics of the plasma membrane, but also alter the 
spatial organization of PI(4,5)P2, a critical phospholipid that regulates the spatiotemporal 
properties of plasma membrane mesodomains.  We demonstrate that these effects result 
in the suppression of clonal expansion upon activation of primary CD4+ T cells.  These 
data highlight the intrinsic effects of n-3 PUFA on the proximal events immediately 
following engagement of the TCR on the CD4+ T cell surface. Modulation of these 
events results in a suppression of T cell proliferation and contributes to an overall anti-
inflammatory environment that may be beneficial for human subjects suffering from 
chronic inflammatory diseases or patients undergoing medical surgeries requiring total 
parenteral nutrition (TPN) (179). 
3.2 Materials and methods 
3.2.1 Plasmids 
ECFP, and YPet were synthesized by Integrated DNA Technologies (Coralville, 
Iowa) into pIDTSMART and subcloned into pLenti vector using BamHI and NotI 
(APPENDIX H; New England Biolabs, Ipswich, MA).  An NheI site was included 
immediately downstream of BamHI for insertion of additional fragments.  cDNA 
containing the first 10 amino acids of Lck [Lck(N10)], the first 15 amino acids of Src 
[Src(N15)], the transmembrane domain of linker for activation of T cells [LAT(TM)], 
and the PH domain of phospholipase-δ [PH(PLC-δ)], were synthesized and subcloned 
into pLenti using BamHI and NheI restriction sites, upstream and in-frame to ECFP or 
YPet.  All plasmids were verified by sequencing (Eton Bioscience, San Diego, CA), and 
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 expressed as fusion probes in 293T cells followed by examination under microscopy and 
Western blotting. 
3.2.2 Generation of lentivirus 
Lentivirus was generated as previously described with minor modifications for 
lentivirus (180, 181).  Individual pLenti constructs were co-transfected with pLP-1, pLP-
2, and pVSV-G (Life Technologies, Grand Island, NY) into HEK293T/17 (ATCC CRL-
11268) using calcium phosphate precipitation (APPENDIX I and J).  Medium 
containing the virus was harvested 3X within 72 h of transfection.  Lentivirus was then 
concentrated using a concentrator (Clontech, Mountain View, CA), resuspended in 
RPMI media (Irvine Scientific, Santa Ana, CA) containing 5% fetal bovine serum, 1% 
glutamax (Life Technologies), and 1% penicillin-streptomycin (Life Technologies), and 
stored at -80 °C until the time of the transduction. 
3.2.3 Animal husbandry and CD4+ T cell isolation  
Animal protocols have been approved by the Institutional Animal Care and Use 
Committee at Texas A&M University and follow the U.S. Public Health Service 
guidelines.  Fat-1 transgenic mice on a C57BL/6 background, generously provided by 
Dr. Jing X. Kang (Department of Medicine, Harvard University), were bred, genotyped, 
and phenotyped as previously described [APPENDIX A; (94, 136, 177)].  Wild type and 
Fat-1 litter-mate controls were fed a 10% safflower diet ad libitum in a 12:12 light:dark 
cycle.  CD4+ T cells were purified by removing the spleen aseptically and labeling with 
magnetic CD4 (L3T4) microbeads according to manufacturer’s protocol (APPENDIX 
B; Miltenyi Biotec, Auburn, CA).   CD4+ T cells were cultured in complete RPMI 
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 media, 20 ng/mL rIL-2 (eBioscience, San Diego, CA), and 20 μM 2-mercaptoethanol 
(Sigma Aldrich, St Louis, MO), until the start of the downstream assay (within h).  For 
rescue experiments using exogenous PI(4,5)P2, cells were treated after lentiviral 
transduction with PI(4,5)P2 dissolved in PBS supplemented with 0.0025% of protein 
stabilizer (Echelon Biosciences, Salt Lake City, UT) for one hr, at 37 °C, 5% CO2, 
collected, and washed, before FRET experiments.  
In the diet experiment, 4 to 6 weeks old C57BL/6 mice were fed either an n-6 
PUFA enriched 5% corn oil diet, 0.95% DHA (low n-3 PUFA) or 4% DHA (high n-3 
PUFA) triglyceride-enriched diet.  Diets differed only in their oil composition, either 
(control) 5% corn oil by weight or a mixture of 57% pure DHA triglyceride (Martek, 
Columbia, MD) and corn oil (0.95:4.05 or 4:1 w/w).  Additional diet components, 
expressed as g/100 g, were 20 casein, 41.9 sucrose, 22 corn starch, 6 cellulose, 3.5 AIN-
76 mineral mix, 1 AIN-76 vitamin mix, 0.3 DL-methionine, 0.2 choline chloride, and 5 
dietary oil (68, 78, 142).  Mice were fed ad libitum for 3 to 4 weeks in a 12:12 light:dark 
cycle and diet changed daily to prevent the formation of oxidative byproducts. 
3.2.4 Lentiviral transduction 
CD4+ T cells were resuspended to a final concentration of 7.5 x 106 cells/mL, 
seeded into a 24 well plate and incubated with lentivirus for 48 h before imaging in the 
presence of 2 μg/mL polybrene (APPENDIX K).  Typically ECFP-containg lentivirus 
was added 8 h prior to YPet lentivirus to optimize the level of the fluorophores for 
imaging.  After 48 h of incubation, CD4+ T cells were collected, washed, resuspended in 
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 300 μL of Leibovitz’s media, and seeded onto poly-L-lysine coated 35 mm glass bottom 
dishes (MatTek, Ashland, MA) for imaging. 
3.2.5 Microscopy and image analysis 
FRET experiments were conducted using the Zeiss LSM 510 META laser scanning 
confocal microscope with an excitation at 458 nm for ECFP, and 514 nm for YPet by the 
equipped argon laser.  Emissions were detected between 480 – 520 nm for ECFP, and 
between 535 – 590 nm for YPet.  Samples were imaged with a 63X oil objective with a 
numerical aperture of 1.2, and recorded in 8-bit mode.  Images were processed using the 
accompanying software and values were exported and analyzed in Microsoft Excel. 
FRET was analyzed by acceptor photobleaching to detect the increase in ECFP 
signal.  A region of interest was drawn around the plasma membrane, and 
photobleaching was conducted by illuminating the region of interest for 200 iterations 
with the laser.  For each cell, four images were recorded: i) YFPPRE, YPet fluorescence 
before photobleaching; ii) CFPPre, ECFP fluorescence before photobleaching; iii) 
YFPPost, YPet fluorescence after photobleaching; and iv) CFPPost, ECFP fluorescence 
after photobleaching.  Corrections to the fluorescence intensities were also made by 
conducting acceptor photobleaching cells expressing only the ECFP and YPet probes to 
determine the bleaching of ECFP during photobleaching (CFPBleach), and the bleed-
through of YPet into the CFP channel (CFPYFP).  Corrections to the CFP intensities 
before and after photobleaching were calculated as follows: 
 CFPPre, Corrected = CFPPre – CFPYFP Bleed (Eq.1) 
 CFPPost, Corrected = (CFPPost-CFPYFP) + CFPBleach (Eq. 2) 
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 To determine the FRET efficiency (E%), the corrected CFP values were used in the 
following equation: 
 E%= CFPPost, Corrected-CFPPre, Corrected
CFPPost, Corrected
X100 (Eq. 3) 
To determine FRAP, the following equation was used to analyze cells expressing 
only the YPet probe where F(t) is fluorescence intensity at time (t), F(∞) is the 
fluorescence intensity after recovery, F(0) is the initial fluorescence intensity, and k is 
the rate of fluorescence intensity recovery after photobleaching: 
 F(t)=[F(∞)-F(0)]×[1-exp(-kt)]+F(0) (Eq. 4) 
3.2.6 CFSE assay 
After CD4+ T cell isolation, cells were labeled with CFSE as previously 
described [APPENDIX M; (94, 141)].  In brief, 5 mM of CFSE (Life Technologies) in 
dimethyl sulfoxide (DMSO, Sigma Aldrich) was added into 1 x 106 cells/mL in PBS 
(Life Technologies) containing 0.1% BSA (Roche Diagnostics), incubated at 37 °C for 
30 min, before rapid chilling by adding excess of ice-cold complete RPMI and incubated 
for 5 min on ice.  Cells were then collected, washed with PBS, and resuspended to a 
final cell concentration of 2 x 106 cells/mL.  Cells were then cultured in 96 well plates 
either unstimulated, or stimulated with plated anti-CD3 (Clone 145-2C11, 0.2 µg/mL, 
eBiosciences) and suspended anti-CD28 (Clone 37.51, 1 µg/mL, eBiosciences) for 72 h, 
at 37 °C.  On the day of analysis, cells were collected, washed with PBS, and then 
resuspended in staining buffer (eBioscience) containing 1 µg/mL of PI (Miltenyi 
Biotec).  Samples were then processed using a BD Accuri C6 flow cytometer (BD 
Bioscience, San Joe, CA). 
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 3.2.7 Statistical analysis 
All experiments were conducted with at least four animals, and data were 
expressed as mean ± sem unless otherwise noted.  Using GraphPad Prism (La Jolla, CA), 
data were analyzed by two-tailed Student’s t-test between genotypes with a single 
treatment, one-way ANOVA between multiple groups, or by two-way ANOVA between 
genotypes and treatments.  In cases where the F statistic was significant (P < 0.05) in 
ANOVA, a Tukey post-hoc test was conducted.  P < 0.05 was considered to be 
statistically significant. 
3.3 Results 
3.3.1 Using raft and non-raft markers to probe the effects of n-3 PUFA on plasma 
membrane mesodomains 
We have previously shown that n-3 PUFA perturb the membrane lipid bilayer by 
increasing the liquid order of plasma membrane mesodomains in CD4+ T cells 
genetically enriched with n-3 PUFA (94), and in CD4+ T cells isolated from mice fed a 
diet enriched in n-3 PUFA, e.g., DHA (178).  To further probe the effects of n-3 PUFA 
on the plasma membrane mesodomains, in a series of FRET experiments, we utilized the 
raft markers Lck(N10) and LAT(TM), in which the 10 N-terminal amino acids of Lck 
and the transmembrane domain LAT are fused to fluorescent reporters.  For comparative 
purposes, we also investigated the properties of the non-raft marker Src(N15), which 
contains the 15 N-terminal amino acids of c-Src (182).   
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Figure 3.1.  Expression of (A) wild type; and (B) K40L mutant PH(PLC-δ)-EGFP constructs in CD4+ T cells isolated from wild type 
and Fat-1 transgenic mice. CD4+ T cells were isolated using positive selection and cultured in the presence of 10 μM 2-
mercaptoethanol and 40 ng/μL recombinant IL-2 for 1 hr at 37 °C, 5% CO2, prior to lentiviral transduction of the PH(PLC-δ)-EGFP 
construct (n = 3 per genotype).  CD4+ T cells were then further cultured for 48 h at 37 °C, 5% CO2 before labeling with APC-CD4 for 
flow cytometry analysis. Percentages of wild type and Fat-1 CD4+ T cells transduced with wild type (2.73 ± 1.29 and 2.58 ± 0.82 for 
wild type and Fat-1, respectively) and K40L mutant (15.34 ± 6.72 and 11.21 ± 6.19 for wild type and Fat-1, respectively) constructs. 
 
 
 
Mammals are unable to convert n-6 PUFA into n-3 PUFA, thus we utilized the Fat-1 
transgenic mouse model, in which the plasma membrane is enriched with n-3 PUFA 
upon feeding a diet high in n-6 PUFA (141, 176).  We hypothesized that the presence of 
n-3 PUFA in the plasma membrane would increase the FRET efficiency between the 
lipid raft markers, since increased liquid order would favor an increase in the 
coalescence of lipid raft mesodomains.  We utilized a lentivirus system to transduce the 
reporter plasmids in order to avoid activating the CD4+ T cells with antibodies or 
chemicals (183, 184). Using this system, the presence of n-3 PUFA did not affect the 
lentiviral transduction efficiency (Figure 3.1).  We verified our FRET approach by 
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 performing a series of control experiments (Figure 3.2).  We first expressed the FRET 
standards C5V, C32V, and Cerulean in 293T cells and calculated the FRET efficiencies 
using Eq. 3 to determine the FRET efficiencies using our microscope system and 
conditions [Figure 3.2; (185)].  We then determined the FRET efficiencies of the 
Lck(N10)/Lck(N10) FRET pair in 293T cells and primary CD4+ T cells to evaluate the 
change between photobleaching the whole cell versus a region of interest, where we saw 
no statistical difference between the two approaches (Figure 3.2B).  This is important to 
ensure that the diffusion of YPet outside of the region of interest is slow enough to 
accurately measure FRET efficiency immediately after photobleaching.  We then 
optimized the iterations of photobleaching in order to ensure maximum photobleaching 
without prolonged laser exposure to minimize effects on cell viability (Figure 3.2C).   
 
 
Figure 3.2.  Experimental FRET optimization.  (A)  FRET efficiencies of the C5V, C32V, and cerulean standards measured using 
acceptor photobleaching.  C5V, C32V, and cerulean generated by S.S. Vogel and described previously(185), were obtained from 
Addgene (#26394 for C5V, #26396 for C32V, and #27795 for cerulean).  293T cells were transfected with C5V and C32V plasmids, 
and acceptor photobleaching was determined using a Zeiss 510 LSM microscope. FRET efficiency (E%) was determined by 
comparing the CFP intensity before and after acceptor photobleaching.   Published values for C5V is 45.1% ± 4.42%, C32V is 25.6 ± 
4.89%(186).  (B) Comparison between FRET efficiencies of Lck(N10)/Lck(N10) obtained from acceptor photobleaching of the 
region of interest versus whole cell in 293T cells and primary CD4+ T cells.   (C)  Relative intensities of PH(PLC-δ)-YPet in the YFP 
channel monitored throughout the photobleaching scheme in primary CD4+ T cells using 200 and 400 iterations for photobleaching. 
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 After performing these control experiments, we measured the FRET efficiency 
between the various raft and non-raft markers (Figures 3.3).  As predicted based on our 
previous data showing that n-3 PUFA increase the liquid order of the plasma membrane, 
the incorporation of n-3 PUFA into the plasma membrane increased the FRET 
efficiencies of the lipid raft markers Lck(N10)/Lck(N10), and Lck(N10)/LAT(∆CP), 
compared to the non-interacting markers Lck(N10)/Src(N15) (Figure 3.3D & E).  Since 
the diffusion of membrane proteins can be influenced by whether they are localized in 
lipid raft mesodomains (187), we also determined the rate of fluorescence recovery after 
photobleaching (FRAP) of the raft markers Lck(N10) and LAT(∆CP).   FRAP of 
Lck(N10) in CD4+ T cells enriched with n-3 PUFA exhibited a 20% decrease relative to 
the FRAP of Lck(N10) expressed in wild type CD4+ T cells (Figure 3.3G).  We did not 
observe a difference in the FRAP of LAT(∆CP) between genotypes, perhaps due to the 
slow rate of recovery exhibited by LAT(∆CP) (Figure 3.3H).  Collectively, the results 
from the FRET and FRAP experiments indicate that n-3 PUFA alter the dynamics of the 
lipid raft mesodomains in the plasma membrane. 
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Figure 3.3.  n-3 PUFA perturb the biophysical properties of the plasma membrane by increasing the interaction of fluorescent lipid 
raft markers Lck(N10)/Lck(N10), and Lck(N10)/LAT(ΔCP) detected using FRET, and decreasing the rate of FRAP of the lipid raft 
marker Lck(N10).  (A, B, and C) Schematic diagrams of the interaction between neighboring fluorescent probes targeted to the raft 
or the non-raft membrane fraction of the plasma membrane.  Lck(N10) and Src(N15) consist of the first 10 and 15 N-terminal amino 
acids of Lck and Src, respectively.  LAT(ΔCP) consists of the first 36 amino acids, representing the extracellular, transmembrane, 
and the membrane anchoring portions of LAT.  Splenic CD4+ T cells were incubated with lentivirus containing (D) 
Lck(N10)/Lck(N10), (E) Lck(N10)/LAT(ΔCP), or (F) Lck(N10)/Src(N15) before FRET by acceptor photobleaching (n = 4 per 
genotype).  FRET efficiency (E%) was determined by comparing the CFP intensity before and after acceptor photobleaching, and 
normalized to the FRET efficiency obtained from the C5V standard (*P < 0.05 between genotypes).  The rate of recovery after 
photobleaching was also determined for CD4+ T cells expressing (G) Lck(N10)-YPet and (H) LAT(ΔCP)-YPet (*P < 0.05 between 
genotypes). 
 
 
    
3.3.2 Incorporation of n-3 PUFA into the plasma membrane decreases the non-raft pool 
of PI(4,5)P2 
Since we have shown that the lipid raft mesodomains in the plasma membrane 
are perturbed by the presence of n-3 PUFA, and PI(4,5)P2 couples the mesoscale raft 
domains with membrane cytoskeleton compartments (14, 188, 189), we hypothesized 
65 
 
 that incorporation of n-3 PUFA into the plasma membrane alters the spatial organization 
of PI(4,5)P2 relative to raft and non-raft mesodomains.  Utilizing the raft markers 
[Lck(N10) and LAT(∆CP)] and the non-raft marker [Src(N15)] in combination with the 
PI(4,5)P2 reporter PH(PLC-δ) (Figure 3.4), we tested our hypothesis in a series of FRET 
experiments.  Although n-3 PUFA increased the FRET efficiencies between lipid raft 
markers (Figure 3.3), the FRET efficiency between PH(PLC-δ) and either Lck(N10) or 
LAT(∆CP) was not affected in CD4+ T cells enriched with n-3 PUFA (Figures 3.4D & 
E).  This was corroborated by measuring the co-localization between GM1, a well-
characterized lipid raft marker (190, 191), and PH(PLC-δ), which showed no difference 
in the presence of n-3 PUFA (APPENDIX L; Figure 3.5).  The FRET efficiency 
between PH(PLC-δ) and the non-raft marker Src(N15), however, was decreased by 20% 
in CD4+ T cells enriched with n-3 PUFA (Figure 3.4F).  These results suggest that the 
incorporation of n-3 PUFA into the plasma membrane not only influences the 
biophysical properties of the phospholipid bilayer, but also alters the spatial organization 
of PI(4,5)P2 by depleting the non-raft pool of PI(4,5)P2.   
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Figure 3.4.  n-3 PUFA decrease the interaction of fluorescent non-raft and PI(4,5)P2 markers as detected using FRET, and exogenous 
PI(4,5)P2 can rescue the non-raft population of PI(4,5)P2 in Fat-1 CD4+ T cells.  (A, B, and C)  Schematic diagrams of the interaction 
between neighboring fluorescent probes targeted to the raft or the non-raft membrane fraction of the plasma membrane, and 
PH(PLC-δ), a PI(4,5)P2 reporter.  CD4+ T cells were incubated with lentivirus containing (D) Lck(N10)/PH(PLC-δ), (E) LAT(ΔCP)/ 
PH(PLC-δ), or (F) Src(N15)/PH(PLC-δ) before FRET by acceptor photobleaching (n = 4 per genotype).  FRET efficiency (E%) was 
determined as described in Figure 1 (*P < 0.05 between genotypes).  Fat-1 CD4+ T cells were isolated and transduced with (G) Lck-
ECFP and PH-YPet; or (H) Src-ECFP and PH-YPet for 48 h before they were incubated with 1.25 μM PI(4,5)P2 or PBS (0 μM) for 
one hr.  Cells were analyzed as described in Figure 3.3. A two-tailed t-test was used to compare FRET efficiencies within specific 
concentrations (* P < 0.05 at specific concentrations of PI(4,5)P2).  
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Figure 3.5 – Colocalization between the lipid raft marker GM1 and PI(4,5)P2 is not altered in the presence of n-3 PUFA.  Splenic 
CD4+ T cells were positively selected and incubated with lentivirus containing pLenti-PH(PLC-δ)-GFP for 48 h (n = 4 per genotype).   
Cells were collected, washed, labeled with Alexa 647 Cholera Toxin B (final concentration 10 μg/mL) and crosslinked with anti-
Cholera Toxin B [Vybrant Lipid Raft Labeling Kit (Life Technologies)] according to manufacturer’s protocol (APPENDIX L).  (A)  
Cells were imaged using a Zeiss 510 META confocal microscope.  (B) The plasma membrane region of the cell was drawn and 
Pearson’s coefficient was determined using NIS-Element (Nikon). 
 
 
 
We have previously demonstrated that the incorporation of n-3 PUFA into the 
plasma membrane of CD4+ T cells decreases the amount of overall PI(4,5)P2 by 50%, 
resulting in suppressed actin remodeling upon anti-CD3/anti-CD28 stimulation (177).  
The suppression of PI(4,5)P2-dependent actin remodeling, however, was recovered by 
incubation with exogenous PI(4,5)P2.  However, recent studies have suggested that 
different pools of PI(4,5)P2 are responsible for various signaling pathways, such as 
calcium signaling and actin remodeling (42-44).  Therefore, we hypothesized that 
exogenous incubation of PI(4,5)P2 with CD4+ T cells enriched in n-3 PUFA would 
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 rescue the non-raft pool of PI(4,5)P2.  Using the lipid raft marker Lck(N10) and 
PI(4,5)P2 marker PH(PLC-δ), the FRET efficiency before and after incubation with 
exogenous PI(4,5)P2 did not differ between wild type and CD4+ T cells enriched with n-
3 PUFA (Figure 3.4G).  In contrast, using the non-raft marker Src(N15) and PH(PLC-
δ), the FRET efficiency of CD4+ T cells enriched with n-3 PUFA increased to the level 
of wild type CD4+ T cells (Figure 3.4H).  These data indicate that exogenous PI(4,5)P2 
increases the non-raft pool of PI(4,5)P2 in CD4+ T cells enriched with n-3 PUFA to a 
level comparable to wild type cells. 
3.3.3 Exogenous PI(4,5)P2 rescues the suppression of T cell proliferation in CD4+ T 
cells enriched with n-3 PUFA 
We have previously shown that CD4+ T cells enriched with n-3 PUFA exhibit 
suppressed T cell proliferation following anti-CD3/anti-CD28 stimulation (78, 94).  
Since exogenous PI(4,5)P2 restores the non-raft pool of PI(4,5)P2 (Figure 3.4H), and can 
rescue PI(4,5)P2-dependent actin remodeling (177), we hypothesized that exogenous 
PI(4,5)P2 would also reverse the suppressed proliferative phenotype in CD4+ T cells 
enriched with n-3 PUFA.  Using carboxyfluorescein succinimidyl ester (CFSE) 
fluorescence as a marker of T cell proliferation, and propidium iodide (PI) fluorescence 
as a marker of cell viability, cell division was determined based on the number of 
distinct CFSE fluorescence intensity peaks (Figure 3.6).  The proliferation index of each 
population was determined using the generational data, providing an indicator of the 
proliferation capacity of the population.  CD4+ T cells enriched with n-3 PUFA 
exhibited a suppressed (~20% lower) T cell proliferative capacity compared to wild type 
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 (Figure 3.6D).   Importantly, the n-3 PUFA suppressed phenotype was rescued to wild 
type levels upon pre-treatment with exogenous PI(4,5)P2.  These findings demonstrate 
that i) incorporation of n-3 PUFA into the plasma membrane of CD4+ T cells not only 
alters the spatial organization of PI(4,5)P2 by decreasing the non-raft pool of PI(4,5)P2, 
but also suppresses T cell proliferation; and ii) replenishment of the non-raft pool of 
PI(4,5)P2 (Figure 3.4) and rescue of PI(4,5)P2-dependent actin remodeling in CD4+ T 
cells enriched with n-3 PUFA (177), restore full proliferation capacity. 
 
 
 
Figure 3.6.  Exogenous PI(4,5)P2 rescues the n-3 PUFA-induced suppression of T cell proliferation.  Representative scatterplots and 
CFSE profiles of (A) unstimulated, and (B) anti-CD3/anti-CD28 stimulated CD4+ T cell cultures.  Splenic CD4+ T cells were stained 
with CFSE, then cultured (n = 4 per genotype) either in unstimulated or stimulated conditions for 72 h in triplicate.  Cells were 
collected and gated by propidium iodide staining to exclude dead cells.  (C) Cell proliferation was analyzed using the Proliferation 
Wizard in ModFitLT3.2 to determine the percent population at each generation. Different letters represent statistically significant 
differences between the groups (P < 0.05).  (D) Proliferation Index, the amount of total cells divided by theoretical parental 
population, was calculated using ModFitLT 3.2 (192). 
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 3.3.4 CD4+ T cells isolated from mice fed a 4% DHA triglyceride-enriched diet exhibit 
decreased raft PI(4,5)P2, non-raft PI(4,5)P2, and lymphoproliferation that was rescued 
by exogenous PI(4,5)P2 
 In order to determine whether dietary n-3 PUFA such as DHA could recapitulate 
the phenotypes seen in Fat-1 CD4+ T cells, C56BL/6 mice were fed 5% corn oil (CO)-
enriched (control), 0.95% DHA-triglyceride-enriched, or 4% DHA-triglyceride-enriched 
diet.   Using the raft and non-raft probes of Lck(N10) and Src(N15), respectively, in 
conjunction with the PI(4,5)P2 probe PH(PLC-δ), we detected decreased FRET 
efficiencies between CD4+ T cells isolated from mice fed the control diet, and 4% DHA-
triglyceride-enriched diet using the combination of Lck(N10)/PH(PLC-δ) and 
Src(N15)/PH(PLC-δ), suggesting that both the lipid raft and non-raft pools of PI(4,5)P2  
are perturbed (Figure 3.7C & D).  Decreased PI(4,5)P2 was also correlated with 
suppressed lymphoproliferation, as seen in Fat-1 CD4+ T cells (Figure 3.7E).  
Importantly, incubating CD4+ T cells with exogenous PI(4,5)P2 reversed the DHA-
mediated suppression of lymphoproliferation caused by decreased PI(4,5)P2, 
demonstrating that decreased status of PI(4,5)P2 directly suppresses lymphoproliferation. 
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Figure 3.7.  DHA decreases the interaction of fluorescent raft and non-raft probes with PI(4,5)P2 marker detected using FRET, 
resulting in suppressed lymphproliferation that can be rescued by exogenous PI(4,5)P2 in CD4+ T cells.  (A and B)  Schematic 
diagrams of the interaction between neighboring fluorescent probes targeted to the raft or the non-raft membrane fraction of the 
plasma membrane, and PH(PLC-δ), a PI(4,5)P2 reporter.  CD4+ T cells were incubated with lentivirus containing (C) 
Lck(N10)/PH(PLC-δ), or (D) Src(N15)/PH(PLC-δ) before FRET by acceptor photobleaching (n = 4 per genotype).  FRET efficiency 
(E%) was determined as described in Figure 3.3 (*P < 0.05 between genotypes).  (E)  Splenic CD4+ T cells were stained with CFSE, 
then cultured (n = 6 per diet) either in unstimulated or stimulated conditions for 72 h in triplicate.  Cells were collected and gated by 
propidium iodide staining to exclude dead cells.  Proliferation Index was calculated using ModFitLT 3.2 (192).  **P < 0.01 as 
determined by one-way ANOVA followed by post-hoc test. 
 
 
 
3.4 Discussion 
The use of fish oils, containing bioactive EPA and DHA, for their anti-inflammatory 
properties is growing exponentially.  It is, therefore, important to elucidate the 
mechanisms by which n-3 PUFA exert their anti-inflammatory properties.  Previous 
studies have examined the extrinsic effects of n-3 PUFA (i.e. generation of novel 
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 metabolites to act upon receptors and enzymes) (118, 119, 193, 194), as well as the 
effects of n-3 PUFA downstream of TCR engagement with MHCII antigen presentation 
(78, 94, 136, 177).  Since lipid raft mesodomains in the plasma membrane play a critical 
role in initiating T cell activation (67, 71), and n-3 PUFA are incorporated into the 
plasma membrane, we hypothesized that n-3 PUFA suppress T cell activation by altering 
i) the biophysical properties of lipid raft mesodomains; and ii) the spatial organization of 
PI(4,5)P2 relative to lipid raft and non-raft mesodomains.  By using lipid raft and non-
raft markers in a series of FRET experiments, we demonstrate for the first time in 
primary CD4+ T cells that n-3 PUFA alter the topology of the lipid raft mesodomains.  
The increase in FRET efficiency between the lipid raft markers observed in CD4+ T cells 
enriched in n-3 PUFA can be interpreted either as an increase in the size of the lipid raft 
mesodomains, or an increase in the stability of the lipid raft mesodomains.  In both 
cases, the enhancement of lipid raft mesodomains would be expected to decrease the 
average diffusion of the lipid raft marker, since it has been shown that an association 
with lipid raft mesodomains retards the diffusion rate of these markers (195, 196).  This 
is consistent with the FRAP data reported in Figure 3.3.  From an immunological 
perspective, this perturbation in the plasma membrane biophysics results in a 
suppression of T cell proliferation [Figure 3.6; (94, 141)].  Interestingly, other forms of 
perturbation to the plasma membrane topology can change the threshold for T cell 
activation.  For example, incubation of Jurkat T cells with 7-ketocholesterol decreased 
the membrane order and resulted in a suppression of downstream T cell signaling (71).  
In addition, some human autoimmune diseases can be attributed to changes in the lipids 
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 associated with lipid raft mesodomains (197).  For example, CD4+ T cells isolated from 
patients with systemic lupus erythematosus exhibit elevated levels of glycosphingolipids 
associated with lipid rafts, and this alteration was correlated with hyperaction of T cells.  
By correcting glycosphingolipid metabolism in CD4+ T cells isolated from systemic 
lupus erythematosus patients, normal T cell function was restored, demonstrating the 
direct relationship between lipid raft mesodomains and T cell function (76, 198).  In fact, 
the lipid order of the plasma membrane can influence the differentiation of naïve CD4+ T 
cells into effector CD4+ T cells, highlighting the importance of lipid raft mesodomains in 
dictating the function of CD4+ T cells (73, 75, 77). 
Since the organization of lipid raft mesodomains is closely linked with the actin 
cytoskeleton, and the actin cytoskeleton is regulated by PI(4,5)P2 (23), we hypothesized 
that the incorporation of n-3 PUFA into the plasma membrane of CD4+ T cells alters the 
spatial organization of PI(4,5)P2.  Indeed, we have previously shown that n-3 PUFA in 
CD4+ T cells reduced the amount of total PI(4,5)P2 by 50%, and this reduction was 
correlated with a suppression of PI(4,5)P2-dependent actin remodeling necessary for 
proper T cell activation (177).  Surprisingly, the increase in FRET efficiency between 
lipid raft markers in the presence of n-3 PUFA did not correlate with a change in the 
lipid raft pool of PI(4,5)P2; rather, the non-raft pool of PI(4,5)P2 was decreased (Figure 
3.4).  In the context of PI(4,5)P2-dependent actin remodeling, this may not be surprising, 
as this remodeling has been shown in other cell types to be regulated by a specific 
PIP5K isoform (PIP5Kγ) which is capable of synthesizing the non-raft pool of PI(4,5)P2 
(42-44).  Furthermore, perturbations in the raft and non-raft pools of PI(4,5)P2 using 
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 targeted phosphatase in Jurkat T cells produced different actin-dependent phenotypes 
(39).  These studies demonstrate the compartmentalization of PI(4,5)P2 in the plasma 
membrane (raft and non-raft), and the importance of non-raft PI(4,5)P2 in regulating 
actin remodeling.  It is also noteworthy, that incubation with exogenous PI(4,5)P2 
increased PI(4,5)P2 mass back to wild type levels (Figure 3.4), which is consistent with 
the rescue of PI(4,5)P2-dependent actin remodeling upon stimulation (177).  
We have previously demonstrated that incorporation of n-3 PUFA into the T cell 
plasma membrane suppresses lymphoproliferation upon stimulation (94, 141).  Thus, we 
hypothesized that the rescue of the non-raft pool of PI(4,5)P2 would also reverse the 
suppression of T cell proliferation, linking the biochemistry and cellular biology of the T 
cell membrane with a highly relevant immunological end point.  Using the CFSE assay 
to measure T cell proliferation, we demonstrated that rescue of the non-raft pool of 
PI(4,5)P2 in CD4+ T cells enriched with n-3 PUFA also restored T cell proliferation back 
to wild type levels.   
It is interesting to note that in our dietary model, only CD4+ T cells isolated from 
animals fed a 4% DHA-triglyceride-enriched diet exhibited decreased PI(4,5)P2 in both 
lipid raft and non-raft pools (Figure 3.7).  This may highlight the difference in n-3 
PUFA dose between the genetic Fat-1 model, and the dietary 4% DHA model; indeed, 
examining the fatty acid profiles of the two models highlight the fact that CD4+ T cells 
isolated from animals fed a 4% DHA-triglyceride-enriched diet exhibited 3 – 4 times 
more incorporation of n-3 PUFA, compared to Fat-1 CD4+ T cells (Figure 2.1).  These 
data also suggest that there is a dose-dependent dietary intake of n-3 PUFA that is 
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 required for physiological phenotype, as CD4+ T cells isolated from 0.95% DHA-
triglyceride-enriched diet exhibited no change in PI(4,5)P2.  Therefore, more 
experiments involving dose of n-3 PUFA will be required to clarify the dose-dependent 
response of CD4+ T cells. 
To put the FRET efficiencies into biological perspective, previous studies 
demonstrated that a 3 to 4% change in FRET efficiency correlated to a significant 
decrease in Lck phosphorylation, and suppression of subsequent T cell activation (199).  
Thus the changes demonstrated in this study have biological relevance. 
In conclusion, this study highlights how n-3 PUFA, found in dietary fish oil, directly 
affect the lipid-lipid interactions fundamental to the formation of lipid raft mesodomains 
in the plasma membrane, thereby perturbing downstream signals required for T cell 
proliferation (Figure 3.8).  Thus, our data further support the concept that n-3 PUFA can 
be used rationally for the treatment of chronic inflammatory diseases in which T cells 
are inappropriately activated. 
 
 
Figure 3.8 – Incorporation of n-3 PUFA such as EPA and DHA into the plasma membrane alters its topology by increasing the size 
and/or stability of lipid raft mesodomains (represented by the red headgroup) and by decreasing the non-raft pool of PI(4,5)P2.  
Because the incorporation of n-3 PUFA affects proximal signaling events upon ligation of the TCR with antigen presented in the 
context of the MHCII, this study demonstrates the intrinsic membrane effect of bioactive n-3 PUFA and their potential therapeutic 
use in decreasing T cell proliferation upon activation. 
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 CHAPTER IV  
n-3 POLYUNSATURATED FATTY ACIDS DO NOT ALTER THE POST-
TRANSLATIONAL LIPIDATION STATUS OF CD4+ T CELL 
4.1 Introduction 
To explore an alternative hypothesis regarding the effects of n-3 PUFA on T cell 
activation, the post-translational modification of signaling proteins was examined.  Post-
translational modification of proteins by lipids is an important regulator of protein 
function due to the ability of the lipids to change the localization, the activation, and/or 
the binding partner of the specific protein (200).  Three prevalent lipidation processes 
occur in eukaryotes, and they include fatty acids, isoprenoids, and 
glycosylphosphatidylinositols.  We therefore opted to focus on the post-translational 
modifications of proteins by fatty acids since many of the signaling proteins involved in 
T cell activation are post-translationally modified by fatty acids (i.e. LCK, LAT, FYN) 
(200).  In addition, EPA and DHA have been shown to alter the fatty acyl composition 
of cells (68), which could lead to a perturbation in the post-translational modification of 
signaling proteins, and/or the localization of these modified proteins.  
In N-myristoylation, a myristate group (14 carbon fatty acid chain) is irreversibly 
added to the N-terminal glycine residue via an amide linkage.  This reaction is catalyzed 
by N-myristoyltransferase (NMT) that recognizes the consensus sequence MGXXXS/T 
where the underlined glycine is the site of myristoylation, and the first methionine is 
commonly removed (201).  To date, two N-myristoyltransferases have been identified in 
humans, NMT1 and NMT2.  In contrast, S-acylation, specifically palmitoylation, 
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 commonly involves the reversible attachment of a palmitic acid (16 carbon fatty acid 
chain) to the cysteine residue via a thioester bond, although other palmitoylation 
modifications do occur (i.e. N-palmitoylation, O-palmitoylation) (201).  Unlike N-
myristoylation, there are no known consensus sequences for the site of palmitoylation; 
moreover, there are more than 20 palmitoyl acyltransferases identified in mammalian 
genome (202).  By adding fatty acids to a protein, the modification provides a 
hydrophobic interface to allow for membrane association.  For example, palmitoylation 
can be used to regulate the association between a protein and the raft phase for integral 
raft proteins (203).  
Not surprisingly, receptors and kinases involved in T cell activation are post-
translationally modified.  CD4, the marker of CD4+ T cells, is palmitoylated at cysteines 
394 and 397 (204).   LCK is myristoylated at glycine 2 and palmitoylated at cysteine 3 
and cysteine 5; all three sites are required for stable membrane insertion and association 
(200).  Similarly, LAT is palmitoylated at cysteines 26 and 29, and these palmitoylation 
events are essential for optimal localization of LAT to detergent-resistant membranes, 
and subsequent recruitment and activation of the signalsome (205).  Finally, FYN, a Src 
family kinase that has been implicated to play a role in T cell activation, is also 
myristoylated at glycine 2 and palmitoylated at cysteines 3 and 6 (206).  Post-
translational modifications of LCK, LAT, and FYN are necessary for the localization to 
lipid rafts and downstream function for T cell activation (200).  Therefore, an alternative 
hypothesis, that n-3 PUFA alter the post-translational modification of signaling proteins 
such as LCK, LAT, and FYN in CD4+ T cells, will be pursued. 
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 4.2 Materials and methods 
4.2.1 CD4+ T cell isolation  
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at Texas A&M University and followed the U.S. Public Health Service 
guidelines.  Wild type and Fat-1 1 transgenic mice on a C57BL/6 background, 
generously provided by Dr. Jing X. Kang (Department of Medicine, Harvard 
University), were fed a 10% safflower diet ad libitum in a 12:12 light:dark cycle 
[APPENDIX A; (94, 136, 177)].  CD4+ T cells were enriched by removing the spleen 
aseptically and labeling with magnetic CD4 (L3T4) microbeads according to 
manufacturer’s protocol (APPENDIX B; Miltenyi Biotec, Auburn, CA).   CD4+ T cells 
were cultured in complete RPMI media, supplemented with 20 ng/mL rIL-2 
(eBioscience, San Diego, CA).  15 x 106 cells in 4 mL were seeded in 35 mm plate and 
incubated for 1 hr before loading with 15-azidopentadecanoic acid (APPENDIX N). 
4.2.2 Treatment of CD4+ T cell with 15-azidopentadecanoic acid 
 15-azidopentadecanoic acid (Life Technologies, Grand Island, NY) dissolved in 
DMSO (50 mM) was added to each cell culture to a final concentration of 50 µM, and 
incubated for 24 h.  Cells were then collected, washed, and homogenized in 
homogenization buffer composed of 50 mM Tris-HCl, pH = 8, 1% SDS (w/v), 100 µM 
of sodium orthovanadate, 1X sigma protease cocktail, and 250 units of benzonase 
nuclease.  Protein lysates from two cell cultures were pooled and concentrated using 
centrifugal concentrator (3 kDa cut-off, Millipore, Billerica, MA).  Protein concentration 
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 was then determined using the bicinchoninic acid assay (Thermo Scientific, Rockford, 
IL) and protein concentration was adjusted to 4 µg/µL for Click chemistry. 
4.2.3 Click chemistry 
 Click chemistry was performed using the Click-iT kit (Life Technologies) 
according to the manufacturer’s protocol.  Briefly, 200 µg of cellular protein was 
combined with 100 µL of Click-iT reaction buffer containing PEG4 carboxamide-
propargyl biotin (Life Technologies), 10 µL of ddH2O, vortexed for 5 sec, before 
addition of CuSO4 and component C.  The reaction was vortexed for 5 sec, and 
incubated for 3 min at 23 °C for 3 min.  Finally, component D was added to the reaction 
and incubated for 30 min at 23 °C for 30 min, protected from light.  After the reaction, 
protein was precipitated according to the manufacturer’s protocol.  Briefly, 400 µL of 
MeOH was added to the reaction first, followed by 150 µL of CHCl3 and 400 µL of 
ddH2O.  Phase separation was conducted by centrifuging the mixture for 5 min at 18,000 
g.  Most of the upper aqueous phase was removed, retaining the interface and lower 
phase.  Protein was pelleted by an addition of 450 µL of MeOH, followed by 
centrifugation for 5 min at 18,000 g.  The supernatant was removed, and the protein 
pellet was washed with an additional 450 µL of MeOH.  Protein was pelleted again with 
centrifugation for 5 min at 18,000 g, followed by the removal of the supernatant.  The 
pellet was air dried for 10 min before it was resuspended in a homogenization buffer 
containing 50 mM Tris-HCl, pH = 7.5, 15 mM EGTA, pH = 7.5, 100 mM NaCl, 0.1% 
Triton X-100, 500 µM of sodium orthovanadate, 1X Sigma protease cocktail, and 10 
80 
 
 mM β-mercaptoethanol.  The protein concentration was determined by the Commassie 
Plus Protein assay (Pierce, Rockford, IL).   
4.2.4 Immunoprecipitation using protein G Dynabeads 
100 µg of protein was combined with rabbit polyclonal IgG anti-Lck (Millipore) 
for 90 min at 4 °C before addition of Protein G Dynabeads for overnight incubation at 4 
°C.  The next day, the protein-antibody complex was collected using DynaMagnet, and 
boiled in the presence of 2X pyronin.  Samples were then loaded on 4-20% Tris-glycine 
polyacrylamide precast gel (Invitrogen) and separated for 2.5 h at 4 ºC.  Proteins were 
then transferred onto polyvinylidene fluoride membranes at 400 mA for 90 min.  
Membranes were blocked at room temperature for 1 h in 4% nonfat dry milk.  Primary 
antibody against biotin (mouse anti-biotin, Jackson ImmunoResearch, West Grove, PA) 
was incubated overnight at 4 ºC.  Membranes were subsequently washed and incubated 
with secondary horseradish peroxidase conjugated rabbit anti-mouse IgG (KPL) and 
developed using Pierce SuperSignal West Femto maximum sensitivity substrate.  
Membranes were then scanned using Fluor-S Max MultiImager system (BioRad, 
Hercules, CA) and analyzed using QuantityOne (BioRad). 
4.3 Results 
4.3.1 Incorporation of azido-palmitic acid is superior to the alkynyl-palmitic acid probe 
in Jurkat T cells 
 In order to probe the post-tranlsational lipidation of signaling proteins in CD4+ T 
cells, we employed the highly sensitive Click chemistry using labeled palmitic acid and 
biotin (201, 207).  Click chemistry involves the Huisgen cycloaddition of an azide and 
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 an alkyne in the presence of copper as a catalyst at room temperature (208), thus we 
determined whether azido- or alkynyl-palmitic acid was better for detecting the 
palmitoylation of proteins in CD4+ T cells.  By using Jurkat T cells as a proxy, we 
determined that incubating T cells with azido-palmitic acid yielded better signal when 
detecting palmitoylation in proteins using immunoblotting (Figure 4.1).  For subsequent 
experiments, azido-palmitic acid was used to detect palmitoylation in CD4+ T cells. 
 
 
Figure 4.1.  Azido-palmitic acid is superior relative to alkynyl-palmitic acid in labeling palmitoylated proteins in Jurkat T cells.  1 x 
107 Jurkat T cells were seeded in a 35 mm culture dish with 3 mL of RPMI media supplemented with 2% FBS overnight at 37 ºC, 5% 
CO2.  Cells were treated as indicated and 100 μg of protein lysate was used for Click chemistry.  Subsequently, 60 μg of protein 
lysate was used for Western blotting after protein precipitation subsequent to the chemistry reaction and detected by immunoblotting.  
 
4.3.2 Global palmitoylation is not affected by n-3 PUFA in unstimulated primary CD4+ 
T cells 
CD4+ T cells were isolated from wildtype and Fat-1 mice, and subsequently 
incubated the azido-palmitic acid, followed by Click chemistry.  Contrary to previous 
results suggesting that n-3 PUFA altered the palmitoylation of signaling proteins, global 
palmitoylation status was not affected in Fat-1 CD4+ T cells (Figure 4.2A).  To examine 
whether palmitoylation was affected in specific proteins, we chose to perform 
immunoprecipitation of LCK in order to isolate and detect its specific palmitoylation.  
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 Similar to our observation for global palmitoylation, n-3 PUFA did not affect the 
palmitoylation of LCK in CD4+ T cells (Figure 4.2B). 
 
 
Figure 4.2.  Palmitoylation is not affected in Fat-1 CD4+ T cells.  (A) 1.5 x 107 splenic CD4+ T cells were positively selected and 
seeded in a 35 mm culture dish with 4 mL of RPMI media supplemented with 2% FBS and rIL-2 overnight overnight.  Cells were 
treated with 50 μM of azido-palmitic acid for 24 h and 2 wells were pooled to create 1 sample.  Subsequently, 100 μg of protein 
lysate was used for Click chemistry and palmitoylation was detected by immunoblotting.  Numbers on the side represent molecular 
weights of the marker.  (B) Palmitoylation of Lck is not affected in Fat-1 CD4+ T cells.  Cells were selected and processed as in (A), 
and was subsequently immunoprecipitated (IP) using polyclonal rabbit IgG anti-Lck.  Palmitoylated Lck was detected by 
immunoblotting, and quantified. 
 
 
 
4.4 Discussion 
Contrary to previously published reports, which observed that palmitoylation of 
signaling proteins in CD4+ T cells were decreased in the presence of n-3 PUFA such as 
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 EPA (209, 210), our data indicate that palmitoylation of LCK was not impacted by the 
presence of n-3 PUFA.  There are two possibilities for these apparent differences.  First, 
different methods of palmitoylation detection were used in each experiment.  In the 
previously published reports, palmitoylation was detected by radiolabeled 16-
[125I]iodohexanoic acid, compared to the use of azido-palmitic acid.  A second 
possibility is that the cell type was different, immortalized human Jurkat T cells versus 
primary mouse CD4+ T cells.  Because malignant transformed Jurkat T cells are 
continuously growing, it may be possible that effect of n-3 PUFA on palmitoylation is 
only observed under rapid post-translational turnover when CD4+ T cells are activated. 
If palmitoylation of signaling proteins is not altered by the presence of n-3 
PUFA, then the displacement of signaling proteins at the IS is not due to inhibition of 
enzymatic palmitoyltransferase activity, but rather, due to the unique biophysical 
properties of n-3 PUFA that allow these fatty acids to alter the size and/or stability of 
mesoscale lipid rafts, thus altering the localization of proteins at the plasma membrane.  
It would be interesting to test whether the localization of palmitoylated proteins at the IS 
is altered by n-3 PUFA.  It could be possible that even if the signaling proteins are 
palmitoylated, the localization of these proteins are altered at the plasma membrane. 
To date, there are no structural data on palmitoyl acyltransferases, and substrate 
specificity for these enzymes has focused on their target proteins.  It would be interesting 
to examine whether n-3 PUFA can bind to the palmitic acid binding pocket of these 
acyltransferases and act as a substrate inhibitor, or whether these palmitoyl 
acyltransferases are not affected enzymatically by n-3 PUFA.  Based on our data, one 
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 would speculate that n-3 PUFA do not affect the enzyme activity of these palmitoyl 
acyltransferases. 
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 CHAPTER V  
SUMMARY AND CONCLUSIONS 
5.1 Summary 
 Epidemiological studies have suggested that high intake of EPA and DHA 
derived from diets rich in fish is correlated with decreased incidence of chronic 
inflammatory diseases (211, 212).  This is especially important given the fact that 
chronic inflammation is associated with a plethora of diseases, such as cardiovascular 
diseases (213, 214), ulcerative colitis (54, 123, 211, 215), rheumatoid arthritis (216, 
217), neurological disorders (218, 219), metabolic disorders (220, 221), and cancer (222-
224).  It has only been recently appreciated that obesity can be considered as low-grade 
chronic inflammation that drives changes in not only adipose tissues, but immune cells 
as well, leading to systemic inflammation (225-228).  This is especially relevant since 
the Centers for Disease Control and Prevention reported in 2013 that 69% of the U.S. 
population is overweight or obese (229).  One could only imagine the burden this health 
risk will put on the health care system in the United States.  In the absence of obesity, 
there is a balance between adipocytes and the various immune cells such as M2-like 
macrophages, TH2 and Treg cells, and eosinophils, contributing to an anti-inflammatory 
environment.  With the development of obesity, however, there is a switch in cell types 
associated with the adipose tissue; there is an increase in pro-inflammatory immune cells 
such as M1-like macrophages, CD4+ TH1 cells, CD8+ effector T cells, and mast cells.  
Concomitantly, there is a decrease in immune cells such as eosinophils, TH2 cells, and 
anti-inflammatory Treg cells.  Pro-inflammatory adipokines such as MCP-1 and LTB4 are 
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 released, along with the pro-inflammatory cytokines such as TNF-α and IL-1β, creating 
a pathophysiological, inflammatory environment (230).  Thus, research on innocuous 
bioactive compounds such as EPA and DHA found in fish oil is urgently needed to 
combat the inflammation epidemic.  More critically, examining the biochemical and 
biophysical mechanisms by which n-3 PUFA such as EPA and DHA exert their 
beneficial, anti-inflammatory effects can potentially lead to the identification of common 
mechanisms by which signaling cascades can be modulated at the plasma membrane 
level. 
 
 
Figure 5.1.  Effects of n-3 PUFA on lipid-lipid interactions and lipid-protein interactions.  Data from our lab, and this work, suggest 
that upon incorporation of n-3 PUFA into the plasma membrane increase the size and/or stability of the mesoscale lipid rafts.  In 
addition, n-3 PUFA also decrease the level of PI(4,5)P2 in the plasma membrane, resulting in reduced actin cytoskeleton and the 
dysregulation of the mesoscale lipid rafts.  Physiologically, this translated into decreased lymphoproliferation upon activation. 
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  As highlighted in the obesity example, inflammation is orchestrated by many cell 
types (54, 72, 130).  The focus of this body of work is on the CD4+ T cell population due 
to its ability to differentiate into additional T cell subsets that are involved in both pro- 
and anti-inflammatory responses.  Previous studies have shed light on how n-3 PUFA 
such as EPA and DHA exert their anti-inflammatory effects, but the phenotypes 
observed were associated with later events during the inflammation process (68, 78, 94, 
133-147, 167, 231).  To identify the nexus where n-3 PUFA exert their effects, the studie 
reported herein examined the events before and proximal (within minutes) after T cell 
activation.  Data presented herein clearly demonstrate that the incorporation of n-3 
PUFA into the plasma membrane increased the interaction between lipid raft probes, 
consistent with previous data that n-3 PUFA increase the size of lipid rafts in HeLa cells 
as measured by clustering analysis of a cholesterol-dependent H-Ras probe (93), and in 
CD4+ T cells as determined by the generalized polarization value of Laurdan, a 
lipophilic probe that is sensitive to its lipid environment [Figure 5.1A, (94)].  The 
effects of n-3 PUFA on plasma membrane microdomains may be cell-specific.  
Although B cells isolated from mice fed a fish oil-enriched diet exhibited a similar 
increase in membrane order (95), treatment of immortalized Jurkat T cells with EPA or 
DHA exhibited an opposite trend (67, 232).  This may be due to intrinsic differences in 
the cell types, but also highlights the need to examine each cell specifically, since 
incorporation of n-3 PUFA into the plasma membrane may have cell-specific effects.  
Additionally, not all n-3 PUFA are effective at perturbing plasma membrane lipid rafts.  
Phenotypes are not interchangeable when cells are treated with EPA or DHA (172, 233), 
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 and biophysical studies have demonstrated that EPA and DHA do not disrupt lipid rafts 
with equal efficiency  (91).  Adding to the complication, 1-palmitoyl-2-
docosahexaenoylphosphatidylethanolamine preferentially segregates into the non-raft 
plasma membrane, while 1-palmitoyl-2-docosahexaenoylphosphatidylcholine prefers the 
mesoscale raft domains of the plasma membrane (89), demonstrating that the 
headgroups of the phospholipids can also shape the mechanism by which these n-3 
PUFA modulate plasma membrane properties.  Clearly, more biophysical, biochemical, 
and molecular studies are needed to understand how these n-3 PUFA affect the plasma 
membrane to modulate downstream signaling and impact physiology. 
In addition to altering the biophysical properties of the CD4+ T cell plasma 
membrane (Figure 5.1A), the concentration of PI(4,5)P2 was decreased, and non-raft 
pool of PI(4,5)P2 was also altered, even before T cell activation commenced.  As a result, 
PI(4,5)P2 metabolism (within minutes) was blunted, and actin remodeling (within 30 
minutes) was also suppressed (Figure 5.1B).  Since actin remodeling was suppressed, 
the stabilization of lipid rafts necessary for the formation of the IS would also be 
affected.  One possible mechanism by which actin remodeling was suppressed was the 
failure of WASP to be recruited to the IS.  On a physiological level, enrichment of the 
plasma membrane with n-3 PUFA resulted in suppressed lymphoproliferation, as 
previously reported (94, 138, 141).  Importantly, these defects, including i) altered non-
raft pool of PI(4,5)P2; ii) suppressed actin remodeling upon stimulation; and iii) 
suppressed lymphoproliferation could be rescued by incubation with exogenous 
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 PI(4,5)P2, demonstrating that the modulation of PI(4,5)P2 by n-3 PUFA directly 
influences T cell biochemistry and function. 
In order to recapitulate phenotypes seen in the genetically modified Fat-1 mouse 
model, CD4+ T cells were also isolated from mice fed a 4% DHA-triglyceride enriched 
diet, and parallel experiments were conducted.  Phenotypes such as i) decreased basal 
PI(4,5)P2; ii) altered non-raft pool of PI(4,5)P2; iii) repressed actin remodeling upon 
stimulation; and iv) suppressed lymphoproliferation, were all consistent with effects seen 
in the genetic Fat-1 CD4+ T cells.  As mentioned previously, the 4% DHA-triglyceride-
enriched diet provides approximately 5% DHA as total energy (kcals).  On an energy 
intake basis, this is within the physiological range achievable though diet (173-175).  
Although in this body of work, there were no adverse effects related to the intake of 
DHA at this high level, some concerns have been raised.  Since n-3 PUFA exert anti-
inflammatory effects, high doses of these bioactive compounds may be, in fact, immune-
suppressive.  Studies have demonstrated that n-3 PUFA reduced resistance to 
Mycobacterium tuberculosis infection in guinea pigs by altering T cell function (234), 
and in mice by suppressing macrophage function (235).  In addition, dietary fish oil 
exacerbated an infection model of colitis by altering T cell populations (236), illustrating 
the need for additional research on not only the mechanisms of how n-3 PUFA exert 
their anti-inflammatory effects, but also the optimal dose.   
 The described work is also one of the few examples of linking biochemical 
mechanisms (i.e., perturbations at the plasma membrane) to cellular consequences (i.e., 
suppression of lymphoproliferation).  Although both biochemical and physiological 
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 studies are important in determining how n-3 PUFA operate on a molecular or 
physiological level, the work presented in this dissertation connects the molecular 
mechanisms of n-3 PUFA, to a physiological phenotype.  This is important because 
small changes on the biochemical level can have a profound impact at the physiological 
level, and this is often underappreciated.  For example, incubation of Jurkat T cells with 
a 2:1 ratio of cholesterol:7-ketocholesterol, which would affect the packing of mesoscale 
lipid rafts, only changed the generalized polarization of Laurdan by 0.12, yet IL-2 
secretion was decreased by 40% (71).  Similarly, a 3 to 4% change in FRET efficiency 
correlated to a significant decrease in Lck phosphorylation, and suppression of 
subsequent T cell activation (199).  These highlight how small biochemical changes can 
have big physiological impact. 
5.2 Future directions 
5.2.1 T cell receptor and mechanotransduction 
 Mechanotransduction is the ability of the cell to sense mechanical force, and 
transmit the mechanical cue as cellular signaling (237).  This process is important for 
many physiological processes, including the ability to hear (238), and to touch (239).  
Mechanotransduction is becoming more important, because it has been recently 
recognized that cells can sense extracellular matrices and distinguish rigidity, density, 
and topography of the extracellular matrix in order to modulate focal adhesions (240, 
241).  Cancer cells, however, show abnormal focal adhesions, suggesting a dysregulation 
in mechanosensory function (242-244).  In the context of CD4+ T cell activation, the T 
cell receptor itself has been recently identified as an anisotropic mechanosensor, where T 
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 cell activation occurred when force is applied in a perpendicular fashion (245).   TCR 
acting as a mechanosensor was further verified by using micromanipulation of T cells 
bound to artificial antigen presenting cells (246), by imaging the pushing and pulling 
phases of T cell activation (247), and by using atomic force microscopy (248).  One way 
T cells can sense the mechanical force may be the rigidity of the substrate, as IL-2 
secretion is correlated to the elasticity that is presented to the T cell (249).  The rigidity 
of the antigen has also been shown to influence peripheral blood T cell activation and 
secretion of IL-2, demonstrating the relevance to human health and disease (250).  Not 
surprisingly, the ability to sense the mechanical force is intricately regulated by actin 
cytoskeleton (251, 252), and mechanosensing by T cell receptors requires actin 
cytoskeleton, as demonstrated by imaging actin dynamics (247), and by treating cells 
with blebbistatin, an inhibitor of actin contraction (249). 
Fundamental to mechanosensing is the force-from-lipid principle (253, 254), in 
which mechanosensing transmembrane proteins can sense force applied by the bilayer 
mismatch of tension, bending, and membrane curvature of the bilayers (255).  Since the 
incorporation of n-3 PUFA into the plasma membrane has been shown to affect the 
elasticity of the plasma membrane (81, 82), and the present study has demonstrated the 
effects of n-3 PUFA on the actin cytoskeleton upon T cell activation, one would 
hypothesize that the incorporation of n-3 PUFA into the plasma membrane of the CD4+ 
T cells will affect the mechanotransduction of the T cell receptor at the i) lipid-lipid 
level; and ii) lipid-protein (cytoskeletal) level.  In order to test this hypothesis, the cell 
stiffness can be probed by using atomic force microcopy, as demonstrated previously 
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 with regard to the role of Nck, RhoA, and Src in regulating cytoskeletal dynamics (180, 
256).  Additionally, by varying the rigidity of the substrate (249), it is possible to 
determine whether CD4+ T cells enriched with n-3 PUFA require higher force threshold 
to become activated, as measured by Ca2+ and IL-2 secretion.  To determine whether the 
actin cytoskeleton plays a role related to the effect of n-3 PUFA on 
mechanotransduction, exogenous PI(4,5)P2 can be introduced to see whether rescuing 
PI(4,5)P2-dependent actin remodeling is effective at also rescuing mechanotransduction. 
5.2.2 Effects of n-3 PUFA on the TCR and LAT interaction upon T cell activation 
 Once a cognate antigen presented in the major histocompatibility class II engages 
the CD4+ T cell receptor, tyrosine kinases Lck and ZAP70 are activated and 
subsequently phosphorylate the adaptor protein linker for activation of T cells (LAT), 
leading to the assembly of the signalsome for downstream signaling.  Although 
segregated clusters of TCR+ and LAT+ islands may form before T cell activation, 
precisely where the LAT+ protein islands are located is still controversial (257).  One 
proposed model (membrane island model) suggests that while TCR+ protein islands exist 
in the bulk membrane as higher-ordered protein structure, LAT+ protein islands exist in 
lipid rafts of the plasma membrane.  Upon TCR-MHCII engagement, additional TCR+ 
protein islands coalesce, and LAT+ protein islands concatenate with TCR+ protein 
islands without mixing.  This allows LAT+ proteins to be phosphorylated to propagate 
downstream signaling (65).  In the alternative model (sub-synaptic vesicles model), LAT 
is localized to vesicles that come into contact with activated TCR clusters to allow for 
LAT phosphorylation without LAT transport into the plasma membrane (activation of 
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 LAT in trans) (258, 259).  In either case, since n-3 PUFA perturb the spatial 
organization of the plasma membrane (membrane island model), and previous data from 
this laboratory has shown that n-3 PUFA alter the trafficking of proteins to the plasma 
membrane [sub-synaptic vesicles model, (260)], one would hypothesize that the 
incorporation of n-3 PUFA into the plasma membrane of the CD4+ T cells affects the 
interaction between activated TCR and LAT at the plasma membrane level (membrane 
island model) or the plasma membrane, sub-synaptic vesicle level (sub-synaptic vesicles 
model).  In order to test this hypothesis, the localization of TCR and LAT at the plasma 
membrane can be detected using super-resolution microscopy.  Super-resolution 
microscopy can also be used to determine the localization of LAT vesicles, and whether 
n-3 PUFA affect this population of signaling proteins.  In addition, FRET probes for 
TCR and LAT can be generated and used in order to probe how n-3 PUFA influence the 
engagement of these two signaling proteins for sustained downstream signaling (7, 260). 
5.3 Conclusions 
 This body of work demonstrates, using both genetic and dietary models, that n-3 
PUFA such as DHA can suppress CD4+ T cells, in part, by modulating the biophysical 
properties of the plasma membrane.  n-3 PUFA increase the size of lipid rafts in the 
plasma membrane, and suppress CD4+ T cell activation by decreasing the basal level and 
altering the spatial organization of PI(4,5)P2, resulting in perturbations to PI(4,5)P2 
metabolism, suppression of actin remodeling, and a decrease in lymphoproliferation 
upon T cell activation.  One potential mechanism by which n-3 PUFA suppress actin 
remodeling is through the inhibition of WASP recruitment to the IS, which is regulated 
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 by PI(4,5)P2.  By adding exogenous PI(4,5)P2 back to CD4+ T cells enriched with n-3 
PUFA, phenotypes such as i) decreased PI(4,5)P2; ii) altered PI(4,5)P2 localization; iii) 
inhibited actin remodeling; and iv) suppressed lymphoproliferation, are reverted back to 
wild type levels, demonstrating the direct link between the regulation of PI(4,5)P2 and n-
3 PUFA. 
The alternative hypothesis, that n-3 PUFA suppressed post-translational 
lipidation of signaling proteins in CD4+ T cells, was also tested, albeit in a preliminary 
fashion.  The data indicate that n-3 PUFA do not affect the post-translational lipidation 
of one signaling protein, LCK, in CD4+ T cells, suggesting that the effects of n-3 PUFA 
on CD4+ T cells are exerted at the plasma membrane, by perturbing the size of lipid 
rafts, and PI(4,5)P2-dependent actin remodeling.  The possibility that other central 
signaling proteins undergo altered post-translational modification in CD4+ T cells 
enriched with n-3 PUFA remains to be investigated. 
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 APPENDIX A 
PHENOTYPING FAT-1 MICE 
Reagents: 
• Acetone 
• 0.1 M KCl (cold) 
• Folch reagent (CHCl3:MeOH at 2:1 v/v) 
• 6% HCl in MeOH 
• Hexane 
• Dichloromethane (CH2Cl2) 
 
Procedures: 
Preparation of Glass Tubes 
1. Add 1 mL of acetone in 12 mL of glass tube.  Prepare about double the amount of tubes that is 
required since about half will leak. 
2. Draw a line at the top of the acetone to record whether acetone evaporated. 
3. Incubate for 1 hr at 80 °C. 
4. If acetone evaporated, do not use those tubes for further experiments. 
5. If acetone did not evaporate, discard the acetone, leave the tubes upside down, and label them well. 
6. Prepare a second set of tubes.  These do not need to be evaporated. 
7. Prepare a set of 2 mL Eppendorf tubes for homogenization.  Add 1ML of cold 0.1 M KCl into each 
tube and store on ice. 
 
Homogenization of Mouse Tails and Isolation of Lipids 
1. For each blade, can cut 2 samples (one sample per side).  Similarly, for each glass slide, can cut 2 
samples (one sample per end). 
• Must use the non-coated side for cutting. 
2. Cut the tails into very small chunks (the smaller the better) with the blade.  Insert the tail fragments 
into the 2 mL Eppendorf tube with 0.1 M KCl.  Store on ice. 
3. Homogenize with Polytron blade on ice for 45 sec at maximum speed.  Check to ensure the all 
materials have been homogenized.  Store on ice. 
• Note that hair won’t be homogenized. 
4. Transfer the homogenate into the non-leak proof glass tubes and add 5 mL of Folch reagent. 
5. Vortex for 1 min, centrifuge at 300 rpm, 5 min, at 4 °C. 
• Make sure that the blue protective rubber is used when centrifuging. 
6. Transfer the lower phase into the leak proof 12 mL glass tube, and dry down the solution under N2. 
• This takes about 30 to 45 min. 
7. Redissolve in 3 mL of 6% HCl in MeOH. 
8. Flush the samples with N2 before incubation. 
9. Vortex the samples for 1 min and incubate at 76 °C for 15 h (overnight). 
10. Prepare 4 mL glass vials with green caps.  Use label markers to clearly mark the vials. 
 
Isolation of FAME 
1. Need to perform this step ASAP after the incubation.  Can store at 4 °C for 2 to 4 h after incubation, 
but not longer than that. 
2. Add to each sample 1 mL 0.1 M KCl and 2 mL hexane. 
3. Vortex for 1 min.  Centrifuge at 3000 rpm, 5 min, 4 °C. 
4. Transfer upper layer into the 4 mL glass vials with green caps.  Dry down under N2. 
• This step takes about 15 to 20 min. 
5. Redissolve in 100 μL of CH2Cl2. 
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 6. Flush samples with N2 before storage. 
7. Vortex the samples and store at -20°C. 
Preparation for Gas Chromatography 
1. Warm up and stabilize the GC overnight.  Follow the instructions on the machine. 
2. Make sure the vials in A11 and WB9 are both full of CH2Cl2. 
3. Prepare the sequence to run on GC. 
4. Prepare the GC vials by putting in the inserts into the GC vials. 
5. Load 25 μL of Nuchek 68A standard.  You can start running the standard.  Put 1 sample of standard at 
the end of the sequence as well. 
6. Vortex the samples well.  Load 25 μL of sample into each GC vial.  Put it in the sequence. 
7. Flush all samples (and standard) under N2. 
8. To analyze the chromatogram, follow the instructions on the machine. 
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 APPENDIX B 
ISOLATING CD4+ T CELLS 
Reagents: 
Dry Reagents Wet Reagents 
• Scissors and forceps for animal surgery 
• 70 µm Cell Strainer  
• (BD 352350) 
• 30 µm MACS pre-separation filter  
(Miltenyi 08-771-2) 
• MACS separation columns (LS columns) 
(Miltenyi 130-042-401) 
• Syringes  just need to plunger part  
(BD 309585) 
• QuadroMACS Separation Unit  
(Miltenyi 130-090-976) 
• 100 mm Petri dish 
(BD 351029) 
• Auto MACS Running Buffer (MACS 
Separation Buffer) 
(Miltenyi 130-091-221) 
• CD4 (L3T4) Microbeads, mouse 
(Miltenyi 130-049-201) 
• PBS 
(GIbco, 14190) 
• RPMI Complete Media 
(see below) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI 
(Irvine Scientific 9159) 
200 92.94   
Heat-inactivated FBS 
(Irvine Scientific, 300320439) 
10.8 5.02   
Glutamax 
(Gibco, 35050-061) 
2.2 1.02 200 mM 4 mM 
Pen-strep 
(Gibco, 15140-148) 
2.2 1.02 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Procedures: 
Isolation of Cells from Spleens 
1. Remove the spleen from a mouse and place the spleen in 15 mL conical tube containing 3 mL of 
MACS buffer. 
• Remove as much fat as possible from the spleen. 
2. Place 70 μm cell strainer inside a 100 mm Petri dish and wet the membrane by adding 5 mL of MACS 
buffer. 
3. Place a 30 μm MACS pre-separation filter on top of a new 15 mL conical tube.  Wet the filter with 2 
mL MACS buffer. 
4. Transfer the spleen with the 3 mL MACS buffer onto the cell strainer and use the plunger to mesh 
(gently push, not grind) the tissue inside the Petri dish. 
• Want to keep the tissue wet at all time. 
• Continue until only connective tissue is left on the membrane. 
• Use Petri dish or else cells will adhere to the plate. 
5. Wash the plate with the MACS buffer in the Petri dish. 
6. Remove the cell strainer and transfer the 8 mL of buffer onto the 30 μm MACS pre-separation filter 
slowly (small volume at a time to prevent clogging). 
7. Wash the cell strainer by washing it inside the Petri dish with 5 mL of MACS buffer.  Wash the Petri 
dish again, and apply to the 30 μm MACS pre-separation filter. 
8. Remove the filter, close the lid, and gently invert the tube.  Take 20 μL and count using Coulter 
counter (4 μm cut off).   
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 9. Centrifuge cell suspension at 300 g for 10 min and aspirate off the supernatant. 
• Use plastic tip attached to glass pipette to reduce the suction force. 
 
Isolation of CD4+ T Cells 
1. Tap the bottom of the tube to loosen the pellet and then add 90 μL/107 total cells of MACS buffer to 
get a good suspension. 
• Know the amount of cells by using the Coulter counter.  The approximate volume of cells is 13.5 
mL (some is lost in wetting the membranes). 
• Can only load up to 2 x 109 total cells (108 labeled cells) per LS column. 
• Make sure to record the starting cell numbers for calculating yields. 
2. Add 10 μL/107 total cells of CD4 (L3T4) microbeads directly into the suspension. 
3. Mix well by pipetting and incubate for 15 min at 4 °C (use refrigerator, do not shake). 
4. Wash cells by filling up the 15 mL conical tube with cold MACS buffer.  Mix by inversion, centrifuge 
at 300 g for 10 min, and then aspirate off the supernatant. 
• Use plastic tip attached to glass pipette to reduce the suction force. 
5. Tap the bottom of the tube to loosen the pellet and then add 500 μL/108 total cells of MACS buffer to 
get a good suspension. 
 
Running the LS Column 
1. Snap the LS column into the QuadroMACS Separator.  Place a basin under the column for waste.  
Pre-wet the LS column with 1 mL of cold MACS buffer.  Let the buffer slowly drip through. 
2. Apply the cell suspension onto the column. 
• Can collect the flow-through to collect CD4- cell population. 
3. To rinse column, first wash the tube from Step 5 (Isolation of CD4+ T Cells) with 9 mL of cold 
MACS buffer and then apply 3 mL to the column.  Allow the buffer to run through the column before 
applying an additional 3 mL twice. 
• This washes the unlabeled cells through the column. 
4. Remove the columns from the separator and place it on 15 mL conical tube for collection. 
5. Pipette 5 mL of cold MACS buffer onto the column.  Immediately flush out by applying the plunger 
supplied with the column.  Push the plunger into the column all the way. 
• This fraction contains the magnetically labeled cells. 
6. Fill the tube with an additional 5 mL of cold MACS buffer.  Invert to wash well. 
7. Centrifuge the elution at 300 g for 10 min.  Aspirate off the supernatant. 
8. Fill the tube with 10 mL of ice cold PBS.  Wash by inversion. Take 20 μL of the suspension and count 
using the Coulter Counter. 
9. Centrifuge the elution at 300 g for 10 min.  Aspirate off the supernatant.  Proceed to downstream 
applications. 
 
Notes: 
• All the steps are performed in cell culture hood except the removal of the spleen from the mouse. 
• Store and use MACS buffer on ice, but perform rest of procedure at room temperature. 
• Pour out 50 mL of MACS buffer into a conical tube so that the stock MACS does not get 
contaminated. 
• Remember to prepare the Coulter Counter solution the day before (dispense into the cuvette). 
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 APPENDIX C 
PI(4,5)P2 EXTRACTION 
Purpose: To extract acidic phospholipids (i.e. PI(4,5)P2) from non-adherent cells for further analysis (see 
Quantification of PIP2 Using Abcam Anti-PIP2 (ab11039)). 
 
Reagents: 
• 1:1 MeOH:CHCl3 (20 mL MeOH and 20 mL CHCl3) 
• 80:40:0.5 MeOH:CHCl3:12N HCl (40 mL MeOH, 20 mL CHCl3, 0.25 mL 12 N HCl) 
• 12 N HCl (concentrate) 
• 1 N HCl (4.2 mL 12 N HCl in 50 mL ddH2O) 
 
Procedures: 
• All reagents and cells should be on ice. 
• Cells should be in low-retention 1.5 mL Eppendorf tubes (Phenix, MH-815SA). 
 
Cell Collection and Extraction of Neutral Lipids 
1. Spin down the cells at 4000 g, 5 min, 4 °C.  Aspirate off the supernatant.   
• With 0.3 x 106 cells, should be able to see a pellet that resembles an RNA pellet. 
2. Wash the cell with PBS to remove any residual medium/serum by resuspending the pellet with 1 mL 
of ice-cold PBS.  Spin down at 4000 g, 5 min, 4 ºC.  Aspirate off the supernatant. 
3. Add 800 μL (1:1) MeOH:CHCl3 and vortex for 1 min.  Centrifuge at 7500 g for 5 min at 4 °C.   
Aspirate off the supernatant. 
• With 0.3 x 106 cells, should be able to see a pellet that resembles an RNA pellet. 
• The pellet may actually be at the bottom of the tube rather than the side. 
 
Extraction of Acidic Lipids and Phase Split 
11. Add 400 μL (80:40:0.5) MeOH:CHCl3:12 N HCl to the pellet, and vortex for 5 minutes (30 sec on, 30 
sec off).  Pulse to 3000 g at 4 °C to get all solvents down to the bottom.   
12. Add 80 μL of 1 N HCl to the 400 μL of solvents from the above step and vortex for 15 seconds.  
Centrifuge at 18000 g for 2 min at 4°C to separate the organic and aqueous phases. 
• The aqueous layer is very small (just beneath the meniscus), so be very careful. 
13. Collect the organic layer (lower phase) and put into a clean low-retention 1.5 mL Eppendorf tubes and 
dry under N2. 
• Can use normal fine glass pipet once comfortable in controlling the speed of the suction, but if 
need to, can make homemade extra fine glass pipette: 
1. Turn on the Bunsen burner in the fume hood. 
2. Take the glass pipette and hold the top of the pipette with hand, and the bottom of the pipette with 
pliers. 
3. Warm the pipette very briefly over the flame (5 seconds max). 
4. Once the pipette becomes pliable, pull the pipette with the pliers to elongate the pipette. 
5. The pipette will be extended, but it will be closed at the end.  Clip a few centimeters above the 
ending to create an opening for the elongated, extra fine glass pipette. 
 
Storage Conditions of Products/Reagents: 
• All solvents should be chilled on ice until cooled before using. 
 
 Notes: 
• This protocol was modified from Ivanova PT et al (2007), Methods in Enzymology. 
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 APPENDIX D 
PI(4,5)P2 QUANTIFICATION USING ABCAM ANTI-PIP2 
Purpose: To quantify the amount of PI(4,5)P2 after acidic extraction (see Extraction of PI(4,5)P2 from 
Non-adherent Cells). 
 
Reagents: 
• PBS Buffer (Gibco, 21600-069). 
o Filter PBS buffer through a sterile cup (Nalgene, 450-0080). 
• 96 well flat bottom polystyrene microplate, not-treated (Corning, 9017) 
• Plate sealers (Genemate, T-3021-7) 
• IgG free bovine serum albumin (Roche, 03 116 956 001). 
• 50 µM PIP2 Standard (Echelon Biosciences, P-4502) 
• Protein Stabilizer (Echelon Biosciences, K-GS01) – Add 50 µL of PS to 20 mL of PBS. 
• Anti-PIP2 (Abcam, ab11039) 
• Goat anti-mouse secondary antibody (KPL, 074-1806) 
• TMB High Sensitivity Substrate Solution (BioLegend, 421501) 
• 1N H2SO4 Stop Solution (Sigma, 258148) 
o Dilute stock 18M H2SO4 by adding 2.8 mL of stock H2SO4 and 47.2 mL of ddH2O. 
 
Procedures: 
Preparation of Samples and Standards 
1. Prepare 50 µM PI(4,5)P2 by dissolving a vial of PI(4,5)P2 (K-4502) with 400 µL of PBS-PS Vortex 
the sample extremely well and sonicate for 1 minutes in ice-cold water bath.  Spin down the samples 
briefly and leave on ice. 
2. Prepare 6 tubes corresponding to 7.5 μM, 5 μM, 2.5 μM, 1 μM, 0.5 μM, 0.2 μM, and 0.1 μM 
3. Make 7.5 μM by adding 27 μL of 50 μM and 153 μL of PBS-PS. 
4. Make 5 μM by adding 18 μL of 50 μM and 162 μL of PBS-PS.  Make subsequent 5-fold serial 
dilution (1 μM and 0.2 μM) by adding 30 μL of standard and 120 μL of PBS. 
5. Make 2.5 μM by adding 9 μL of 50 μM and 171 μL of PBS-PS.  Make subsequent 5-fold serial 
dilution (0.5 μM and 0.1 μM) by adding 30 μL of standard and 120 μL of PBS. 
6. Dissolve your phospholipid samples in appropriate amount of PBS (each well requires 150 µL of 
sample).  Vortex very well and sonicate for 1 minutes in ice-cold water bath.  Spin down the samples 
briefly and leave on ice. 
 
Sample Coating and Blocking 
1. Set up the standards by adding 55 μL/well.  Add an additional 95 μL/well of PBS for the standards. 
2. Set up the samples by adding 150 μL/well. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 7.5 μM 7.5 μM           
B 5 μM 5 μM           
C 2.5 μM 2.5 μM           
D 1 μM 1 μM           
E 0.5 μM 0.5 μM           
F 0.2 μM 0.2 μM           
G 0.1 μM 0.1 μM           
H Blank Blank           
3. Seal the plate and incubate for 1.5 hour at room temperature on a shaker at 800 rpm.  Wrap the plate 
in aluminum foil. 
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 4. Wash the plate with sterile PBS 3X.  Discard the solution in the well and add 200 µL/well of PBS.  
Tap the plate gently 10 times and discard the solution.  Dry the plate by tapping the plate gently on a 
piece of paper towel.  Repeat two more times. 
5. Block the well by adding 100 µL/well of 5% BSA in PBS.  Seal the plate and incubate for overnight 
at 4 °C.  Wrap the plate in aluminum foil. 
 
Primary Antibody Incubation 
1. Wash the plate with sterile PBS 3X.   
2. Dilute the primary anti-PIP2 1:2500 in 5% BSA in PBS.  Add 100 µL/well of diluted primary 
antibody.  Seal the plate and incubate for 1.5 h at room temperature on a shaker at 800 rpm.  Wrap the 
plate in aluminum foil. 
 
Secondary Antibody Incubation 
1. Wash the plate with sterile PBS 3X.   
2. Dilute the secondary goat anti-mouse 1:5000 in 5% BSA in PBS.  Add 100 µL/well of diluted 
secondary antibody.  Seal the plate and incubate for 1 hr at room temperature on a shaker at 800 rpm.  
Wrap the plate in aluminum foil. 
 
Detection 
1. Wash the plate with sterile PBS four times. 
2. After the last PBS wash, add 100 μL of TMB solution to each well in the dark. 
3. Allow the colour to develop for 5 to 10 minutes by covering the plate with aluminum foil and in the 
dark 
4. Stop the colour development by adding 100 μL of 1N H2SO4 stop solution. 
5. Read absorbance at 450 nm. 
 
Expected Results: 
• Note that the standard curve is a nonlinear regression curve fitted with sigmoidal dose response.  This 
means to use the 4-parameter or 5-parameter curve fit; there are very subtle differences (eg. an 
additional parameter in 5-parameter) between the two models, but does not make real differences in 
the absolute values. 
 
Storage Conditions of Products and Reagents: 
• Place all diluted primary and secondary antibodies on ice before use. 
 
Notes: 
• Always have the next reagent ready in basins – do not allow the plate/strip to dry! 
• This protocol is adopted from the Abcam protocol for indirect ELISA. 
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 APPENDIX E 
IMMUNOFLUORESCENCE 
Purpose: To examine actin morphology in unstimulated and stimulated CD4+ T cells. 
 
Reagents: 
• Keep all wet reagents at 4 °C, except antifade at -20 °C. 
Dry Reagents Wet Reagents 
• Coverglass (Corning, 2935-225) 
• Lab-Tek II 2-well glass chamber slide (Nalge, 
154461) 
• Anti-CD3 (eBioscience, 16-0031-85) 
• Anti-CD28 (eBioscience, 14-0281) 
• Rabbit anti-WASp (Santa Cruz, #) 
• Alexa 568-Phalloidin (Invitrogen, A12380) 
• FITC-Cholera Toxin B (Sigma, C1655) 
• Alexa 647-TCRβ (BioLegend, 109218) 
• Alexa 488-Zap 70 (Invitrogen, MHZap7020) 
• Goat anti-Rabbit Alexa 647(Inviroten, A21246) 
• Coverglass antifade reagent medium 
(Invitrogen, P36934) 
• 100 mM glycine (Sigma, G7126) 
o Make 100 mM by dissolving 7.507 g of 
glycine in 1 L PBS 
• 0.1%(w/v) Poly-L-Lysine solution (Sigma, 
P8920) 
• 20% PFA in PBS (EMS, 15713-S) 
• 10% Triton X-100 (Fluka, 93443) 
• Blocking solution 
o 1% IgG-free BSA (Roche, 03116956001) 
o 0.1% NaN3 (Sigma, S2002) 
o 98.3% PBS (Gibco, 21600-069) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 200 92.94   
Heat-inactivated FBS (Irvine Scientific, 
300320439) 
10.8 5.02   
Glutamax (Gibco, 35050-061) 2.2 1.02 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 2.2 1.02 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Procedures: 
Precoating chamber slides for seeding cells 
1. Must perform this the day before the 
assay. 
2. Dilute 10X poly-L-Lysine solution with 
sterile H2O to 1X (0.1% w/v to 0.01% 
w/v). 
3. Precoat Lab-Tek II 2-well glass chamber 
slides with 0.01% poly-L-lysine by adding 
2 mL of 0.01% poly-L-Lysine/well for 30 
min at room temperature.  Replace the lids 
Precoating chamber slides for plated CD3/CD28 
activation 
1. Must perform this the day before the assay. 
2. Dilute 10X poly-L-Lysine solution with sterile H2O 
to 1X (0.1% w/v to 0.01% w/v). 
3. Precoat Lab-Tek II 2-well glass chamber slides 
with 0.01% poly-L-lysine by adding 2 mL of 0.01% 
poly-L-Lysine/well for 30 min.  Replace the lids 
back on while the chamber slides are incubating. 
4. Aspirate excess solution and sterile the slides under 
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 back on while the chamber slides are 
incubating. 
4. Aspirate excess solution and sterile the 
slides under UV light for 1 hr.  Leave the 
lids off. 
5. The next day, wash chamber slides with 1 
mL of warm complete RPMI once time.  
Add warm complete RPMI into each 
chamber, shake gently by hand, and then 
aspirate off the media.   
6. Prewarm the coated chamber slides with 
200 μL of warm complete RPMI 3 times at 
37 °C for 30 min at least.  Leave in the 
incubator until seeding. 
UV light for 1 hr.  Leave the lids off. 
5. Dilute anti-CD3 (stock 1 mg/mL) 1:1000 and anti-
CD28 (stock 1 mg/mL) 1:100 in PBS in a single 
tube. 
• Example, if need 1 mL, add 1 µL of anti-CD3, 
10 µL of anti-CD28, and 989 µL of PBS. 
• Add 200 µL of antibodies per chamber slide.  
For control (unstimulated), add 200 µL of PBS 
per chamber slide. 
6. Incubate chamber slides on a shaker (gently) in the 
4 °C walk-in cold room at a speed setting of 4, 
overnight.  Replace the lids back on to ensure 
sterility. 
7. The next day, wash chamber slides with 1 mL of 
warm complete RPMI once time.  Add warm 
complete RPMI into each chamber, shake gently by 
hand, and then aspirate off the media.   
8. Prewarm the coated chamber slides with 200 μL of 
warm complete RPMI 3 times at 37 °C for 30 min 
at least.  Leave in the incubator until seeding. 
Isolation of CD4+ T Cells 
1. Follow Isolation of T cells protocol. 
2. After isolation of T cells, resuspend the CD4+ T cells with warm complete RPMI to get a final 
concentration of T cells at 5 x 106 cells/mL in RPMI media. 
3. Seed 1 mL/well dropwise by adding the cell suspension onto the 200 µL complete media in the well.  
This equates to 5 x 106 cells per well. 
• Final anti-CD3 concentration = 0.17 µg/mL (but is actually higher since plated, not suspended). 
• Final anti-CD28 concentration = 0.83 µg/mL (but is actually higher since plated, not suspended). 
4. Incubate at 37 °C for 30 minutes. 
 
Fixing the Cells 
1. Make 4% PFA by combining 4 mL of 20X PFA and 16 mL of PBS. 
• Always make PFA fresh (i.e. the same day of experiment). 
2. Wash the cells on the chamber slides with PBS 3 times for 2 min each, then immediately fix the cells 
in the freshly made 4% PFA for 20 min at room temperature. 
3. Rinse the samples with PBS 2 times for 2 min each, and incubate cells with 10 mM glycine in PBS for 
10 min at room temperature. 
• This step is performed to quench aldehyde groups. 
• Stock at 100 mM, so dilute 1:10 in PBS. 
4. Wash the chamber slides with PBS 2 times for 2 min each, and permeabilize the cells by using 0.2% 
Triton X-100 in PBS for 5 min at room temperature. 
• Stock at 10%, so dilute 1:50 in PBS. 
5. Wash the chamber slides with PBS 3 times for 2 min each. 
6. Incubate cells in blocking solution at 4 °C overnight in a humid chamber. 
• Humid chamber consists of the plastic slide holders.  Alternate between slide and wet Kimwipe 
PBS. 
 
Applying Antibody  
1. Wash the chamber slides with PBS 3 times for 2 min each. 
2. Dilute the antibody in the following manner in the dark. 
Antibody Stock Dilution Final Per well 
Anti-cholera toxin B 250 μg/mL 1:25 10 μg/mL 8 µL antibody + 192 µL Blocking 
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 Phalloidin 200 U/mL 1:10 20 U/mL 20 µL antibody + 180 µL Blocking 
Anti-TCRβ 500 μg/mL 1:10 50 μg/mL 20 µL antibody + 180 µL Blocking 
Anti-Zap70 200 μg/mL 1:15 13μg/mL 13 µL antibody + 187 µL Blocking 
Anti-WASp 200 μg/mL 1:50 4 μg/mL 4 µL antibody + 196 µL Blocking 
3. Incubate each chamber slide with 200 μL per well at room temperature for 1 hr in a humid chamber.  
The slides much be protected from light. 
• Wrap aluminum foil around the humid chamber and put in a drawer for extra protection against 
light exposure. 
• Cells are labeled much better when antibodies applied sequentially.  This means that only one 
antibody is incubated in each well for 1 hr, followed by 2 washes with PBS for 2 min each, and 
then add the second antibody.  The order of application does not seem to affect the fluorescence, 
but typically if one antibody is much stronger, apply that one first. 
4. (If required) Dilute the secondary antibody in the following manner in the dark. 
Antibody Stock Dilution Final Per well 
Goat anti-Rabbit Alexa 647  2 mg/mL 1:300 6 μg/mL 0.67 µL antibody + 199.4 µL 
Blocking 
5. Incubate each chamber slide with 200 μL per well at room temperature for 1 hr in a humid chamber.  
The slides much be protected from light. 
• Wrap aluminum foil around the humid chamber and put in a drawer for extra protection against 
light exposure. 
6. Prepare the ProLong medium during the last 1 hr antibody incubation by thawing at room temperature 
for 1 hr (stored in -20 °C freezer). 
7. Wash the chamber slides with PBS 3 times for 2 min each. 
 
Preparation for Wash 
1. Use slide separator to remove the chamber.  Put slides on a slide holder for subsequent washes. 
2. Incubate the slides in 70% ethanol once for 2 min.  
3. Incubate the slides in 95% ethanol once for 2 min. 
4. Incubate the slides in 100% ethanol once for 2 min. 
5. Incubate slides in fresh xylene twice for 2 min each.  This means that one would need two fresh 
xylenes. 
6. Apply a small amount of antifade reagent medium mixture to the coverglass.  Cover the slide while it 
is still wet. 
• Use a glass rod to line the antifade reagent medium on the side of the coverglass, and then cover 
the slide at a 45° angle to avoid bubbles. 
• Use a razor blade to help with the coverslip. 
7. Place the slide on a flat surface in the dark to dry overnight at room temperature in the fume hood.  
Protect from light. 
Finalizing the Slides 
1. Seal the coverglass to the slide with fingernail polish to prevent shrinkage of mounting medium and 
subsequent sample distortion. 
2. After sealing, let it dry for at least 15 min, then store the slide upright in a slide box at -20°C.  
Desiccant may be added to the box to ensure that the slide remains dry. 
3. Examine sample under fluorescence microscopy. 
 
Expected Results/Outcome 
• Actin fluorescence should be high in stimulated and low in unstimulated, with localization at the 
periphery of the cells. 
• Zap70 should be recruited to the periphery of the cells upon stimulation. 
 
Storage Conditions of Products/Reagents 
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 • Antibodies should be stored at the appropriate temperature (check the product sheet); however, stored 
diluted antibodies on ice before applying them onto the chamber slides. 
• Blocking solution should be stored on ice after preparation. 
 
Notes 
• When imaging, always do a 3D z-stack to ensure that fluorescence is contributed to the plasma 
membrane, and not cytoplasm.  Actin should be recruited to the plasma membrane upon stimulation 
• If use the Chapkin lab microscope, excitation and emission are already set up.  The buttons for them 
are the following: 
Antibody Fluorophore Excitation/Emission for Chapkin Lab Microscope 
Anti-cholera toxin B FITC FITC 
Phalloidin Alexa 568 TRITC 
Anti-TCRβ Alexa 647 Cy3 
Anti-Zap70 Alexa 467 FITC 
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 APPENDIX F 
T CELL STIMULATION USING ANTI-CD3/ANTI-CD28 COATED BEADS 
Purpose: To examine the recruitment of proteins in unstimulated and stimulated CD4+ T cells upon anti-
CD3/anti-CD28 coated beads. 
 
Reagents: 
• Keep all wet reagents at 4 °C, except antifade at -20 °C. 
Dry Reagents Wet Reagents 
• Coverglass (Corning, 2935-225) 
• Lab-Tek II 2-well glass chamber slide 
(Nalge, 154461) 
• Anti-CD3/anti-CD28 coated beads (Invitrogen, 
#114.53D) 
• 0.1%(w/v) Poly-L-Lysine solution (Sigma, P8920) 
• Complete RPMI Media 
 Vol 
(mL) 
% Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 200 92.94   
Heat-inactivated FBS (Irvine Scientific, 300320439) 10.8 5.02   
Glutamax (Gibco, 35050-061) 2.2 1.02 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 2.2 1.02 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Procedures: 
Precoating chamber slides for seeding cells 
9. Must perform this the day before the assay. 
10. Dilute 10X poly-L-Lysine solution with sterile H2O to 1X (0.1% w/v to 0.01% w/v). 
11. Precoat Lab-Tek II 2-well glass chamber slides with 0.01% poly-L-lysine by adding 2 mL of 0.01% 
poly-L-Lysine/well for 30 min at room temperature.  Replace the lids back on while the chamber 
slides are incubating. 
12. Aspirate excess solution and sterile the slides under UV light for 1 hr.  Keep the sterilized slide with 
lid on at RT overnight in the hood. 
13. The next day, wash chamber slides with 1 mL of warm complete RPMI once. 
14. Dynabeads come at a concentration of 4 x 107 beads/mL.  Since the bead:cell ratio is 1:1, want to use 
3.5 x 106 beads.  This equates to approximately 87.5 µL of beads per well.   
15. To wash the beads take the appropriate amount of beads into a 1.5 mL Eppendorf tube.  Add at least 
an equal amount of cold PBS.  Vortex for 5 sec, and then set it on the Dynabead magnet (Life Tech, 
#12321D) for 1 min.  Aspirate off the supernatant with the tube still on the magnet. 
16. Remove the bead/tube from the magnet, then resuspend the beads in 200 μL per well of complete 
RPMI media, and then add the beads into the wells.  Incubate at 37 °C for 30 min at least. 
 
Isolation of CD4+ T Cells 
5. Follow Isolation of T cells protocol. 
6. After isolation of T cells, resuspend the CD4+ T cells with warm complete RPMI to get a final 
concentration of T cells at 3.5 x 106 cells/mL in RPMI media. 
7. Seed 1 mL/well dropwise by adding the cell suspension onto the 200 µL complete media in the well.  
This equates to 3.5 x 106 cells per well. 
8. Incubate at 37 °C for 30 minutes. 
9. Continue to Immunofluorescence. 
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 APPENDIX G 
IMMUNOISOLATION 
Purpose: To isolate immunological synapse from CD4+ T cells to detect signaling complex formations 
upon T cell activation. 
 
Reagents: 
• Keep all wet reagents at 4 °C. 
Dry Reagents Wet Reagents 
• 15 mL conical tube 
• 2 mL microcentrifuge tube 
• 1.5 mL microcentrifuge tube 
• BioMag separator  
(Polyscience, #84102S-1) 
• DynaMag separator 
(Invitrogen, #123-21D) 
• N2 cavitation apparatus 
(Parr Instrument, #4635) 
• Homogenization buffer 
• Dynabeads mouse T-activator CD3/CD28 
(Invitrogen, #114.53D) 
• PBS 
(Gibco, 21600-069) 
• Homogenization buffer A (store at – 20 ⁰C) 
Components Amount for 500 mL Final Conc 
250 mM Sucrose 42.75 g 250 mM 
1 M Sodium HEPES, pH = 7.2  
26.03 g/100 mL (Acros, 32726100) 
5 mL 10 mM 
1 M MgCl2 
In solution (Sigma, M-1028) 
1 mL 2 mM 
500 mM NaF 
2.10 g/100 mL 
10 mL 10 mM 
ddH2O 484 mL  
• Complete homogenization buffer 
o Dilute 10 mM activated sodium orthovanadate 1:100 in homogenization buffer A 
o Dilute protease inhibitor cocktail 1:25 in homogenization buffer A 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 200 92.94   
Heat-inactivated FBS (Irvine Scientific, 
300320439) 
10.8 5.02   
Glutamax (Gibco, 35050-061) 2.2 1.02 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 2.2 1.02 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Procedures 
Isolation of CD4+ T Cells  
1. Follow Isolation of T cells protocol. 
2. After isolation of T cells, resuspend the CD4+ T cells with warm complete RPMI to get a final 
concentration of T cells at 1.5 x 107 cells/1 mL in RPMI media.   
 
Preparation of Dynabeads and Cell-Bead Conjugates 
10. Dynabeads come at a concentration of 4 x 107 beads/mL.  Since the bead:cell ratio is 1:2, want to use 
7.5 x 106 beads. 
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 • This equates to approximately 187.5 µL of beads per sample. 
11. Transfer an appropriate amount of beads into a new tube, and wash the beads by adding an equal 
volume of PBS.  Vortex the sample for at least 5 seconds. 
• Normal tip should be sufficient for transferring the beads. 
12. Place the tube on the DynaMag separator for 1 min, then discard the supernatant.  Remove the tube 
from the magnet and resuspend the washed Dynabeads in 500 µL per 187.5 µL of beads using culture 
medium. 
13. Transfer 1 mL of cell suspension into a 2 mL microcentrifuge tube.  Add 500 µL of beads.  Mix well 
by pipetting gently. 
14. Allow for cell-bead conjugates to form by leaving on ice for 7 minutes.  Flick the tube occasionally. 
15. Transfer the bead-cell conjugate to 37 ⁰C and incubate for 30 min.   
• Can do shorter time if desired. 
• Conjugate formation can be monitored under microscope. 
16. After incubation, immediately add 1 mL of ice cold complete homogenization buffer. 
17. Spin the cells at 2000 rpm for 1 min at 4 ⁰C. 
18. Resuspend in the cells in 1 mL of ice cold complete homogenization buffer. 
19. Transfer the cells into the cavitation chamber. 
 
Cavitation Bomb Apparatus (Parr Instrument, #4635) and Cavitation of the Sample 
1. Install the whole apparatus in the 4 ⁰C overnight. 
2. The outlet of the cavitation bomb apparatus needs to be fitted with a silicone tube that allows for the 
sample to be discharged into a 15 mL conical tube.  Insert the tube through a hole in the cap of a 15 
mL conical tube.  Punch 5 to 10 holes in the cap with an 18 gauge syringe needle to allow the release 
of over-pressure from the sample. 
• Make sure that the tube is in tight fit with the cap, but not obstructed. 
3. Refer to the following figure for the valves: 
 
4. Ensure that valve 5 is closed.  Apply 1 mL of the sample to the conical bottom of the chamber and stir 
at full speed on the magnetic stir plate. 
5. Close the bomb and attach the hose from the filling connection (black tubing in the figure).  Confirm 
that valves 1, 2, 3, and 5 are closed.  Open valve 4. 
6. Pressurize the bomb by slowly turning valve 1 until the pressure guage on the filling connections 
indicates full pressure (i.e. > 1500 psi). 
7. Carefully open control valve 2 of the filling connection.  Fill the cavitation bomb to the desired 
pressure (i.e. 800 psi) and then close valve 2. 
8. As the nitrogen dissolves into the sample within the next 15 seconds, the pressure will drop.  Readjust 
the pressure to the desired level (i.e. 800 psi) and then close inlet valve 4. 
9. Close valve 1 on the N2 tank. 
10. Release the pressure from the filling connection and the hose by opening valves 3 and 2 in that order. 
11. Detach the filling hose from the cavitation bomb and incubate the bomb for 7 minutes. 
12. Screw the cap of the 15 mL tube that is already connected to the tube onto a new 15 mL conical tube 
to collect the sample. 
• Although there are small holes in the cap to release overpressure, use caution when collecting the 
sample because overpressure could cause silicon tube to pop off the cap, causing loss of sample. 
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 13. Release the sample by slowly opening valve 5.  Ensure that the sample flows at a rate of a few drops 
per second. 
14. After the sample has been released into the tube, transfer the sample to 1 new 1.5 mL microcentrifuge 
tube.  Fill the 15 mL conical tube with 3 mL of complete homogenization buffer. 
15. Release the excess pressure from the cavitation bomb by opening valve 4. 
16. Rinse the bomb with PBS and wipe the inside dry. 
 
Preparation of Samples for Analysis 
1. Conduct the following in 4 ⁰C. 
2. Retrieve the beads by placing the 1.5 mL microcentrifuge tube with the samples in the Dynabead 
magnet for 5 minute.  During the 5 min incubation, gently invert the tube together with the magnet 
several times to release as many beads as possible trapped in the foam. 
3. Take 100 µL of the homogenate for determining the yield.   
4. Remove the foam first then the supernatant with a Pasteur pipette attached to a vacuum pump and a 
bottle trap.  Keep the samples on ice. 
5. Wash the samples 3X by resuspending in 1 mL of ice cold homogenization buffer in the 1.5 mL 
microcentrifuge tube (step 14 from above) and retrieve as in Step 2 after each wash. 
6. After the last wash, resuspend the beads in 100 µL of ice cold complete homogenization buffer.   
7. Proceed to Commassie blue assay and Western blot. 
 
Notes: 
• Instead of making sodium pervanadate, use the “activated” sodium orthovanadate available in the -20 
⁰C at 1:100 dilution. 
o 100 mM sodium vanadate (Sigma-Aldrich) 
1. Dissolve 950 mg of sodium orthovanadate in 40 mL of ddH2O. 
2. Adjust pH to 10.2 with HCl.  Solution should be orange. 
3. Heat in a microwave until solution starts to boil.  Solution should be clear. 
4. Adjust pH to 10.2 with 1 M NaOH carefully. 
5. Heat in a microwave until solution starts to boil. 
6. Check the pH is between 9.9 and 10.1.  Repeat Steps 2 through 5 if necessary. 
7. Store in aliquots at -20 ⁰C. 
o 10 mM pervanadate 
1. 10 µL of 100 mM sodium vanadate (see above) 
2. 10 µL of 30% H2O2 
3. 80 µL of ddH2O 
4. Leave the solution at room temperature for 10 min, then use immediately to prepare the 
homogenization buffer 
• Instead of making 1000X CLAP, use the protease inhibitor cocktail (Sigma) available in the -20 ºC at 
1:25 dilution 
o 1000X CLAP (Sigma-Aldrich) 
1. 5 mg of chymostatin 
2. 5 mg of leupeptin 
3. 5 mg of antipain 
4. 5 mg of pepstatin 
5. Dissolve in 500 µL of DMSO.  Store at -20 ⁰C in 50 µL aliquots 
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 APPENDIX H 
CLONING 
Overall Flowchart: 
Day Steps 
1 
PCR insert 
Gel purification of insert 
Restriction digest of vector and insert 
Verification of digest using agarose gel 
Gel Purification of digested vector and insert 
Ligation of vector and insert 
2 Bacterial transformation of plasmid 
3 Overnight Culture 
4 Miniprep of plasmid 
5  Verification of plasmid using sequencing 
 
Day 1 (PCR, Gel Purification, Restriction Digest, Gel Purification, Ligation): 
 
Generation of Insert with Unique Restriction Cut Sites 
Reagents: 
• Keep all wet reagents at 4 °C. 
Dry Reagents Wet Reagents 
 • 5’ and 3’ primers diluted in nuclease-free water 
• 25 mM MgCl2 
• 10 mM dNTPs 
• 10X reaction buffer 
• Pfu polymerase 
• Nuclease-free water 
 
Procedures: 
1. Use CLC sequence viewer to determine the restriction cut sites that you are going to use.  In general, 
pick 2 restriction cut sites that are in the multiple cloning sites of the vector (MSCV for retrovirus and 
pLenti for lentivirus). 
2. Check to make sure that these multiple cloning sites do not exist in your coding sequence (CDS).  If 
they do exist, then you are just cutting your CDS and thus would give you fragments. 
3. In the end, you will choose two restriction sites that are present in the multiple cloning sites of the 
vector but absent in your coding sequence. 
4. Design primers for your coding sequence that contain your chosen restriction cut sites. 
a. Upstream (5’, forward) primers 
i. Start with 5 x C 
ii. Restriction site sequence 
iii. If including fluorescent tag at the C-terminus, then add Kozak sequence (ACC ATG).  
iv. If including fluorescent tag at the N-terminus, then omit the Kozak sequence since it will be 
present before the fluorescent tag.  Verify that this is the case using CLC sequence viewer. 
v. 12 to 15 complementary nucleotides from the 5’ region of your CDS. 
vi. Should have 5’-CCCCC-(Cut Site)-(Kozak Sequence, if needed)-(12/15 of CDS)-3’ 
b. Downstream (3’, reverse) primers 
i. Start with 5 x C 
ii. Restriction site sequence 
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 iii. If including fluorescent tag at the N-terminus, then add STOP codon (5’-3’: ATC, ATT, or 
ACT). 
iv. If including fluorescent tag at the C-terminus, then omit STOP codon since it will be present 
after the fluorescent tag.  Verify using CLC sequence viewer. 
v. 12 to 15 complementary nucleotides from the 3’ region of your CDS. 
vi. Should have 3’-(12/15 of CDS)-(STOP, if needed)-(Cut site)-CCCCC-5’ 
5. Make sure the primers adhere to the following rules: 
a. Use http://www.idtdna.com/analyzer/applications/oligoanalyzer/ for analysis.  Use Default 
Settings and we will alter Mg2+ concentrations in our PCR reactions to optimize the reactions. 
b. 18-30 oligonucleotides long.  The longer end of this range allows higher specificity and gives 
more space to add restriction enzyme sites and additional sequences. 
c. Melting temperature (Tm) between 65 to 70 °C.  Make sure the primers are not more than 5 °C 
different from each other.  Equation for Tm: Tm = 4(G+C) 2(A + T) 
d. Annealing temperature (Ta) of 10 to 15 °C lower than the Tm. 
e. GC content of each primer between 40 to 60%. 
f. In the CDS, have uniform distribution of G and C nucleotides, as clusters of G’s or C’s can cause 
non-specific priming. 
g. Avoid long runs of the same nucleotide. 
h. Ensure that there are no self- or cross-complementary sequences.  Complementary sequences will 
encourage formation of hairpins and primer dimmers and will compete with template for use of 
primer and reagent. 
i. If possible, terminate the primers at the 3’ end with C or A since neither C nor A nucleotide 
wobbles, allowing specificity and stability. 
j. If possible, make the 3’ end slightly AT rich to avoid mispriming. 
6. Dilute the primers by the following protocol: 
a. Add appropriate nuclease-free H2O to the lyophilized primers to make the final concentration of 
100 µM. 
b. Flick the tube a few times and then allow the tube to sit at room temperature for 10 minutes.  
Flick the tubes a few more times and spin down briefly. 
c. Aliquot 100 µL of the primer into 0.6 mL Eppendorf tubes.  Label with the date, primer name, 
and initial. 
d. Store the primers in -80 °C. 
e. To make a working solution, dilute the stock 1:10 (i.e. add 30 µL of stock into 270 µL of 
nuclease-free water).  This makes a 10 µM working concentration (100 µg/mL). 
7. Make the following reaction tubes of MgCl2, primers, and nuclease free water. 
 Tube 1 
(Control) 
Tube 2 
(Control) 
Tube 3 
(No Template) 
Tube 4 
(No MgCl2) 
Tube 5 Tube 6 
5’ primer 5 0 5 5 5 5 
3’ primer 0 5 5 5 5 5 
25 mM MgCl2 4 4 4 0 4 8 
ddH2O 9 9 6 8 4 0 
8. Make the master mix containing the following components. 
Reagents Amounts 
10X Buffer 35 
10 mM dNTPs 7 
DMSO (if required) 35 
Nuclease-free H2O 165 (135 if DMSO included) 
Pfu (2.5 U/µL) 3 
Total 210 
• If product has high secondary structure (G-C rich), then add DMSO to a final concentration of 
10% to destabilize secondary structures. 
9. Add 30 µL of master mix into each reaction tube.  Final volume at this point is 48 µL. 
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 10. Add 2 µL of template DNA into each reaction tube except for Tube 3 (no template control).  Template 
concentration should be around 10 to 20 ng/µL (this concentration can be varied depending on the 
amplification efficiency). 
11. Use the following cycling program: 
Temperature Time Cycles 
95 °C 30 sec 
5 40 °C 30 sec 
72 °C 72 sec 
95 °C 30 sec 
30 60 °C 30 sec 
72 °C 2 min 
72 °C 10 min 1 
8 °C O/N 1 
• Pfu polymerase has an elongation rate of 1000 base/min.  Adjust the 72 °C elongation step time 
(in grey) to allow for Pfu polymerase to extend.  For example, if product is 1500 bases, then 
1500/1000 = 1.5 min.  Round 1.5 min to 2 min to allow for full extension. 
• For particularly long products (≥2 kb), can increase number of cycles, amount of polymerase, 
amount of template DNA. 
 
Agarose Gel Electrophoresis 
Reagents: 
Dry Reagents Wet Reagents 
• Agarose gel electrophoresis 
• Visi-Blue Converter plate 
(Bioexpress, U-2202) 
• Agarose (Phenix, RXA-2100MS) 
• 10X TAE buffer (Sigma, T9650) 
• Hyperladder IV 1 kb Ladder (Bioline, BIO-33029) 
• 5X sample buffer (Bioline, BIO-33029) 
• Gel-Green (RGB-4105) 
• 1X TAE buffer 
o Dilute 10X TAE buffer in nuclease-free ddH2O.  Store at 4 ºC. 
 
Procedures: 
1. Make 0.75% agarose gel: 
a. Weigh 0.75 g of agarose and transfer into a 250 mL conical flask.   
b. Add 100 mL of 1X TAE and twirl a few times to allow for some mixing.   
c. Microwave for 90 seconds.  Swirl the mixture and microwave for an additional 30 sec.  Check 
again and microwave as required.  Prepare the gel rig while agarose is dissolving.   
d. Allow the gel to cool to 60 °C, and add 7 µL of Glow-green. 
e. Pour the agarose into the tray, making sure no bubbles are formed.  Use a P10 tip to either pop 
the bubbles or move it to the end of the gel.  Insert the 10 well comb. 
f. Allow the agarose to solidify and cool down. 
2. Prepare sample by adding 5 μL of sample buffer to the reaction. 
3. Load the sample (all 20 µL) in the 0.75% agarose gel and run the sample for 45 min at 100 V in the 
cold room. 
4. Place the Visi-Blue converter plate on top of the UV transilluminator, and place a glass plate on the 
top of the coverter plate for cutting the gel.  Wear dark reader glasses or place the amber screen over 
the gel in order to visualize the bands. 
5. To determine whether the PCR was successful, look for the appropriate size band for the product.  If 
the bands are at the correct size, and the intensity is good (i.e. don’t have to expose the gel for a long 
time), continue to the next step. 
6. Excise the gel with the appropriate size PCR product band, and continue with PCR product 
purification. 
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 PCR Product Purification 
Reagents: 
Dry Reagents Wet Reagents 
• Supplied by Qiagen PCR Purification Kit 
#28104 
• If need additional columns, can order from 
Denville CM500-250, which are compatible 
with Qiagen buffers 
• Supplied by Qiagen PCR Purification Kit 
#28104 
 
Procedures: 
1. Follow the protocol provided by Qiagen PCR Purification Kit #28104. 
2. Elute the DNA with warm (i.e. 50 °C) nuclease-free H2O so that the buffer won’t affect the ligation. 
3. After elution, make sure to quantify the amount of DNA By using the Nandrop. 
 
Restriction Digest 
Reagents: 
• Keep all wet reagents at 4 °C. 
• Make sure the NEBuffer does not have any precipitates 
Dry Reagents Wet Reagents 
• 0.2 mL PCR tube 
(GeneMate, C-3328-
2) 
• 10X NEBuffer (NEB, depends on which restriction enzymes you use). 
• 10X BSA (NEB, B9001S), if required. 
• Restriction Enzymes (NEB, depends on which ones you use). 
• Nuclease-free H2O 
 
Procedures: 
1. Use CLC sequence viewer to determine the restriction cut sites that you are going to use.   
2. Set up the following reaction in a sterile microcentrifuge tube, adding the restriction enzyme last. 
Reagents Amounts 
DNA (0.5 to 1 µg) 1 to 5 µL 
10X NEBuffer 2 µL 
10X BSA (if needed) 2 µL 
Restriction Enzymes 0.3 to 1 µL (1 to 4 units per enzyme) 
Nuclease-free H2O  to 20 µL 
Total 20 µL 
• Always make a master mix and aliquot into the samples. 
• Check the compatibility of the buffer with the restriction enzyme by looking up 
https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder 
• Make sure to use the buffer that has the highest % activity for the two enzymes chosen. 
• Check if BSA is required for a particular pair of restriction enzymes. 
• Always try to get High Fidelity enzymes (HF).  These enzymes have reduced star activity (non-
specific digestion), and have 100% activitiy in Buffer 4 (CutSmart Buffer in May 2013). 
• Include a negative control of no enzyme (uncut) 
3. Gently mix the reaction flicking the reaction and then centrifuge briefly to collect the reagents to the 
bottom of the tubes. 
4. Incubate at the recommended temperature and time.  The reaction is usually at 37 °C for 1 hour.  If 
using High Fidelity enzymes (HF), can incubate as short as 15 min. 
5. Terminate the reaction by heat inactivation if mentioned for the reaction enzyme.  This can be found 
at https://www.neb.com/tools-and-resources/interactive-tools/enzyme-finder and search for your 
specific enzyme.  This is usually 65 ºC for 20 min, or 80 ºC for 20 min. 
6. Run the whole sample on a 0.75% gel.  Make sure to load the negative control for both the vector and 
the insert to verify that the restriction digest has worked. 
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 7. Repeat PCR Product Purification and PCR Product Purification. 
 
Ligation Reaction 
Reagents: 
• Keep all wet reagents at 4 °C. 
• Make sure the NEBuffer does not have any precipitates 
Dry Reagents Wet Reagents 
• 0.5 mL low DNA-binding microcentrifuge 
tubes 
• Promega T4 DNA Liganse (Cat# 26808109) 
• Promega Ligase Buffer (Cat# 27464304) 
• Nuclease-free H2O 
 
Procedures: 
1. Briefly centrifuge the digested vector and insert, ligase buffer, and ligase to collect the reagents to the 
bottom of the tubes. 
2. Set up a 1:1, 2:1, 3:1 molar ratio of insert:vector DNA by the following calculations: 
ng of vector x kb (size of insert)
kb (size of vector)
 × Molar ratio of 
Insert
Vector
=ng of insert 
• Example: if the insert is 1500 bp, and vector is 7031 bp, and want to use 50 ng of vector, then 
how much ng of insert is needed for a 2:1 reaction? 
50 ng of vector x 1500 bp (insert)
7031 bp (vector)
 × Molar ratio of  
2 Insert
1 Vector
=21.3 ng of insert 
3. Set up the following reactions, adding the enzyme last.  Note that the volume can be scaled up linearly 
if required. 
Reaction Components Control 1:1 2:1 3:1 
10X Ligation Buffer, T4 DNA 
ligase 1 µL 1 µL 1 µL 1 µL 
Linear Vector (50 ng) 1 µL Variable Variable Variable 
PCR product (Insert) 0 µL Variable Variable Variable 
T4 DNA ligase (3 Weiss U/µL) 0.5 µL 0.5 µL 0.5 µL 0.5 µL 
ddH2O 5.5 µL Variable Variable Variable 
Total 10 µL 10 µL 10 µL 10 µL 
4. Mix the reactions by pipetting up and down. 
5. Incubate the reactions for 3 hour at room temperature. 
• After the reactions are complete, can store at -20 °C if required for a maximum of 1 week. 
• If positive control for the transformation worked, but the transformations from the ligations did 
not, can set up higher ligation ratios if required (i.e. 10:1, or even 30:1). 
6. Heat inactivate by placing the reactions at 65 °C for 10 minutes to inactivate any proteins in the 
mixture and to dissociate noncovalently ligated DNA ends. 
 
Day 2 (Transformation): 
 
Transformation 
Reagents: 
• Keep all wet reagents at 4 °C. 
Dry Reagents Wet Reagents 
• Spreading loop • Competent DH5α bacterial cells 
• LB broth, no antibiotic 
 
Procedures: 
1. Preheat the following equipments 
a. Heat block: 42 °C 
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 b. Shaking incubator: 37 °C 
c. Appropriate drug resistant agar plate (i.e. ampicillin or kanamycin): warm to room temperature. 
2. Bring competent bacterial cells out of the –80 °C and thaw it on ice.  Should take around 10 minutes. 
3. Add 5 µL of the ligation reaction to the 1.5 mL tube containing the competent cells (should contain 50 
µL).  Mix gently with the pipette by stirring, not pipetting up and down. 
• Add a negative control (5 µL ddH2O instead of ligation reaction), and a positive control (5 µL of 
complete vector, i.e. uncut vector). 
4. Incubate on ice for 30 minutes. 
5. Incubate at 42 °C heat block for 45 seconds. 
6. Incubate on ice again for 2 minutes. 
7. Add 900 µL of SOC media without drug to the 1.5 mL tubes containing the competent bacterial cells 
and the ligation mix. 
8. Incubate for 1 h at 37 °C at 200 rpm on a shaking incubator. 
• Colour should turn from clear to cloudy. 
9. Pipette 50 µL of bacterial colony onto the plate and spread using the spreading loop.  Try not to poke 
the agar plate.  Repeat with 200 µL of bacterial colony onto a second plate 
10. Once the spreading is done on both halves, invert the plate and incubate at 37 °C overnight. 
 
Day 3 (Overnight Culture): 
 
Overnight Culture (Small Scale) 
Reagents: 
• Keep all wet reagents at 4 °C. 
Dry Reagents Wet Reagents 
• Inoculation loop 
• 15 mL polypropylene culture tube 
• LB broth with antibiotic (ampicillin or 
kanamycin) 
 
Procedures: 
1. The next morning, check to see whether there are colonies. 
• Look for white and cloudy colonies. 
• Very small clear colonies are bad. 
• Also check to see whether negative control (i.e. ddH2O) has any colonies. 
2. If enough colonies are found (i.e. 2 to 4 colonies for one sample), circle around the colonies that you 
want to pick. 
3. Saran wrap or parafilm the plates and place in 4 °C.  Will not pick the colonies until approximately 
4:30 pm because don’t want the culture to overgrow. 
4. Prepare growth media by adding 5 mL of LB medium with antibiotic (ampicillin at final concentration 
of 50 µg/mL) into each 15 mL polypropylene bacterial culture tube. 
• Label clearly with the plasmid and the number. 
• Make one tube of negative control (i.e. no colony). 
5. At 4:30 pm, use a inoculation loop, and (literally) pick a colony from the agar.  Move the loop up and 
down in the LB medium to ensure that the colony has transferred into the liquid medium. 
6. Label clearly with the plasmid and the number. 
7. Make one tube of negative control (i.e. no colony). 
8. Cap the tubes loosely to allow for air flow. 
9. Incubate overnight on a shaker at 37 °C at 200 rpm. 
 
Day 4 (Miniprep) 
 
Miniprep 
Reagents: 
• Keep all wet reagents at 4 °C. 
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 Dry Reagents Wet Reagents 
• Spreading loop 
• Qiagen Mini Kit #12125 
• LB broth 
• 50 mg/mL stock ampicillin 
• 50% glycerol in ddH2O 
 
Procedures: 
1. The next day, take 500 µL of the bacterial culture and combine it with 500 µL of 50% glycerol.  
Vortex, and store at – 80 °C.  Make sure that this culture is labeled precisely how the original culture 
is labeled, since if the clone is confirmed in later stages, the large scale growth will come from the 
glycerol stock. 
2. With the remaining bacterial culture, follow the protocol from Qiagen Mini kit #12125 to obtain 
plasmids from each colony. 
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 APPENDIX I  
CALCIUM PRECIPITATION – 293T CELL TRANSFECTION 
Day 1 (around 9 am) – Plating of 293T Cells 
Reagents: 
Dry Reagents Wet Reagents 
• 100 mm cell culture plate (BD 
Bioscience, 353803) 
• Complete DMEM media (see below) 
• Dulbecco’s phosphate buffered saline (Gibco, 14190) 
• 0.05% Trypin-EDTA (Gibco, 25300) 
• Complete media 
 Vol (mL) % Stock Conc Final Conc 
DMEM, high glucose formula (Gibco, 10569-010) 500 88.34   
FBS (Hyclone, SH30070.03) 55 9.72   
Pen-strep(Gibco, 15140-148) 5.5 0.97 P 10000 U/mL S 10 mg/mL 
P 100 U/mL 
S 0.1 mg/mL 
 
Procedures: 
1. Warm all media, DPBS, and trypsin to room temperature. 
2. Put complete media into plate.  Incubate at 37 ºC incubator until seeding. 
Size of Plate Amount of media 
6 wells 1.5 mL 
12 wells 500 μL 
3. From the master flask (T175) of 293T cells (i.e. this is the flask that is continuously passaged), 
aspirate off the media and then wash the cells with ~5 mL of DPBS. 
4. Aspirate off the DBPS, and add 3 mL of trypsin to the flask.  Incubate in the 37 ºC incubator for 3 
min.  Move the flask around so that trypsin can be distributed around the plate.  Check under a 
microscope to see whether all the cells have been dislodged.  This should take no more than 5 
minutes. 
5. Harvest the cells by adding 7 mL of media to the flask, and transferring the 10 mL into a 50 mL 
conical tube.  Add an additional 5 mL of complete media to the flask to wash.  Combine with the 
previous 10 mL to have a final volume of 15 mL of media. 
6. Count cell concentration using a hemacytometer. 
7. Centrifuge cells at 100 g for 5 min.  Aspirate off the supernatant. 
8. Resuspend the 293T cells in complete media. Plate 293T cells by seeding 500 μL dropwise into each 
plate.  This will allow the density of the cells to reach around 80% confluent.  
 Size of Plate Cell Concentration for Seeding 
6 wells 5 x 105 cells/500 μL 
12 wells 2.5 x 105/500 μL 
a. Density is very important because transfection efficiency goes down if cells are too clumped 
together. 
 
Day 2 – 4 (start around 9 am) – Virus preparation in 293T cells 
Reagents: 
Dry Reagents Wet Reagents 
• 1.5 mL Eppendorf tube 
• 0.45 μm Acrodisc® Syringe Filter with 
HT Tuffryn® Membrane (Pall Life 
Science, 4184) 
• Complete DMEM media (see above) 
• Dulbecco’s phosphate buffered saline (Gibco, 
14190) 
• 0.05% Trypin-EDTA (Gibco, 25300) 
• 2M CaCl2, filtered.  Stored in -20 °C 
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 • 50 mM chloroquine, filtered.  Stored in -20 °C 
• 2X Transfection Buffer (see below) 
• 2X Transfection Buffer 
o Adjust pH to 7.5 (very critical for the success of the infection).  pH will drift over time, so make 
fresh batch if problems arise. 
o Filter sterilize after pH is adjusted. 
o Store in -20 °C.  Buffer can freeze-thaw a couple of times without compromising transfection 
efficiency. 
 Amount Final Conc 
HEPES 6.5 g 50 mM 
NaCl 8.0 g 270 mM 
Na2HPO4 0.106 g 1.5 mM 
ddH2O 500 mL  
 
Procedures: 
1. Warm complete media and DPBS to room temperature. 
2. Take out the 100 mm plate that contains the plated 293T cells. 
3. Aspirate off the media and wash with ~5 mL of DPBS. 
4. Aspirate off the DPBS and add complete media into the wells. 
Size of Plate Amount of media 
6 wells 2 mL 
12 wells 750 μL 
5. Prepare 1.5 mL Eppendorf tubes for each plasmid that will be transfected (see table below). 
Size of Plate DNA ddH2O 
6 wells 5 µg Up to 94 μL 
12 wells 2 µg Up to 37.5 μL 
6. Add 2M CaCl2 into the Eppendorf tube.  Mix well by vortexing. 
Size of Plate 2M CaCl2 
6 wells 31.25 µL 
12 wells 12.5 µL 
7. Set the vortexer to a speed of 6, vortex the Eppendorf tube containing i) DNA; ii) ddH2O; and iii) 
CaCl2; and add 500 µL of transfection buffer dropwise to the plasmid tube while the tube is vortexing.  
Size of Plate Transfection Buffer 
6 wells 125 µL 
12 wells 50 µL 
8. Add 50 mM chloroquine into the plate immediately before adding the DNA content from 3. 
Size of Plate 50 mM chloroquine 
6 wells 1 µL 
12 wells 0.4 µL 
9. Add the mixture from Step 3 into the appropriate plate dropwise with gentle swirl of the plate.  
Quickly replace the dish in the incubator once the batch is complete. 
• Add dropwise to spread the DNA around the plate.  Cells die easily if DNA is too concentrated in 
one area. 
• There may be a pH change (i.e. colour change).  This is normal. 
10. After 6 hours, replace the media with fresh complete media.  Do not wash with DPBS. 
Size of Plate Amount of media 
6 wells 2 mL 
12 wells 1 mL 
11. Incubate for 24 hours.  The next day, can check for transfection efficiency under the microscope. 
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 APPENDIX J  
GENERATING LENTIVIRUS 
Purpose: To generate lentivirus to transducer plasmids into cells.   Lentiviral transduction has been tested 
on NIH 3T3 cells and primary CD4+ T cells. 
 
Day 1 (around 9 am) – Plating of 293T Cells 
Reagents: 
Dry Reagents Wet Reagents 
• 100 mm cell culture plate 
(BD Bioscience, 353803) 
• Complete DMEM media (see below) 
• Dulbecco’s phosphate buffered saline (Gibco, 
14190) 
• 0.05% Trypin-EDTA (Gibco, 25300) 
• Complete media 
 Vol (mL) % Stock Conc Final Conc 
DMEM, high glucose formula (Gibco, 10569-010) 500 88.34   
FBS (Hyclone, SH30070.03) 55 9.72   
Pen-strep(Gibco, 15140-148) 5.5 0.97 P 10000 U/mL S 10 mg/mL 
P 100 U/mL 
S 0.1 mg/mL 
 
Procedures: 
9. Warm all media, DPBS, and trypsin to room temperature. 
10. Put 10 mL of media into each P100 mm plate.  Incubate at 37 ºC incubator until seeding. 
11. From the master flask (T175) of 293T cells (i.e. this is the flask that is continuously passaged), 
aspirate off the media and then wash the cells with ~5 mL of DPBS. 
12. Aspirate off the DBPS, and add 3 mL of trypsin to the plate.  Incubate in the 37 ºC incubator for 3 
min.  Move the flask around so that trypsin can be distributed around the plate.  Check under a 
microscope to see whether all the cells have been dislodged.  This should take no more than 5 
minutes. 
13. Harvest the cells by adding 7 mL of media to the flask, and transferring the 10 mL into a 50 mL 
conical tube.  Add an additional 5 mL of complete media to the flask to wash.  Combine with the 
previous 10 mL to have a final volume of 15 mL of media. 
14. Count cell concentration using a hemacytometer. 
15. Centrifuge cells at 800 rpm for 3 min.  Aspirate off the supernatant. 
16. Resuspend the 293T cells to a final concentration of 6 x 106 cells/mL in complete media. Plate 293T 
cells in 100 mm plate by seeding 1 mL (6 x 106 cells) dropwise into each plate.  This will allow the 
density of the cells to reach around 80% confluent by Day 2. 
a. Density is very important because infection efficiency goes down if cells are too clumped 
together. 
 
Day 2 – 4 (start around 9 am) – Virus preparation in 293T cells 
Reagents: 
Dry Reagents Wet Reagents 
• 1.5 mL Eppendorf tube 
• 0.45 μm Acrodisc® Syringe Filter with HT 
Tuffryn® Membrane (Pall Life Science, 4184) 
• Complete DMEM media (see below) 
• Dulbecco’s phosphate buffered saline (Gibco, 
14190) 
• 0.05% Trypin-EDTA (Gibco, 25300) 
• 2M CaCl2 (Fisher, C79-500), filtered.  Stored in 
-20 °C 
• 50 mM chloroquine (MP Bio, 193919), filtered.  
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 Stored in -20 °C 
• 2X Transfection Buffer (see below) 
• pGag.pol and pHCMV-G (for MSCV plasmid) 
• pLP1, pLP2, and pVSV-G (for lentiviral 
plasmid) 
• 2X Transfection Buffer 
o Adjust pH to 7.5 (very critical for the success of the infection).  pH will drift over time, so make 
fresh batch if problems arise. 
o Filter sterilize after pH is adjusted. 
o Store in -20 °C.  Buffer can freeze-thaw a couple of times without compromising transfection 
efficiency. 
 Amount Final Conc 
HEPES (Acros Organics, 3272610000) 6.5 g 50 mM 
NaCl (Sigma, S3014-1KG) 8.0 g 270 mM 
Na2HPO4 (Fisher, S373-500) 0.106 g 1.5 mM 
ddH2O 500 mL  
• Complete media 
 Vol (mL) % Stock Conc Final Conc 
DMEM, high glucose formula (Gibco, 10569-010) 500 88.34   
FBS (Hyclone, SH30070.03) 55 9.72   
Pen-strep(Gibco, 15140-148) 5.5 0.97 P 10000 U/mL S 10 mg/mL 
P 100 U/mL 
S 0.1 mg/mL 
 
Procedures: 
12. Warm complete media and DPBS to room temperature. 
13. Take out the 100 mm plate that contains the plated 293T cells. 
14. Aspirate off the media and wash with 3 mL of DPBS. 
15. Aspirate off the DPBS and add 10 mL of complete media onto the cell. 
16. Prepare 1.5 mL Eppendorf tubes for each plasmid that will be transfected (see table below). 
DNA pLP-1 pLP-2 pVSV-G ddH2O 
24 µg 16 µg 6 µg 8 µg Up to 375 μL 
17. Add 125 µL of 2M CaCl2 into the Eppendorf tube.  Mix well by vortexing. 
18. Set the vortexer to a speed of 6, vortex the Eppendorf tube containing i) DNA; ii) ddH2O; and iii) 
CaCl2; and add 500 µL of transfection buffer dropwise to the plasmid tube while the tube is vortexing. 
19. Add 8.4 µL of 30 mM chloroquine into the well immediately before adding the DNA content from 3. 
20. Add the mixture from Step 3 into the appropriate well dropwise with gentle swirl of the plate.  
Quickly replace the dish in the incubator once the batch is complete. 
• Add dropwise to spread the DNA around the plate.  Cells die easily if DNA is too concentrated in 
one area. 
• There may be a pH change (i.e. colour change).  This is normal. 
21. After 6 hours, replace the media with fresh 5 mL of complete media.  Do not wash with DPBS. 
22. Incubate for 24 hours. Collect the media at 48 h, 52 h, and 56 hours after transfection.  Collect the 
media by taking up the 5 mL of media and put it in a 50 mL conical tube.  Replace the plate with 5 
mL of fresh media, and place it back in the incubator.  Store collected media at 4 °C (i.e. fridge) until 
all fractions have been collected.  Pool all the fractions (i.e. collect the media after 48 h, 52 h, and 56 
h in the same 50 mL conical tube), and 
23. Once all the fractions have been collected, filter the supernatant through a 0.45 μm syringe filter into 
50 mL conical tubes.  Can only have approximately 30 mL of supernatant in each conical tube since 
will be adding additional solutions into the supernatant for concentrating. 
 
Day 4 – 5 – Virus Concentration (Lenti-X Concentrator) 
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 Reagents: 
Dry Reagents Wet Reagents 
• 1.5 mL Eppendorf tube 
• 50 mL Conical tube 
• Complete RPMI Media (see below) 
• Lenti-X Concentrator (Clontech, 631231) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 88   
Heat-inactivated FBS 
(Irvine Scientific, 300320439) 
50 10   
Glutamax (Gibco, 35050-061) 5.5 1 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 5.5 1 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
 
Procedures: 
1. After filtering the supernatant through the 0.45 μm syringe filter, add 1 volume of Lenti-X 
concentrator to 3 volumes of supernatant.  Mix by inversion. 
• Just need a rough estimate of the volume of supernatant (some will be loss during the filtering).  
Divide the amount by 3 and that’s the amount of Lenti-X concentrator to add. 
• For example, if you have 30 mL of viral supernatant, 30/3 = 10 mL of Lenti-X concentrator to 
add. 
2. Incubate the mixture at 4 ºC overnight. 
3. Centrifuge samples at 1500 g for 45 min at 4 ºC.  After centrifugation, an off-white pellet will be 
visible. 
4. Carefully remove supernatant while not disturbing the pellet. 
5. Gently resuspend the pellet in 1:5 or 1:10 of the original volume (i.e. If start with 30 mL, resuspend in 
3 mL for 1:10 concentration).  The pellet will be sticky, but should go into solution quickly. 
6. Incubate for 10 min in the fridge to allow the pellet to fully dissolve, then immediately aliquot the 
samples in 1 mL volume.  Store at -80 ºC. 
 
Day 4 – 5 – Virus Concentration (Ultracentrifuge) 
Procedures: 
1. Alternatively, if Lenti-X concentrator is not available, one can concentrate the virus using an 
ultracentrifuge. 
2. Put the viral supernatants into Beckman 1X3-1/2 P.A. Tube (Beckman, 326823) or compatible tubes.  
Need to fill up the tube close to full so that the tube does not collapse during the spin. 
3. Need to balance the tubes by adding media to the tubes. 
• Balancing is extremely important because if the tubes are not balanced properly, then the 
ultracentrifuge will not operate.  Further, imbalance will damage the ultracentrifuge and even 
cause injuries! 
4. Put the tubes in the SW28 rotor, and spin at 25000 rpm for 1.5 hr at 4 ºC. 
• Set the centrifuge at 1.75 h since it takes awhile for the ultracentrifuge to reach 25000 rpm. 
5. After the spin, carefully take out the tubes and remove the supernatant gently.  One should see a very 
small white pellet at the bottom of the tube. 
6. If you have more supernatant (i.e. same virus), then you can repeat steps 2 – 5 again to pellet more 
virus until all the supernatant is concentrated. 
7. Pellet can be suspended into appropriate medium.  The solution is stored in the fridge overnight to 
allow the pellet to fully dissolve. 
7. The next day, aliquot the samples in 1 mL volume.  Store at -80 ºC. 
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 APPENDIX K  
LENTIVIRAL TRANSDUCTION OF CD4+ T CELLS 
Purpose: To infect CD4+ T cells with lentivirus containing PH-PLCδ1-GFP in order to examine 
colocalization of PI(4,5)P2 with the plasma membrane (CellMask PM marker), and the nucleus (DAPI). 
 
Reagents: 
Dry Reagents Wet Reagents 
• 6 well plates 
• 15 mL conical tubes 
• Chamber coverglass (Nunc, 155380) 
• Leibovitz’s media (Gibco, 21083-02) 
• Sterile PBS 
• CellMask Deep Red plasma membrane stain 
(Life Technologies, C10046) 
• DAPI (Life Technologies, D1306) 
• 4 mg/mL polybrene (Sigma, H9269-10G) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 87   
Heat-inactivated FBS  
(Irvine Scientific, 300320439) 
50 10   
Glutamax (Gibco, 35050-061) 5.5 1 200 mM 4 mM 
Pen-strep (Gibco, 15140-148) 5.5 1 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
o 2-mercaptoethanol (Sigma, M7522) must be added fresh to the media. 
 Dilute 1 µL of 2-mercaptoethanol in 1.43 mL of complete RPMI media.  This makes a 10 
mM solution. 
 Make 1:1000 dilution (i.e. if using 1 mL of media, then add 1 µL of the 10 mM solution) into 
the media to make a final concentration of 10 µM. 
o Recombinant mouse IL-2 (eBioscience, 14-9021).  Must be added fresh to the media. 
 Stock concentration at 100 μg/mL.  Make 1:2500 dilution into media to achieve a final 
concentration of 40 ng/mL. 
  
Isolation of splenic CD4+ T cells (Day 1) 
1. Follow isolation of splenic CD4+ T cell protocol.  
2. Resuspend the cell pellet in warm complete RPMI media to a final concentration of 12 x 106 cells/mL. 
3. Seed 1 mL of CD4+ T cells into each well.  Need the following number of wells: 
4. Incubate for at least 1 hr at 37 ºC, 5% CO2 before viral transduction. 
 
Viral transduction of PH-PLCδ1-GFP into CD4+ T cells (Day 1) 
1. Dilute polybrene to 8 µg/mL in complete RPMI media.  Add 20 µL of polybrene stock to 1 mL of 
complete RPMI media. 
2. Quickly thaw the virus in the water bath and once thawed, immediately add 100 µL of diluted 
polybrene to 1 mL of virus. 
3. Incubate for at least 36 hr at 37 ºC, 5% CO2.  Protect the cells transduced from light. 
 
Coating (Day 2) 
1. Dilute 10X poly-L-Lysine solution (Sigma, P8920) with sterile H2O to 1X (0.1% w/v to 0.01% w/v). 
2. Precoat Lab-Tek 2-well chambered coverglass (Nalge, 154461) with 0.01% poly-L-lysine by adding 2 
mL of 0.01% poly-L-Lysine/well for 30 min at room temperature.  Replace the lids back on while the 
chamber slides are incubating. 
3. Aspirate excess solution and sterile the slides under UV light for 1 hr.  Leave the lids off. 
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 4. On Day 3, wash chambered coverglass with 1 mL of warm Leibovitz’s media once.  Add the warm 
media into each chamber, shake gently by hand, and then aspirate off the media.   
5. Prewarm the coated chambered coverglass with 200 μL of warm Leibovitz’s media.  Leave in the 
incubator until seeding. 
 
Dye Loading (Day 3) 
1. Collect the cells into 15 mL conical tubes by pipetting up and down vigorously to dislodge the cells 
from the plastic bottom.  Wash the wells with 2 mL of complete RPMI media, pipette up and down, 
and collect into the conical tubes.  Repeat once more. 
2. Check under the microscope to ensure that most of the cells have been collected.  If not, repeat the 
wash step described above. 
3. Spin down the cells at 350 g, 5 min, room temperature.  Aspirate off the media. 
4. Wash the cells once with PBS.  Take 20 μL and count using a Coulter counter. 
5. Spin down the cells at 350 g, 5 min, room temperature.  Aspirate off the PBS. 
6. Resuspend the cells to a final concentration of 5 x 106 cells/mL in Leibovitz’s media. 
7. Take the following over to Dr. Barhoumi’s lab: 
1. P1000 pipette – seed cells. 
2. P1000 tips – seed cells. 
3. Coated chambered coverglass with 200 μL of Leibovitz’s media. 
4. Resuspended cells in Leibovitz’s media. 
5. Timer 
 
Imaging (Day 3) – Dr. Barhoumi’s Lab 
1. Seed 1 mL of CD4+ T cells into each well to achieve 5 x 106 cells per chamber.  Incubate at 37 ºC, 5% 
CO2 for 30 min to allow the cells to settle. 
2. Bring to Dr. Barhoumi for imaging.   
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 APPENDIX L  
CROSSLINKING CHOLERA TOXIN B FOR IMMUNOFLUORESCENCE 
Purpose: To examine the spatial relationships between specific protein of interest and GM1 ganglioside-
enriched domains (i.e. lipid rafts) of the plasma membrane by crosslinking cholera toxin B. 
 
Reagents: 
Dry Reagents Wet Reagents 
• Coverglass (Corning, 2935-225) 
• Lab-Tek II 2-well glass chamber slide 
(Nalge, 154461) 
• Sterile PBS (Gibco, 14190) 
• Vybrant Alexa Fluor 555 Lipid Raft Labeling Kit 
(Molecular Probes, V-34404) 
• 0.1%(w/v) Poly-L-Lysine solution (Sigma, P8920) 
• Coverglass antifade reagent medium (Invitrogen, 
P36934) 
• 100 mM glycine (Sigma, G7126) 
o Make 100 mM by dissolving 7.507 g of glycine in 
1 L PBS 
• 20% PFA in PBS (EMS, 15713-S) 
• 10% Triton X-100 (Fluka, 93443) 
• Blocking solution 
o 1% IgG-free BSA (Roche, 03116956001) 
o 0.1% NaN3 (Sigma, S2002) 
• 98.3% PBS (Gibco, 21600-069) 
• Rabbit anti-WASp (Santa Cruz, #sc-8353) 
• Alexa 568-Phalloidin (Invitrogen, A12380) 
• Goat anti-Rabbit Alexa 647(Invitrogen, A21246) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 87   
Heat-inactivated FBS  
(Irvine Scientific, 300320439) 
50 10   
Glutamax (Gibco, 35050-061) 5.5 1 200 mM 4 mM 
Pen-strep (Gibco, 15140-148) 5.5 1 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
o 2-mercaptoethanol (Sigma, M7522) must be added fresh to the media. 
 Dilute 1 µL of 2-mercaptoethanol in 1.43 mL of complete RPMI media.  This makes a 10 
mM solution. 
 Make 1:500 dilution (i.e. if using 1 mL of media, then add 2 µL of the 10 mM solution) into 
the media to make a final concentration of 20 µM. 
o Recombinant mouse IL-2 (eBioscience, 14-9021).  Must be added fresh to the media. 
 Stock concentration at 100 μg/mL.  Make 1:1250 dilution into media to achieve a final 
concentration of 80 ng/mL. 
• PBS (from Vybrant Lipid Raft Labeling Kit) 
o Add 2 mL of 10X PBS to 18 mL of ddH2O. 
o Store a 4 ºC. 
• Cholera Toxin subunit B (CTxB) Conjugate (from Vybrant Lipid Raft Labeling Kit). 
o Dissolve one vial of CTxB conjugate with 100 μL of PBS.  This generates 1 mg/mL stock 
solution. 
o Aliquot into 5 μL and store at -20 ºC for 6 months. 
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 • Anti-CTxB antibody (from Vybrant Lipid Raft Labeling KT). 
o Aliquot into 11 μL and store at -20 ºC for 6 months. 
  
Procedures 
Precoating chamber slides for 
seeding cells 
1. Must perform this the day before 
the assay. 
2. Dilute 10X poly-L-Lysine solution 
with sterile H2O to 1X (0.1% w/v 
to 0.01% w/v). 
3. Precoat Lab-Tek II 2-well glass 
chamber slides with 0.01% poly-
L-lysine by adding 2 mL of 0.01% 
poly-L-Lysine/well for 30 min at 
room temperature.  Replace the 
lids back on while the chamber 
slides are incubating. 
4. Aspirate excess solution and 
sterile the slides under UV light 
for 1 hr.  Leave the lids off. 
5. The next day, wash chamber slides 
with 1 mL of warm complete 
RPMI once time.  Add warm 
complete RPMI into each 
chamber, shake gently by hand, 
and then aspirate off the media.   
6. Prewarm the coated chamber 
slides with 200 μL of warm 
complete RPMI at 37 °C for 30 
min.  Leave in the incubator until 
seeding. 
Precoating chamber slides for plated CD3/CD28 activation 
1. Must perform this the day before the assay. 
2. Dilute 10X poly-L-Lysine solution with sterile H2O to 1X 
(0.1% w/v to 0.01% w/v). 
3. Precoat Lab-Tek II 2-well glass chamber slides with 0.01% 
poly-L-lysine by adding 2 mL of 0.01% poly-L-Lysine/well 
for 30 min.  Replace the lids back on while the chamber 
slides are incubating. 
4. Aspirate excess solution and sterile the slides under UV 
light for 1 hr.  Leave the lids off. 
5. Dilute anti-CD3 (stock 1 mg/mL) 1:1000 and anti-CD28 
(stock 1 mg/mL) 1:100 in PBS in a single tube. 
• Example, if need 1 mL, add 1 µL of anti-CD3, 10 µL 
of anti-CD28, and 989 µL of PBS. 
• Add 200 µL of antibodies per chamber slide.  For 
control (unstimulated), add 200 µL of PBS per 
chamber slide. 
6. Incubate chamber slides on a shaker (gently) in the 4 °C 
walk-in cold room at a speed setting of 4, overnight.  
Replace the lids back on to ensure sterility. 
7. The next day, wash chamber slides with 1 mL of warm 
complete RPMI once time.  Add warm complete RPMI into 
each chamber, shake gently by hand, and then aspirate off 
the media.   
8. Prewarm the coated chamber slides with 200 μL of warm 
complete RPM, at 37 °C for 30 min.  Leave in the incubator 
until seeding. 
 
Isolation of splenic CD4+ T cells (Day 2) 
1. Follow isolation of splenic CD4+ T cell protocol.  
2. Resuspend the cell pellet in warm complete RPMI media to a final concentration of 5 x 106 cells/mL.  
3. Seed 1 mL/well dropwise by adding the cell suspension onto the 200 µL complete media in the well.  
This equates to 5 x 106 cells per well. 
• Final anti-CD3 concentration = 0.17 µg/mL (but is actually higher since plated, not 
suspended). 
• Final anti-CD28 concentration = 0.83 µg/mL (but is actually higher since plated, not 
suspended). 
4. Incubate at 37 °C for 30 minutes. 
 
Cholera Toxin B Labeling (Day 2) 
1. Prepare Cholera Toxin B conjugate. 
• Dilute CTxB conjugate 1:1000 in chilled RPMI media.  Each sample requires 2 mL of working 
conjugate, so add 2 μL of conjugate in 2 mL of chilled RPMI media per sample. 
2. Prepare CTxB antibody. 
• Dilute the antibody 1:200 in chilled RPMI media.  Each sample requires 2 mL of working CTxB 
antibody, so add 10 μL of working CTxB antibody in 2 mL of chilled RPMI media per sample. 
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 3. After the 30 min incubation at 37 ºC, wash the cells in the chamber slides with ice cold PBS 3 times 
for 2 min each. 
4. Add 2 mL of working CTxB conjugate into each well and incubate for 10 min at 4 ºC. 
5. Wash the cells in the chamber slides with ice cold PBS 3 times for 2 min each. 
6. Add 2 mL of working CTxB antibody into each well and incubate for 15 min at 4 ºC. 
7. Wash the cells in the chamber slides with ice cold PBS 3 times for 2 min each. 
 
Fixing the Cells (Day 2) 
Protect the samples from light at this point. 
7. Make 4% PFA by combining 4 mL of 20X PFA and 16 mL of PBS. 
• Always make PFA fresh (i.e. the same day of experiment). 
8. Fix the cells in the freshly made 4% PFA for 20 min at 4 ºC. 
9. Rinse the samples with PBS 2 times for 2 min each, and incubate cells with 2 mL of 10 mM glycine 
in PBS for 10 min at room temperature. 
• This step is performed to quench aldehyde groups. 
• Stock at 100 mM, so dilute 1:10 in PBS. 
10. Wash the chamber slides with PBS 2 times for 2 min each, and permeabilize the cells by using 2 mL 
of 0.2% Triton X-100 in PBS for 5 min at room temperature. 
• Stock at 10%, so dilute 1:50 in PBS. 
11. Wash the chamber slides with PBS 3 times for 2 min each. 
12. Incubate cells in blocking solution at 4 °C overnight in a humid chamber. 
• Humid chamber consists of the plastic slide holders.  Alternate between slide and wet Kimwipe 
PBS.  Cover with foil paper to prevent evaporation. 
 
Applying Antibody (Day 2 – 3) 
8. Wash the chamber slides with PBS 3 times for 2 min each. 
9. Dilute the antibody in the following manner in the dark. 
Antibody Stock Dilution Final Per well 
Phalloidin 200 U/mL 1:10 20 U/mL 20 µL antibody + 180 µL Blocking 
Anti-WASp 200 μg/mL 1:50 4 μg/mL 4 µL antibody + 196 µL Blocking 
10. Incubate each chamber slide with 200 μL per well at room temperature for 1 hr in a humid chamber.  
The slides much be protected from light. 
• Wrap aluminum foil around the humid chamber and put in a drawer for extra protection against 
light exposure. 
• Cells are labeled much better when antibodies applied sequentially.  This means that only one 
antibody is incubated in each well for 1 hr, followed by 2 washes with PBS for 2 min each, and 
then add the second antibody.  The order of application does not seem to affect the fluorescence, 
but typically if one antibody is much stronger, apply that one first. 
11. (If required) Dilute the secondary antibody in the following manner in the dark. 
Antibody Stock Dilution Final Per well 
Goat anti-Rabbit Alexa 
647 
 2 mg/mL 1:300 6 μg/mL 0.67 µL antibody + 199.4 µL Blocking 
12. Incubate each chamber slide with 200 μL per well at room temperature for 1 hr in a humid chamber.  
The slides much be protected from light. 
• Wrap aluminum foil around the humid chamber and put in a drawer for extra protection against 
light exposure. 
13. Prepare the ProLong medium during the last 1 hr antibody incubation by thawing at room temperature 
for 1 hr (stored in -20 °C freezer). 
14. Wash the chamber slides with PBS 3 times for 2 min each. 
 
Preparation for Wash (Day 3) 
8. Use slide separator to remove the chamber.  Put slides on a slide holder for subsequent washes. 
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 9. Incubate the slides in 70% ethanol once for 2 min.  
10. Incubate the slides in 95% ethanol once for 2 min. 
11. Incubate the slides in 100% ethanol once for 2 min. 
12. Incubate slides in fresh xylene twice for 2 min each.  This means that one would need two fresh 
xylenes. 
13. Apply a small amount of antifade reagent medium mixture to the coverglass.  Cover the slide while it 
is still wet. 
• Use a glass rod to line the antifade reagent medium on the side of the coverglass, and then cover 
the slide at a 45° angle to avoid bubbles. 
• Use a razor blade to help with the coverslip. 
14. Place the slide on a flat surface in the dark to dry overnight at room temperature in the fume hood.  
Protect from light. 
 
Finalizing the Slides (Day 3) 
4. Seal the coverglass to the slide with fingernail polish to prevent shrinkage of mounting medium and 
subsequent sample distortion. 
5. After sealing, let it dry for at least 15 min, then store the slide upright in a slide box at -20°C.  
Desiccant may be added to the box to ensure that the slide remains dry. 
6. Examine sample under fluorescence microscopy. 
 
Notes: 
• Vybrant Lipid Raft Labeling Kit  excitation (555 nm) and emission (565 nm).  We use Alexa 647-
CTxB to avoid bleedthrough of Alexa 555-CTxB into the green channel. 
• Adopted from Vybrant Lipid Raft Labeling Kits product information.  Published protocol from 
Chazotte B., (2011), Cold Spring Harb Protoc 5: 576-578. 
• Please see van Zanten TS et al. PNAS (2010) for comments on why labeling and crosslinking CTxB 
is conducted at 4 ºC.  Also see Tanaka KA et al Nat Methods (2010) for comments on mobility of 
molecules (proteins and lipids) even after chemical fixation. 
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 APPENDIX M  
CFSE LABELING OF CD4+ T CELLS 
Objective: To measure T-cell proliferation by dilution of CFSE dye in daughter cells. 
 
Materials: 
Dry Reagents Wet Reagents 
• Titertube Micro Test Tubes  
(Bio-Rad, #223-9391). 
• BSA, IgG free 
(Boehringer Mannheim Laboratory Reagents, #100018) 
• PBS/0.1% BSA (see below). 
• CellTrace CFSE Cell Proliferation kit 
(Invitrogen #C34554) 
• RPMI Complete Media (see below) 
• PBS/0.1% BSA: Filter thorough 0.2 µm filter to sterilize. 
• CFSE: 
• Not light-sensitive until bound to amino acids in cells. 
• To prepare 5 mM CFSE working stock, dissolve one vial (component A) in 18 µl DMSO 
(component B) immediately before use. 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 87   
Heat-inactivated FBS  
(Irvine Scientific, 300320439) 
50 10   
Glutamax (Gibco, 35050-061) 5.5 1 200 mM 4 mM 
Pen-strep (Gibco, 15140-148) 5.5 1 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
o 2-mercaptoethanol (Sigma, M7522) must be added fresh to the media. 
 Dilute 1 µL of 2-mercaptoethanol in 1.43 mL of complete RPMI media.  This makes a 10 
mM solution. 
 Final concentration of 10 µM in the culture is required. 
 
Procedures: 
Preparation of anti-CD3/anti-CD28 Stimulation Plate (Day 0) 
1. The day before labeling, precoat 96 well round bottom culture plate with anti-CD3 by diluating anti-
CD3 in PBS 1:1000.  Add 200 µL per well. 
2. Seal the plate, store at 4°C overnight. 
3. The next day, discard the anti-CD3 solution, and add anti-CD28 diluted in complete media (with 2-
mercaptoethanol) at 1:100 dilution (final concentration in culture = 5 µg/mL).  Incubate at 37 °C until 
ready to seed. 
 
Labeling CD4+ T cells with CFSE 
10. Follow isolation of splenic CD4+ T cell protocol.  
11. Resuspend cells at 1 x 106 cells in 1 mL PBS/0.1% BSA (need 2 x 106 cells/in 2 mL PBS/0.1%BSA). 
12. Add 2µl of 5 mM CFSE/ 1x106 cells in the tube containing cells (add 4 µL to the 2 x 106 cell vial).  
Vortex immediately at highest setting for 3 sec. Now, CFSE is light-sensitive! 
13. Incubate at 37 oC. (in water bath) for 10 min . 
14. Add 5x volume of ice-cold RPMI 1640/10% HI-FBS into the cell suspension (so add 10 mL to the 2 
ml cells), swirl the tube 2-3 times, and incubate for 5 min on ice. 
15. Centrifuge at 350 g for 5 min to pellet the cells.  Aspirate the supernatant. 
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 16. Resuspend the cell pellet in sterile PBS at RT (use 5 mL), spin down (350 g, 5 min at RT) and aspirate 
supernatant. 
17. Resuspend cells in 1 mL complete media with 2-mercaptoethanol. (final cell density at 2 x106 
cells/ml)  
 
Culture and Flow 
1. Add 100 µL cells (0.2 x 106 cells per well) to each well so that the final volume is 200 µL. 
2. Incubate at 37 °C for 3 days. 
3. After culture, spin down culture plate at 350 g for 5 min at RT.  Using 200 uL multi-channel pippette, 
aspirate supernatant. 
• You don’t need to aspirate all the supernatant. Instead, leave a little bit of supernatant to avoid 
touching the plate bottom.  
• Tip: Angle the plate slightly and pipette against the wall to avoid touching the bottom of the 
plate. 
4. Tap plate to resuspend the cells with residual medium.  Add 200 uL staining buffer into each culture 
well and spin down at 350 rpm for 5 min at RT. 
5. Aspirate supernatant as described in step 3. 
6. Resuspend cells in 100 uL staining buffer. 
7. Transfer cell suspension into the small flow Titertubes. 
8. Keep samples on ice until analysis. 
9. Run flow cytometery.  CFSE is detected in FL-1 channel. 
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 APPENDIX N  
MONITORING POST-TRANSLATIONAL MODIFICATIONS IN CD4+ T CELLS 
USING IMMUNOPRECIPITATION 
Purpose: To immunoprecipitate azido-palmitic acid-labeled proteins generated from CD4+ T cells 
incubated with the probe for downstream detection of specific proteins of interest (i.e. LAT, LCK, FYN, 
CD4). 
 
Reagents: 
Dry Reagents Wet Reagents 
• 15 mL conical tube 
• 1.5 mL microcentrifuge tube 
• 35 mm plates 
• NMWL 3000 centrifugal filter 
device (Millipore, UFC500396) 
• Complete RPMI media (with FBS) 
• Complete RPMI media, serum free (without FBS) 
• Click-iT palmitic acid, azide (Invitrogen, C10265) 
• Pierce BCA Protein Assay Kit (Thermo Scientific, 23225 or 
23227) 
• ddH2O 
• Methanol (CH3OH) 
• Chloroform (CHCl3) 
• Protein G Dynabeads (Invitrogen, #100.04D) 
• DynaMagnet (Invitrogen, #123.21D, #123.22D) 
• Rabbit polyclonal IgG anti-Lck (Millipore, #06-583) 
• Rabbit polyclonal IgG anti-LAT (Millipore, #06-807) 
• 5X Pyronin 
• Biotinylated molecular weight marker (Sigma, B2787) 
• Streptavidin conjugated horseradish peroxidase (Invitrogen, 
S911) 
• Complete RPMI Media 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 89.2   
Heat-inactivated FBS (Irvine Scientific, 
300320439) 
50 8.9   
Glutamax (Gibco, 35050-061) 5.5 0.98 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 5.5 0.98 P 10000 U/mL 
S 10000 
μg/mL 
P 100 U/mL 
S 100 
μg/mL 
• Complete RPMI Media with 2% FBS 
 Vol (mL) % Stock Conc Final Conc 
RPMI (Irvine Scientific, 9159) 500 96.1   
Heat-inactivated FBS (Irvine Scientific, 
300320439) 
10 1.9   
Glutamax (Gibco, 35050-061) 5.1 0.98 200 mM 2 mM 
Pen-strep (Gibco, 15140-148) 5.1 0.98 P 10000 U/mL 
S 10000 μg/mL 
P 100 U/mL 
S 100 μg/mL 
• Click-iT palmitic acid, azide (Invitrogen, C10265) 
a. Since want the final concentration of the probe to be at 50 μM, stock concentration will be made 
at 50 mM (1000X stock). 
0.001 g ×
mol
283.41 g
×
L
0.05 mol
×
μL
10-6L
=70.6 μL 
165 
 
 o Since final volume will be at 4 mL (20 x 106 cells in 4 mL in 35 mm plate), will be using 4 μL.   
o Aliquot into 5 μL aliquots, and store in -80 ºC. 
• Homogenization buffer A (can be prepared beforehand and store at 4 °C, good for 3 months). 
Components Amount for 5 mL Final Conc 
1M Tris-HCl, pH = 8.0 
 
0.25 mL 50 mM 
20% (w/v) SDS 
20 g of SDS in 100 mL of ddH2O 
0.25 mL 1%  
ddH2O 4.2 mL   
• On the day of the protein extraction, add the following components (Homogenization buffer B). 
Components Dilution Factor Amount for 5 mL Final Conc 
10 mM Sodium Orthovanadate 
1.839 mg/mL 
1:100 50 μL 100 µM 
 
Sigma Protease Cocktail 1:25 200 μL  
Benzonase Nuclease (Sigma, E1014-5KU) Lot Dependent Lot Dependent (~ 1 μL) 250 units 
• Click-iT biotin, alkyne (Invitrogen, B10185) 
a. Since want the final concentration of the probe to be at 40 μM, stock concentration will be made 
at 4 mM (100X stock). 
0.001 g ×
mol
528.66 g
×
L
0.004 mol
×
μL
10-6L
=472.9 μL 
o Since dilute 1:100 in 100 μL, will be using 10 μL per reaction. 
o Aliquot into 12 μL aliquots, and store in -80 ºC. 
• Immunoprecipitation buffer A 
Components Volume (μL) for 5 mL Final Conc 
500 mM Tris-HCl (pH = 7.5), Fisher #BP153 
6.1 g/100 mL 
500 μL 50 mM 
100 mM EGTA (pH = 7.5), Sigma #E4378 
0.38 g/10 mL 
Add NaOH to get it to dissolve and bring pH up to 7.5 
750 μL 15 mM 
500 mM NaCl, Sigma #S3014 
0.168 g/10 mL 
1 mL 100 mM 
10% Triton X-100, Sigma #X100 
2 mL in 20 mL ddH2O 
50 μL 0.1% 
ddH2O 1.75 mL  
• On the day of the protein extraction, add the following components (Homogenization buffer B). 
Components Dilution Factor Amount for 5 mL Final Conc 
10 mM Sodium Orthovanadate, Sigma 
#S6508 
1.839 mg/mL 
 250 μL 500 µM 
 
Sigma Protease Cocktail, Sigma #P8340 1:25 200 μL  
β-mercaptoethanol, Sigma #M6250 
14.2 M 
 3.5 μL 10 mM 
 
Procedures 
Isolation of CD4+ T Cells 
20. Follow Isolation of T cells protocol. 
21. After isolation of T cells, resuspend the CD4+ T cells with warm complete RPMI to get a final 
concentration of T cells at 15 x 106 cells/1 mL in complete RPMI media. 
22. Leave the cells in the 15 mL conical tubes, and incubate at 37 °C for 1 hr. 
23. Prepare 35 mm plate by adding 3 mL of RPMI media with 2% FBS per plate.  Incubate at 37 °C until 
use. 
166 
 
 24. Seed 1 mL of cells per 35 mm plate.  Incubate overnight at 37 ºC, 5% CO2. 
 
Incubation with Fatty Acid Probes 
1. The next morning, add 4 μL of 50 mM ω-alkyl probes into each plate (50 μM final concentration).  
Incubate at 37 ºC, 5% CO2 for 24 h. 
2. Collect cells by transferring the media into a 15 mL conical tube.  Wash the plate with 3 mL of RPMI 
media with 2% FBS twice to try to collect as many cells as possible.  Pipette up and down in order to 
dislodge cells that are stuck on the plate.  Spin at 350 g, 5 min. 
3. Pool 2 wells per sample by washing 2 wells of cells with 1mL of PBS and transfer into 1.5 mL 
microcentrifuge tube.  Count the number of viable cells using Trypan Blue.  Spin at Spin at 350 g, 5 
min. 
4. Resuspend the pellet in 500 µL of complete homogenization buffer (i.e. A + B).   
• Because of the high number of cells, the lysate will be very viscuous due to the DNA.  Treatment 
with Benzonase will digest the nucleic acids and eliminate any precipitate. 
5. Incubate on a rotator for 30 min at 4 ºC. 
6. Vortex the lysate for 5 minutes to further solubilize proteins and disperse the DNA. 
7. Centrifuge at 14000 g for 20 min at 4 °C. 
 
Protein Concentration 
1. First insert the Millipore YM-3 centrifugal filter reservoir into the provided vial.  This concentrator 
has a molecular weight cut-off of 3 kDa. 
2. Load 500 µL of lysate into the sample reservoir without touching the membrane with the pipette tip.  
Seal the reservoir with attached cap. 
3. Spin the concentrator at 14000 g, at 4 ºC for 30 min.  Check to see the amount of sample retained in 
the sample reservoir.  Should aim for approximately 50 ~100 μL. 
4. If the sample volume in the sample reservoir is more than desired, spin at 14000 g at 4 ºC for more 
time, and check the volume.  Can keep on repeating until the volume in the reservoir is the right 
volume. 
5. Once the volume is optimized, turn the reservoir upside down into a new 1.5 mL microcentrifuge 
tube.  Spin at 1000 g at 4 ºC for 10 min. 
6. Proceed to Pierce BCA Protein Assay Kit (Thermo Scientific, 23225) or store at -80 ºC.   
 
BCA Protein Assay 
1. Preheat an incubator at 37 ºC. 
2. Start by preparing 7 protein standards. 
Final BSA Concentration 
(μg/mL) 
Volume of Homogenization 
Buffer (A) 
(μL) 
Volume and Source of BSA 
(μL) 
2000 0 Remaining volume of 2 mg/mL 
stock 
1500 125 375 μL of 2 mg/mL stock 
1000 325 325 μL of 2 mg/mL stock 
750 175 175 μL of 1500 μg/mL 
500 325 325 μL of 1000 μg/mL 
250 325 325 μL of 500 μg/mL 
125 325 325 μL of 250 μg/mL 
0 400 0 
3. In a 96-well microplate, pipette 10 μL of standards and samples. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 2000 2000 2000          
B 1500 1500 1500          
C 1000 1000 1000          
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 D 750 750 750          
E 500 500 500          
F 250 250 250          
G 125 125 125          
H 0 0 0          
4. Prepare the BCA working solution by mixing 50 parts of reagent A with 1 part of reagent B.  Vortex 
to mix the components well.  Transfer into a reservoir. 
• That means add 50 mL of reagent A and 1 mL of reagent B.  Adjust accordingly. 
5. Using a multichannel pipette, add 200 μL of BCA working solution into each well.  Mix thoroughly 
with a plate shaker for 30 sec. 
6. Cover the plate with an adhesive plate cover and incubate at 37 ºC for 30 min. 
7. Measure the absorbance at 562 nm on a plate reader. 
 
Click Chemistry 
1. Prepare Component C (additive 1) and Component D (additive 2) of Click-iT kit.  These can be stored 
as stock solutions. 
• Component C  add 500 μL of deionized water to Component C and mix until fully dissolved.  
Store at -20 ºC.  Stabile for up to 1 year.  If the colour turns from colourless to brown, it is 
oxidized.  Discard. 
• Component D  add 540 μL of deionized water to Component D mix until fully dissolved.  Store 
at 4 ºC.  Stabile for up to 1 year. 
2. Prepare Click-iT reaction buffer. 
• Dilute biotin-alkyne 1:100 in Component A by adding 10 μL of 4 mM biotin-alkyne and 90 μL of 
Component A. 
• The above is for one reaction, so scale up as required. 
3. To set-up the reaction, add the following reagents in sequence in 1.5 mL microcentrifuge tube (see 
next page for the complete table). 
4. Rotate end-over-end or vortex continuously for 30 min.  Protect from light. 
Reagent Volume (μL) 
Cell Lysate (<200 μg/μL) 50 
Prepared Click-iT reaction buffer 
(with biotin-alkyne) 
100 
ddH2O 10 
Vortex for 5 sec at high setting 
CuSO4 (Component B) 10 
Component C 10 
Vortex for 5 sec at high setting 
Wait for 3 min. 
Component D 20 
Total Volume 200 
 
Protein Precipitation 
1. Add 600 μL of methanol to the reaction mixture and vortex for 5 seconds. 
2. Add 150 μL of chloroform and vortex for 5 seconds. 
3. Add 400 μL of ddH2O and vortex for 5 seconds. 
4. Centrifuge for 5 min at 18000 g.  Remove and discard as much upper aqueous phase as possible while 
leaving the interface layer containing the protein precipitate intact. 
5. Add 450 μL of methanol and vortex for 5 seconds. 
6. Centrifuge 5 min at 18000 g to pellet the protein.  Discard the supernatant. 
7. Wash the protein pellet by adding an additional 450 μL of methanol and vortex for 5 seconds.  
Centrifuge for 5 min at 18000 g to pellet the protein again, Discard the supernatant. 
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 8. Allow the pellet to air dry by keeping the tube open covered with a lint-free tissue.  Time length is 
approximately 5 min.  Do not over-dry since this will make solubilizing the proteins difficult. 
9. Store the samples at -20 ºC. 
 
Immunoprecipitation using Streptavidin Dynabeads  
1. Prepare complete immunoprecipitation buffer by combining component A and component B.  Store 
on ice. 
2. Resuspend the protein pellet stored at -20 ºC with 100 μL of complete immunoprecipitation buffer.  
Gentle heat while vortexing can help with the solubilization process. 
3. Determine the protein concentration using Coomassie assay. 
4. Make the following standards in glass tubes. 
Protein 
µg 
BSA 
0.25 µg/µL 
BSA 
1 µg/µL 
BSA 
2 µg/µL 
ddH2O Homogenization 
Buffer 
Coomassie 
Reagent 
0 0 µL   497.5 µL 2.5 µL 500 µL 
0.5 2 µL   495.5 µL 2.5 µL 500 µL 
1.0 4 µL   493.5 µL 2.5 µL 500 µL 
2.0  2 µL  495.5 µL 2.5 µL 500 µL 
4.0  4 µL  493.5 µL 2.5 µL 500 µL 
10.0  10 µL  487.5 µL 2.5 µL 500 µL 
20.0   10 µL 487.5 µL 2.5 µL 500 µL 
5. Make the samples in glass tubes.  Need to make samples for each aliquot. 
Sample Amount ddH2O Coomassie Reagent 
2.5 µL 497.5 µL 500 µL 
6. Perform the assay in triplicates (both samples and standards).  For each standard or sample, load 3 
wells/sample.  Transfer 300 µL to a microtiter plate. 
7. Read at A595 nm immediately. 
8. Combine the following amount of proteins with antibody to a final volume of 500 μL. 
Protein Amount 
(μg) 
Antibody Antibody Range 
(μg) 
100 Anti-LAT at 1 μg/μL 8 – 10 Anti-Lck at 1 μg/μL 4 
9. Place the samples by rotating the tubes on an orbital shaker at 4 ºC for 90 min. 
10. At this time, prepare the Protein G Dynabeads by place the beads on an orbital shaker for 5 min at 
room temperature to completely resuspend the beads.  Transfer 50 μL of Dynabeads to a 1.5 mL 
microcentrifuge tube.  Separate on the magnet for 1 min (or until the supernatant is clear), and remove 
the supernatant. 
11. After 90 min incubation of the samples, quickly spin down the samples and add the antibody-antigen 
(Ab-Ag) mixture to the Dynabeads.  Rotate the samples on an orbital shaker at 4 ºC overnight. 
12. The next day, place the samples on the DynaMagnet for 1 min to clear the supernatant.  Save the 
supernatant as flow-through. 
13. Wash the samples by adding 200 μL of immunoprecipitation buffer and resuspending by gentle 
pipetting.  Separate on the magnet and remove the supernatant (discard).  Repeat the wash two more 
times. 
14. Resuspend the samples in 100 μL of immunoprecipitation buffer and transfer into a new 1.5 mL 
microcentrifuge tube.  This is recommended to avoid co-elution of proteins bound to the tube wall. 
15. Place the tube on the magnet and remove the supernatant. 
16. Add 35 μL of 2X pyronin and gently pipette to resuspend the sample.  Heat the samples at 98 ºC for 
10 min. 
17. Place the tube on the magnet and remove the supernatant to a new tube.  Keep the supernatant in a 
new tube. 
18. Resuspend the beads in 100 μL of immunoprecipitation buffer and transfer into a new 1.5 mL 
microcentrifuge tube.  Place the tube on the magnet and remove the supernatant. 
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 19. Resuspend the beads in 35 μL of immunoprecipitation buffer and combine with the supernatant from 
Step 13. 
 
Notes: 
• The protein concentration for T cells is approximately 65 μg/107 cells (May 2011, Liem & Logan’s T 
cell isolation and protein quantification). 
• Immunoprecipitation is from HFT’s Dissertation (Current Protocols in Protein Science 19.4.5). 
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